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Sheridan Leona Roberts  
Title: The control of Schwann cell myelination during development 
and after nerve injury 
Abstract 
Schwann cells are the principal glial cell of the peripheral nervous system and are 
responsible for axon maintenance, regeneration and increasing saltatory conduction 
of neurons. Schwann cell differentiation and myelination is mediated by a core 
network of transcription factors and signalling pathways, which have been divided 
into two groups; positive and negative regulators. Sox10, NFATc4, Oct6, Krox20 and 
the ERK 1/2 signalling pathway have been characterised as positive regulators of 
Schwann cell differentiation and myelination; with Sox10 and Krox20 also playing 
critical roles in myelin maintenance. On the other hand, transcription factors cJun, 
Pax3, Id2 and signalling pathways Notch and p38 mitogen activated protein (MAP) 
kinases (MAPK) have been identified as negative regulators of Schwann cell 
differentiation and myelin formation. Recently, the HMG transcription factor Sox2 
was identified as a negative regulator of Schwann cell myelination in vitro, however 
its role in Schwann cell myelination in vivo has not yet been studied. This study 
therefore aimed to examine the role of Sox2 overexpression in Schwann cells and 
how it effects Schwann cell differentiation and myelination during development and 
after injury. In addition, we aimed to investigate for the first time the specific role of 
p38α (the major isoform of p38 MAPK) in Schwann cell myelination in vivo, by 
generating Schwann cell specific p38α conditional knockout mice.  
Sox2 is highly expressed in immature Schwann cells, but is downregulated as 
Schwann cells being to mature and differentiate. This study shows that continued 
expression of Sox2 during development and after injury, impairs Schwann cell 
differentiation and myelination by directly downregulating the expression of two core 
transcription factors; Sox10 and Krox20, as well as myelin proteins, P0 and MBP.  In 
addition, we observe that continued Sox2 expression significantly increases 
Schwann cell proliferation and maintains Schwann cells in an immature state. 
Unexpectedly, we also observed that continued Sox2 expression significantly 
increases the number of macrophages present in the nerves of Sox2 overexpressing 
mice at both P60 and 21 days post injury. Phenotypically, Sox2 overexpressing mice 
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show signs of a peripheral neuropathy and animals have impaired motor and 
sensory function. These findings confirm that Sox2 is a negative regulator of 
Schwann cell myelination and suggests that continued Sox2 expression is sufficient 
to drive the progressive development of a peripheral nerve disorder which may 
resemble Charcot-Marie-Tooth type 1 demyelinating neuropathy and congenital 
hypomyelinating neuropathy.  
As a negative regulator of Schwann cell myelination, activity of the p38 MAPK 
pathway has been shown to inhibit myelin formation in vitro and to also induce the 
Schwann cell injury response; by driving Schwann cell dedifferentiation and 
demyelination following injury. Here we show that specific removal of the p38α 
isoform in Schwann cells leads to an increase in myelin thickness at early 
developmental time-points, along with an elevated expression of myelin proteins, P0 
and MBP. Further analysis following nerve injury revealed that removal of p38α 
results in an initial decrease in Schwann cell demyelination, yet improves axon 
remyelination at 21 days post injury. These results demonstrate the specific role of 
p38α in regulating Schwann cell myelination, and how it could be a direct therapeutic 
target for improving nerve repair after injury.   
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Chapter 1 Introduction 
 
The nervous system consists of two parts, the central nervous system and peripheral 
nervous system, both of which are broadly composed of two major cell types, 
neurons and glia. Neuronal cells conduct action potentials (electrical signals) and are 
thus responsible for cellular communication. Glial cells on the other hand are 
essential for neuronal support; this includes neuronal survival, guidance, synaptic 
formation and function, homeostatic regulation of neurotransmitter and potassium ion 
concentrations, as well as regulating the speed of action potentials (Jessen, 2004). 
In the central nervous system there are three main types of glia: microglia, 
astrocytes and oligodendrocytes. In the peripheral nervous system there are also 
three main types of glia: satellite glial cells (SGC), enteric glia and Schwann cells. In 
this introduction we focus on the myelinating cells of the nervous system; 
oligodendrocytes (OG) and Schwann cells (SC) [Figure 1.1] (Jessen, 2004). 
Oligodendrocytes are the myelinating cell of the central nervous system which 
originate from oligodendrocyte precursors. During myelin assembly oligodendrocytes 
send out between 20-60 processes, and selectively myelinate axons which have a 
diameter >0.2µm (Simons and Nave, 2015, Simons and Trajkovic, 2006). The myelin 
sheath formed by oligodendrocytes differs slightly in protein composition compared 
to that formed by Schwann cells [see Section 1.2]; the major myelin proteins are 
proteolipid protein (PLP) and myelin basic protein (MBP), which make up 60-80% of 
the total myelin proteins (Quarles et al., 2005). 
Schwann cells are subdivided into three main types; myelinating Schwann cells, non-
myelinating Schwann cells and terminal/presynaptic Schwann cells. Myelinating 
Schwann cells enwrap all large calibre (>1µm) axons in the peripheral nervous 
system. In contrast to oligodendrocytes, myelinating Schwann cells form a 1:1 ratio 
with axons, they then generate a myelin sheath that insulates the axon, allowing for 
saltatory conduction. Non-myelinating Schwann cells ensheath groups of small 
calibre (<1µm) sensory axons, where they form structures known as Remak bundles 
and provide trophic support to axons (Meier et al., 1999, Monk et al., 2015). 
Terminal/presynaptic Schwann cells, are non-myelinating cells located at the 
neuromuscular junction (NMJ), and cover entire synapses (Monk et al., 2015). 
Terminal/presynaptic Schwann cells express neurotransmitter receptors and help to 
20 
 
regulate synaptic transmission. In addition these cells providing trophic support to 
axons at the NMJ and have been suggested to be important for developmental 
synaptic rearrangement (Monk et al., 2015, Feng and Ko, 2008). 
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Figure 1. 1: Myelinating glia in the nervous system. (A) Oligodendrocytes (green) are the 
myelinating glial cell of the CNS, and wrap multiple axons (blue). (B) Myelinating Schwann 
cells (pink) are the myelinating glial of the PNS, and wrap only one large calibre (motor or 
sensory) axon. (C) Non-myelinating Schwann cells (orange) are present in the PNS, and are 
responsible for ensheathing multiple small calibre sensory axons, forming Remak bundles.  
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1.1 Structure of the myelin sheath 
The Schwann cell myelin sheath is a lipid rich plasma membrane that forms 
numerous wraps around the axon, enabling rapid saltatory conduction of action 
potentials. Schwann cells are suggested to wrap the axon by undergoing a series of 
polymerisation and de-polymerisation steps, resulting in an actin network at the 
leading edge of the Schwann cells inner membrane, enabling it to spread and extend 
around the axon until a multilayer, compacted membrane is formed (Samanta and 
Salzer, 2015). 
Schwann cell polarisation and wrapping of the axons results in the formation of 
distinct domains in the underlying axolemma; these include the internode, the 
juxtaparanode, the paranode, and the nodes of Ranvier [See Figure 1.2].  
The internodal region is the area directly beneath the compact myelin, and is the 
largest region of the myelinated axon reaching up to 1mm in length. The Schwann 
cell inner membrane and axonal membrane are separated at this point by the 
periaxonal space which is about 15 nm wide (Salzer et al., 2008). However, 
Schwann cell and axon interaction along the internode is mediated by a distinct 
subset of cell adhesion molecules which include Nectin-like (Necl) proteins [See 
section 1.4]  
The jutaxparanode is situated in-between the internode and the paranode, and lies 
just beneath the compact myelin. The juxtaparanode is enriched with potassium 
channels i.e. Kv 1. 1 and 1.2 which are thought to regulate the polarisation of action 
potentials. The Juxtaparanode is also composed of the adhesion molecules 
contactin associated protein 2 (caspr2) and the GPI-anchored adhesion molecule 
transient axonal glycoprotein 1 (TAB1); TAB1 which is expressed on the axon 
forming homophilic interactions with the Schwann cell expressed TAB1 on the glial 
paranodal loop, mediating axonal-Schwann cell contact (Salzer et al., 2008). 
Paranodes are specialised axon-glial junctions which are located either side of the 
nodes of Ranvier. At this region the Schwann cells and axonal membrane are at their 
closest point of contact at just 3-5nm apart. The paranodal junctions promote axonal-
Schwann cell adhesion and also provide a barrier that prevents ion diffusion between 
the internode and the nodes of Ranvier during action potential conduction (Salzer et 
al., 2008).  
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The nodes of Ranvier are regions of the axons which are unmyelinated. They are 
densely composed of voltage gated ion channels, predominantly sodium channels 
and are directly responsible for mediating the propagation of action potentials along 
the axon (Salzer et al., 2008). 
  
24 
 
 
 
Figure 1. 2: Structure of the Schwann cell myelin & axonal membrane: Myelinating 
Schwann cells organise the axonal membrane into polarised compartmental structures. 
Schwann cells cover a segment of the axon, termed the internode and organise the axon 
subcellular domains (Schafer and Rasband, 2006). The juxtaxparanodal region branches 
from the internodal region and contains numerous Kv1 channels. The paranodal junction 
separates the juxtaxparanodal region and the nodes of Ranvier and functions as an 
attachment site for myelin as a paracellular and membrane protein diffusion barrier. The 
paranodal junction is composed of axonal cell adhesion molecules; caspr and contactin 
which form cis-interactions with neurofascin-155 on the Schwann cell membrane forming a 
protein binding complex (Charles et al., 2002). Nodes of Ranvier are formed between the 
gaps of myelin sheath, voltage gated Na+ and K+ channels cluster at the nodes of Ranvier 
mediating the transmembrane currents necessary for saltatory nerve conduction (Rasband 
and Trimmer, 2001). Transmembrane cell adhesion molecules Nectin like (Necl) 1 and 2 are 
present along the internode and juxtaparanode, while Necl4 is expressed along the 
Schwann cell adaxonal membrane. Necl-1 and Necl-4 form heterophilic interactions at the 
axon-glial interface, which is critical for normal myelin formation (Maurel et al., 2007, Spiegel 
et al., 2007). The Schwann cell binding partner for Necl2 expressed on the axon remains 
unknown. The abaxonal domain (the outermost wrap of the myelin sheath) is in close 
contact with the basal lamina; a thin layer of highly organised extracellular matrix 
components synthesised by the Schwann cells. The adaxonal domain (the innermost wrap 
of the myelin sheath) is in close contact with the axolemma (axonal cell membrane). 
Cytoplasm-filled channels known as Schmidt Lantermann incisures (SLI), which occur 
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through the compact myelin, connect the adaxonal and abaxonal cytoplasm (Schafer and 
Rasband, 2006, Pereira et al., 2012).  
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1.2 Composition of myelin 
The myelin sheath is an extended plasma membrane that originates from the 
Schwann cell, and wraps around axons. Unlike other membranes which have a high 
protein: lipid ratio, the Schwann cell myelin sheath is composed of a high proportion 
of lipids (70-80%), and a lower proportion of proteins (20%-30%). This high lipid 
content is essential for the provision of electrical insulation (Garbay et al., 2000). It is 
widely accepted that myelin lipids form the lipid bilayer, while the myelin proteins are 
integrated into the lipid bilayers; where they can form homophilic interactions with 
apposing bilayers, linking them together to form compact layers of myelin (Quarles et 
al., 2005).  
In the peripheral nervous system, the myelin sheath contains a variety of different 
lipids, these include cholesterol (20-30% of total lipids), ethanolamine 
phospoglycerides (28-39% of total lipids), Sphingomyelin (10-35% of total lipids), 
cerebrosides (Gal-C) (14-26% of total lipids) and sulfatides (SGal-C) (2-7% of total 
lipids) (Garbay et al., 2000). The myelin sheath also comprises oleic acid (C18:1), 
which is the major fatty acid present in the myelin sheath, accounting for 30-40% of 
the fatty acid in the sciatic nerve (Garbay et al., 2000). 
The myelin sheath also contains a variety of proteins, these include structural and 
signalling compact myelin proteins; myelin protein zero (P0), myelin basic protein 
(MBP) and peripheral myelin protein 22 (PMP22), as well as non-compact myelin 
proteins; myelin-associated glycoprotein (MAG), periaxin (Prx) and connexin 32 
(Cx32) (Garbay et al., 2000). The expression of these myelin proteins is critical for 
the formation of stable myelin, as disruptions in their expression or function is often 
as associated with peripheral neuropathies such as Charcot-Marie-Tooth disease 
[discussed in section 1.9.1.1].  
1.2.1 Compact myelin proteins  
P0 is an integral type 1 membrane glycoprotein which serves as an early marker for 
the Schwann cell lineage (Bhattacharyya et al., 1991, Lee et al., 1997, Zhang et al., 
1995). It is highly expressed by myelinating Schwann cells and accounts for 50-70% 
of the total myelin proteins (Garbay et al., 2000, Poduslo et al., 1985, Poduslo et al., 
1995). P0 comprises a single transmembrane (TM) region, a positively charged 
intracellular domain and an extracellular N-terminal domain. P0 acts as a cell 
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adhesion molecule and plays a key role in myelin compaction by forming homophilic 
interactions between lipid bilayers, as well as myelin stability by forming heterophilic 
interactions that mediate the axon-Schwann cell interaction. Depletion of P0 in 
Schwann cells results in poorly compacted myelin, which is unstable and eventually 
demyelinates, resulting in hypomyelinated peripheral nerves (Giese et al., 1992). 
MBP is expressed by Schwann cells and oligodendrocytes. MBP represents roughly 
5-15% of the total myelin proteins in the PNS and is believed to participate in 
stabilising major dense lines (compacted cytoplasmic regions of Schwann cell 
myelin), stabilising the myelin sheath and also in maintaining the myelin structure, by 
interacting with myelin lipids and P0 (Privat et al., 1979, Martini et al., 1995, Quarles 
et al., 2005). The shiverer mouse which contain a 20kb deletion in the MBP gene, 
that results in MBP not being expressed (Roach et al., 1985), has been shown to 
exhibit uncontrolled shaking, due to the lack of MBP in the CNS (Privat et al., 1979, 
Readhead and Hood, 1990). In contract, the absence of MBP in the PNS 
(specifically within Schwann cells) does not appear to have any dramatic effects 
(Martini et al., 1995). Studies analysing the sciatic nerves of MBP null mice reported 
that axon diameter and myelin sheath formation is normal (Martini et al., 1995).  
PMP22 is a myelin protein with four hydrophobic transmembrane and two 
extracellular domains. It is almost exclusively expressed in compact myelin and 
accounts for 2-5% of the total myelin proteins in the PNS. PMP22 has been shown to 
form complexes with P0; an interaction which might be important for its function 
(D’Urso et al., 1999). Although the functional role of PMP22 in myelination is not 
clearly understood, PMP22 is important for Schwann cell myelination as both the 
depletion and overexpression of PMP22 in Schwann cells is associated with 
peripheral neuropathies such as Charcot-Marie-Tooth type 1A disease. PMP22 null 
mice demonstrate abnormally thick myelin sheaths which appear to cause axonal 
compression (Adlkofer et al., 1995). Nonetheless during adulthood the myelin 
degenerates, resulting in thinly myelin axons and onion bulbs (Adlkofer et al., 1995). 
Similarly, mice overexpressing PMP22 have been reported to exhibit myelin defects, 
characterised by severe hypomyelination and slow nerve conduction velocities 
(Magyar et al., 1996). 
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1.2.2 Non-compact myelin proteins 
MAG is a transmembrane glycoprotein located at the periaxonal membrane of both 
Schwann cells and oligodendrocytes, and represents 1% of the total proteins in the 
PNS. MAG is expressed in Schwann cells at the initial stages of myelination and 
interacts with axonal components; mediating Schwann-axonal contact (Quarles, 
2007). MAG is also expressed in the membranes of the Schmitt-Lanterman 
incisures, lateral loops and inner/outer mesaxons of the myelin sheath. There are 
currently no reported inherited neurological disorders caused by mutations in the 
MAG gene in humans (Quarles, 2007). However, studies carried out on MAG 
knockout mice have revealed that compact myelin formation during development is 
normal, although abnormalities in the periaxonal region of the myelin sheath were 
observed (Li et al., 1994, Montag et al., 1994). Furthermore, as these mice aged 
they appeared show signs of demyelination and eventually axonal degeneration 
(Quarles, 2007, Weiss et al., 2001, Yin et al., 1998). These studies thus suggest that 
MAG plays a role in organising the periaxonal space and acts as a ligand in the 
myelin sheath that binds to the axon receptor to maintain normal myelination and 
axonal structure. (Quarles, 2007).  
Periaxin (Prx) is predominantly expressed at the adaxonal membrane during 
Schwann cell axonal ensheathment, but then shifts to the abaxonal membrane as 
Schwann cells myelinate, where it acts to stabilize the formation of Cajal bands 
(Gillespie et al., 1994, Scherer et al., 1995b, Court et al., 2004). Cajal bands are 
cytoplasmic channels that form in-between the outermost Schwann cell myelin wrap. 
Depletion of Prx in mice does not impair myelination, however results in the 
formation of unstable myelin, which eventually degrades during adulthood resulting 
in hypomyelination and slow nerve conduction velocities (Gillespie et al., 2000). Prx 
is therefore suggested to play an important role in establishing stable myelin units.  
Cx32 is a gap junction protein predominantly located within the Schmidt-Lanterman 
incisures and at the paranodes, where it functions as an intracellular channel 
allowing cytoplasmic continuity and ion diffusion across the myelin sheath (Ressot 
and Bruzzone, 2000). Cx32 is expressed in parallel with the myelinating phenotype 
and believed to play a role in myelin maintenance (Scherer et al., 1995a). Depletion 
or mutations in Cx32 are known to cause Schwann cell demyelination and is related 
to Charcot-Marie-Tooth type 1X (Scherer et al., 1995a).  
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1.3 Schwann cell development  
Schwann cells of the peripheral nervous system originate from neural crest cells 
(NCC) via two intermediate cell types; the first, the Schwann cell precursor and the 
second, the immature Schwann cell. Unlike non-myelinating Schwann cells, in order 
to form mature myelinating Schwann cells, NCC must undergo transition through 
three intermediate cell types, the third being the promyelinating Schwann cell (Mirsky 
et al., 2002). NCC arise from the neural crest at the dorsal neural tube and are 
specified and maintained by a network of regulatory genes including Snail, Sox8, 
Myc, Sox9, FoxD3, Slug and Sox10 (Jacob, 2015, O'Donnell et al., 2006, Aybar et 
al., 2003). While it’s important that the expression of these genes is upregulated for 
NCC specification, it is also important that the expression of genes shown to 
negatively regulate NCC specification are downregulated, these genes include Sox2 
and Kctd15 (Jacob, 2015). Kctd15 interacts with activating enhancer-binding protein 
2α (AP-2α) - a transcription factor required for Sox9 activated expression that inhibits 
its activity and therefore NCC formation (Jacob, 2015, Zarelli and Dawid, 2013). 
Upon separating from the dorsal neural tube, NCC migrate through distinct pathways 
and give rise to a wide range of cell types, including melanocytes in the skin, 
neurons and glial cells; satellite glia, enteric glia and Schwann cells in the peripheral 
nervous system (PNS) (Wakamatsu et al., 2000, Monk et al., 2015, Mirsky and 
Jessen, 1999). The transition of NCC along the Schwann cell lineage into Schwann 
cell precursors occurs between embryonic day 15 to 16 (E15-16) during rat Schwann 
cell development (mouse E12-14), and is primarily mediated by the maintained 
expression of Sox10 (sex determining region Y (SRY) box 10) [discussed further in 
section 1.5.1]. Sox10 is one of the earliest transcription factors expressed in NCC, 
and essential for NCC survival, maintenance of pluripotency and peripheral glia 
specification (Britsch et al., 2001, Finzsch et al., 2010). Sox10 also induces the 
expression of neuregulin-1 receptor ErbB3, which is activated by the upregulated 
expression of neuregulin-1, causing NCC to favour peripheral glia specification 
(Shah et al., 1994, Prasad et al., 2011, Jacob, 2015). Notch signalling also plays an 
important role in the specification of peripheral glia over neuronal differentiation 
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(Wakamatsu et al., 2000). More recently, chromatin remodelling enzymes histone 
deacetylases 1 and 2 (HDAC 1/2) were identified to be essential for the regulation of 
Schwann cell specification from neural crest cells, through their ability to induce 
Pax3 expression in NCCs (Jacob et al., 2014). In turn Pax3 acts to maintain high 
Sox10 levels and to induce the expression of peripheral glial proteins, fatty acid 
binding protein 7 (FABP7) and Protein zero (P0) (Jacob et al., 2014).  
Schwann cell precursors (SCPs) are specifically marked by the upregulated 
expression of cadherin 19 and like NCC they are migratory and proliferative 
(Takahashi and Osumi, 2005, Monk et al., 2015). SCP co-migrate with axons in the 
developing PNS, and are highly dependent on the axonal derive signal NRG1 which 
signals via ErbB2/ErbB3 tyrosine kinase receptors on precursor cells for survival. 
The reliance of Schwann cell precursors on close contact with axons for survival has 
been proposed to help match precursor numbers to axon numbers, and thus prevent 
the survival of SCPs that have strayed away from axons (Jessen et al., 1994, Mirsky 
and Jessen, 1999). In addition to mediating SCP survival, NRG1 further regulates 
SCP proliferation and migration, as well as SCP maturation, which is co-operatively 
regulated by fibroblast growth factor (FGF) (Dong et al., 1995, Dong et al., 1999, 
Jessen and Mirsky, 2005). 
Between E16 and E17 in rats (E14 and E15 in mice), SCPs cease migration and 
begin transition into immature Schwann cells (ISCs), a process driven further by 
Notch signalling. Enforced Notch signalling in vivo accelerates the transition of SCP 
to ISCs, driving the increased expression of S100β (calcium binding protein) and the 
lipid surface antigen O4, while also suppressing the expression of AP2α; a negative 
regulator of the SCP-ISC transition process (Stewart et al., 2001, Woodhoo et al., 
2009). Like AP2α, endothelins are upregulated in SCP helping to support survival, 
nonetheless sustained expression of endothelins acts to delay SCP development by 
antagonising the maturation effect of β-neuregulin. The expression of endothelins 
must therefore be downregulated for the timely transition of SCPs-ISCs (Brennan et 
al., 2000).  
Immature Schwann cells, are markedly different from SCPs, they are capable of 
mediating their own survival and proliferation in the absence of axons, by secreting 
autocrine growth factors such as neurotrophin-3, insulin-like growth factor (IGF) and 
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platelet-derived growth factor-BB (PDGF-BB) (Meier et al., 1999). Furthermore 
immature Schwann cells mediate radial axonal sorting; a process whereby Schwann 
cells separate large diameter axons (>1 µm) destined to become myelinated, from 
small diameter axons (<1 µm) that will remain non-myelinated and are organised into 
Remak bundles [see Figure 1.3].  
Radial sorting of axons occurs perinatally and proceeds until about postnatal day 10 
(P10) in rodent peripheral nerves (Feltri et al., 2015). Schwann cells initially deposit 
their basal lamina around groups of mixed calibre axons forming Schwann cell and 
axon “families”, this process is then followed by Schwann cells sending out 
cytoplasmic processes that resemble lamellipodia into the axon bundles where they 
selectively separate out large calibre axons, principally A and B fibres such as motor 
axons and Aδ sensory fibres to the periphery (Feltri et al., 2015, Webster et al., 
1973). Upon contact with large calibre axons, immature Schwann cells transition into 
the promyelin stage, marked by the expression of octamer 6 (Oct6) and establish a 
1:1 axon-promyelinating Schwann cell relationship; for Schwann cells to match axon 
numbers, they undergo progressive proliferation (Jessen and Mirsky, 2005, Webster 
et al., 1973). Promyelinating Schwann cells then differentiate into myelinating 
Schwann cells, a process regulated by axonal signalling and the activation of myelin 
regulatory transcription factors (Feltri et al., 2015). The remaining small calibre axons 
are ensheathed by immature Schwann cells, which differentiate into non-myelinating 
Schwann cells forming Remak Bundles.  
Abnormalities or impairments in axonal sorting have been shown to result in 
morphological abnormalities in the peripheral nerve. Firstly, if SCPs fail to migrate 
along axons, proliferate, survive and generate immature Schwann cells, this causes 
a complete arrest of radial sorting at the first stage and consequently the majority of 
axons remain naked. Secondly, if immature Schwann cells fail to deposit basal 
lamina or to interact properly with axons, this can result in the failure of Schwann 
cells to appropriately sort axons, resulting in abnormities (Feltri et al., 2015). Three 
categories for axon abnormalities have been established: (1) Radial sorting 
arrest/delay; resulting in Schwann cells surrounding large bundles of mixed calibre 
axons, (2) polyaxonal myelination; caused due to premature differentiation of 
Schwann cells before completion of radial sorting and results in Schwann cells 
myelinating multiple axons, (3) Abnormal ensheathment of Remak bundles; non-
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myelinating Schwann cells ensheath bundles of small and large calibre axons (Feltri 
et al., 2015).  
The Rho GTPase family members Rac1 and Cdc42 have been shown to play a 
fundamental role in radial sorting, through regulating the activation of NF2  (Guo et 
al., 2012, Guo et al., 2013, Benninger et al., 2007).  Rac1 has been shown to 
regulate immature Schwann cell process extensions required for the sorting of 
axons. In Rac1 null mice immature Schwann cells demonstrate defective 
cytoplasmic processes that extended in various directions and often failed to 
envelope axon bundles (Benninger et al., 2007). Cdc42 null mice also demonstrate 
defective radial sorting, as numerous abnormally large axon bundles containing 
unsorted small, medium and large axons are observed in the sciatic nerves of these 
animals (Benninger et al., 2007, Guo et al., 2013). By postnatal day 30 (P30) these 
mice further showed hind limb dysfunction with abnormal clasping (Guo et al., 2013). 
Nonetheless, in both Rac1 and Cdc42 null mice, depletion of NF2 (a tumour 
suppressor gene) rescued the radial sorting and myelination defect, therefore 
demonstrating that Rac1 and Cdc42 regulation of NF2 activation is essential for 
normal radial sorting (Guo et al., 2012, Guo et al., 2013).  
β1 integrin a Schwann cell laminin receptor, has also be shown to play a 
fundamental role in radial sorting (Feltri et al., 2002). β1 integrin null Schwann cells 
develop normally but fail to maintain and extend normal processes around axons, 
similar to that observed in Rac1 null mice (Benninger et al., 2007, Feltri et al., 2002). 
Rac1 was later revealed to drive radial sorting through regulating Schwann cell 
process formation and extension downstream of β1 intergrin (Nodari et al., 2007).  
Many additional proteins including laminins (laminin α2, laminin α4 and laminin ϒ1), 
surface receptor proteins ErbB2 and ErbB3 and cell signalling molecules Jab1 and 
β-catenin have been shown to regulate radial sorting, as disruptions in their 
expression has been shown to cause radial sorting defects during development, 
impaired Schwann cell myelination and the onset of a peripheral neuropathy 
(Reviewed by Feltri et al., 2015). Correct radial sorting at all stages is therefore 
required for Schwann cell myelination and normal function of the peripheral nervous 
system. 
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Figure 1. 3: Schwann cell lineage and factors involved in development. Schematic 
illustration of the main cell types Schwann cells transition through and the molecules 
expressed during development. (A) Migrating neural crest cells transition to (B) Schwann cell 
precursors. Schwann cell precursors thereafter transition to (C) immature Schwann cells 
which then differentiate into two subpopulations of Schwann cells; (D) Promyelinating 
Schwann cells which associate with large diameter axons in a 1:1 ratio, and further transition 
into (E) myelinating Schwann cells, or (F) non-myelinating Schwann cells which ensheath 
groups of small diameter axons, forming Remak bundles. (G) Following nerve injury 
myelinating and non-myelinating Schwann cells transiently differentiate into Repair Schwann 
cells to support nerve repair and regeneration. Adapted from (Jessen and Mirsky, 2005). 
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1.4 Axonal myelination signalling  
Schwann cell myelination and myelin maintenance is dependent upon axonal 
contact, and influenced by axonal diameter, electrical activity and axonal signalling  
(Taveggia et al., 2010). Importantly axonal cues trigger Schwann cell myelination by 
signalling through specific Schwann cell receptors. Current literature suggests that 
Prohibitin 2 expression, Nectin like (Necl) signalling, G-protein coupled receptor 126 
(Gpr126) signalling, and Neuregulin-ErbB signalling play fundamental roles in this 
process (Salzer, 2012, Poitelon et al., 2015). 
Axon-Schwann cell contact is vital for the initiation of Schwann cell myelination, in 
order for Schwann cells to initially contact axons they must respond and polarise 
towards axonal signals. Schwann cells have been shown to polarise their 
cytoplasmic processes (which are formed by microtule and filament structures) 
termed pseudopods, upon Schwann cell-axon contact in response to juxtacrine 
signals from the axonal membrane. Prohibitin 2, a mitochondrial protein, was 
recently identified as a novel molecule expressed in Schwann cell pseudopods (in 
mitochondria and at the cell membrane) and shown to mediate axon-glial contact 
(Poitelon et al., 2015). Blocking Prohibitin 2 expression in Schwann cells (through 
shRNA viral infection), was shown to impair their ability to attach to neurons, in 
Schwann cell-DRG neuronal co-cultures (Poitelon et al., 2015). Moreover, 
experiments carried out on conditional Prohibitin 2 null mice (P0 Cre+; Phb2fl/fl) 
revealed that these mice demonstrated impaired radial sorting, hypomyelination of 
axons and severe motor deficit (Ibid). This study by Poitelon et al. (2015) thus 
highlights how Prohibitin2 expression in Schwann cell pseudopods is essential for 
Schwann cell-axon contact during development and for normal myelination.  
Schwann cells express a number of cell adhesion and recognition molecules on their 
surface that mediates their association with axons. Nectin-like (Necls) cell adhesion 
molecules have been shown to play a fundamental role in the interaction of axons 
and Schwann cells, as well as the initiation of normal myelin formation (Maurel et al., 
2007, Spiegel et al., 2007, Golan et al., 2013). Necls are members of the 
immunoglobulin superfamily of cell adhesions molecules, and consist of five different 
members Necl1, Necl2, Necl3, Necl4 and Necl5 (Maurel et al., 2007). Necl2 and 4 
are expressed in Schwann cell membranes, principally at the internodal region and 
the Schmidt-Lanterman incisures, while Necl2 and Necl1 are expressed by axons. 
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Necl4 acts as a glial binding partner for axonal Necl1 at the internode, mediating 
normal Schwann cell-axon interaction and the distribution of ion channels along 
axons (Maurel et al., 2007, Spiegel et al., 2007, Golan et al., 2013). Necl4 
expression was further shown to be required for the proper establishment of 
myelinated axons and for the organisation of the underlying axonal membrane. In 
vitro experiments revealed that knockdown of Necl4 by short hairpin RNA, resulted in 
a striking inhibition of Schwann cell myelination in Schwann cell-DRG co-cultures. 
Furthermore, the expression of Oct6, a transcription factor expressed by 
promyelinating Schwann cells and Krüppel box 20 (Krox20), a transcription factor 
essential for regulating myelination was dramatically inhibited in these co-cultures 
(Maurel et al., 2007). In vivo studies using Schwann cells specific Necl4 null mice 
experiments further confirmed the importance of Necl4 in Schwann-axon interaction 
and myelination, however they revealed that the role of Necl4 in vivo, differs from 
that previously identified in earlier in vitro studies (Maurel et al., 2007, Spiegel et al., 
2007, Golan et al., 2013). Rather than being hypomyelinated, as expected from the 
earlier studies (Maurel et al., 2007, Spiegel et al., 2007), axons in the nerves of 
Necl4 null mice were hypermyelinated, and displayed a range of myelin 
abnormalities including myelin outfolds, myelin degeneration and the displacement of 
axons. The correct organisation and compartmentalisation of the axonal membrane 
i.e. the localisation of molecular proteins such as Caspr (a specific marker of the 
paranode) and ion channels was disrupted [See Figure 1.2], and mice showed a 
phenotype Charcot Marie Tooth neuropathy [See section 1.9.1.1] (Golan et al., 
2013). Necl4 thus plays a fundamental role in establishing axon-Schwann cell 
interaction, proper myelin formation and the correct organisation of the axonal 
membrane. 
Expression of the adhesion Gpr126 is required autonomously in Schwann cells for 
Schwann cell myelination (Monk et al., 2009, Mogha et al., 2013) and for the 
formation of normal Remak fibres (Monk et al., 2011, Mogha et al., 2013). In 
embryonic zebrafish and mice, the depletion of Gpr126 resulted in the failure of 
Schwann cells to upregulate the expression of the promyelination transcription 
factors Oct6 and Krox20 and to myelinate axons. Schwann cells thus appeared to be 
arrested at the promyelinating stage (Monk et al., 2009, Mogha et al., 2013). 
Furthermore, Gpr126 mutant mice demonstrated delays in radial sorting, a significant 
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increase the number of axons per Remak bundle and aberrant abaxonal cytoplasmic 
protrusions (Monk et al., 2011, Mogha et al., 2013). Treatment with the adenyl 
cyclase activator forskolin was shown to rescue the myelination defects observed in 
Gpr126st49 mutant zebrafish in vivo (Monk et al., 2009), and in Schwann cells 
cultured from Gpr126 null mice (Mogha et al., 2013). These experiments thus 
suggest that Gpr126 regulates myelination by activating adenyl cyclase or raising 
intracellular cAMP. More recent experiments have revealed that Gpr126 is capable 
of directly elevating cAMP levels in COS-7 cells, by coupling with Gi-proteins and Gs 
proteins (Mogha et al., 2013). Thus the suggested mechanism by which Gpr126 
regulates Schwann cell myelination, is through interactions with G proteins causing 
elevation of cAMP levels (Mogha et al., 2013). Recent studies carried out in vitro 
have further identified that Gpr126 is activated through binding to collagen IV 
(Paavola et al., 2014), as well as laminin-211 (Petersen et al., 2015), which are both 
expressed in the Schwann cell basal lamina (Monk et al., 2015, Petersen et al., 
2015). The interaction of Gpr126 with either collagen IV or laminin-211 has been 
shown to facilitate radial sorting and Schwann cell myelination (Paavola et al., 2014, 
Petersen et al., 2015) 
One of the major axonal signalling molecules that regulates the formation of 
myelinating and non-myelinating Schwann cells is neuregulin-1, an epidermal growth 
factor-like ligand. The neuregulin-1 (NRG-1) family comprises more than 15 
membrane-associated and secreted protein isoforms, all of which share an 
epidermal growth (EGF)-like signalling domain required for the activation of their 
receptors (Nave and Salzer, 2006). The NRG-1 protein isoforms have been 
subdivided into several subtypes (NRG1 type I-VII), on the basis of their distinct 
amino-termini. In the nervous system NRG1 type I (NRG1-I) and NRG1-III are the 
most abundant, and in addition to NRG1-II, play a direct role in mediating Schwann 
cell myelination (Nave and Salzer, 2006). 
NRG1-I (also known as heregulin, neu differentiation factor) and NRG1-II (also 
known as glial growth factor) have N-terminal immunoglobulin-like domains. In order 
for these transmembrane forms of NRG1-I and II to signal, they must undergo 
proteolytic cleavage by the metalloproteinases tumour necrosis factor-α-converting 
enzyme (TACE), ADAM19 (β-meltrin) or beta amyloid precursor protein–cleaving 
enzyme1 (BACE1), which causes release of the extracellular signalling domain, 
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enabling it to act as a soluble signal in a paracrine manner (Horiuchi et al., 2005, 
Nave and Salzer, 2006). Unlike NRG1-I and NRG1-II, NRG1-III contains a cysteine 
rich domain (CRD) which acts as a second transmembrane domain, thus following 
cleavage by BACE1 the protein remains tethered to the cell membrane (Velanac et 
al., 2012). NRG1-III therefore serves as a juxtacrine axonal signal. While NRG1-I 
does not appear to play an essential role in Schwann cell myelination during 
development, Schwann cell derived soluble NRG1-I expression has been shown to 
be important for Schwann cell redifferentiation and remyelination following nerve 
injury (Stassart et al., 2013). Following nerve injury, poor Schwann cell remyelination 
and a decrease in the number of redifferentiated Schwann cells was observed in 
mice lacking NRG1-I specifically in Schwann cells (Stassart et al., 2013). NRG1-III 
on the other hand, is the key regulator of peripheral nerve myelination during 
development; it determines the myelinating phenotype and matches myelin thickness 
to axon calibre (Monk et al., 2015, Nave and Salzer, 2006, Taveggia et al., 2005). 
Previous studies have shown that Schwann cells cultured with NRG1-III null neurons 
failed to myelinate and express myelin proteins, while the overexpression of NRG1-
III in Schwann cells enhanced myelin formation (Taveggia et al., 2005). NRG1-III is 
also important for Schwann cell remyelination after injury; it acts to accelerate the 
rate of remyelination and functional recovery at early time-points post injury (Fricker 
et al., 2013). In the absence of axonal NRG1-III Schwann cell remyelination was 
severely delayed, with axon not reaching full remyelinate until 3 months post injury 
(Fricker et al., 2013). 
  
Expression levels of NRG1-III on neurons have further been shown to differ, 
depending on the size and type of neurons; small diameter sensory axons (C-fibre) 
express minimal levels of NRG1-III, whereas large diameter motor and Aδ fibres 
express much higher levels (Taveggia et al., 2005). The levels of NRG1-III 
expressed on the neurons, thus dictates to the Schwann cell its myelin phenotype; 
high levels of NRG1-III drive Schwann cells to myelination, while low levels cause 
Schwann cells to undertake a non-myelinating phenotype. Nonetheless, increasing 
NRG1-III levels in small diameter sensory neurons which are normally unmyelinated, 
has been shown to result in a myelinated axon fate (Taveggia et al., 2005). While 
NRG1-III signalling in large diameter axon is essential for driving Schwann cell 
myelination and normal myelin formation, NRG1-III signalling in small diameter 
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axons is also important. It has been shown to be critical for proper radial sorting of 
axons, the complete ensheathment of small diameter axons by non-myelinating 
Schwann cells, the formation of normal sized Remak bundles and thus normal 
sensory function (Taveggia et al., 2005, Fricker et al., 2009). 
NRGs signal via the epidermal growth factor (EGF) family of receptor tyrosine 
kinases, comprising ErbB1, ErbB2, ErbB3 and ErbB4. Schwann cells express ErbB3 
and ErbB2 receptors which form heterodimers on NRG1 binding to ErbB3. ErbB2 
thereafter triggers the activation of a complex sequence of signalling events that 
mediate myelination (Birchmeier and Nave, 2008). NRG1/ErbB signalling is 
absolutely essential for Schwann cell development and myelination, as the absence 
of ErbB2 in Schwann cells results in the formation of abnormally thin myelin sheaths 
and low expression levels of myelin proteins protein zero (P0) and peripheral myelin 
protein 22 (PMP22) (Garratt et al., 2000).  
Recent studies have highlighted that the NRG1/ErbB signalling in Schwann cells can 
activate multiple downstream signalling events, including the activation of 
calcineurin, Ying Yang 1 (YYI), PI3K (phosphoinositide 3 Kinase) and MAPK 
(mitogen-activated protein kinase)/ERK signalling pathways [See Figure 1.4] 
(Krishnan, 2013, He et al., 2010).  
Calcineurin-NFATc3/4 
Calcineurin is a calcium sensitive serine/threonine protein phosphatase with 2 
catalytic subunits; Calcineurin A (CnA), the catalytic domain and Calcineurin B 
(CnB), the essential catalytic regulatory domain (Rusnak and Mertz, 2000). NRG1 
has been suggested to induce phospholipase C-ʏ (PLC-ʏ)-dependent Ca2+ influx into 
Schwann cells, which in turn causes activation of cytoplasmic calcineurin. 
Calcineurin thereafter promotes de-phosphorylation of NFATc3 and NFATc4, 
enabling their translocate to the nucleus where they binds to DNA, to drive the 
transcriptional gene expression (Kao et al., 2009). Schwann cells express NFATc3 
and NFATc4, which fail to become activated in CnB1 depleted mice; resulting in 
reduced Krox20 and myelin protein expression, along with Schwann cell 
hypomyelination (Kao et al., 2009). In vitro experiments revealed that NFATc3 and 
NFATc4 translocate to the nucleus upon activation, where they synergise with Sox10 
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to drive the transcriptional gene expression of Krox20 and P0, a process which was 
also shown to be blocked by Sox2 (Kao et al., 2009). 
In vitro experiments by Kipanyula et al. (2013) further revealed that the calcineurin-
NFAT signalling pathways are important for potentiating Schwann cell myelination 
and Krox20 expression in response to cAMP. While activation of the calcineurin-
NFAT pathway alone by elevating Ca2+ concentrations is insufficient to drive 
myelination, cAMP treatment alone is sufficient to drive normal Schwann cell 
myelination. Additionally, Schwann cell myelination is further enhanced and the 
expression levels of Krox20 and myelin proteins periaxin and P0 are increased in the 
presence of cAMP, when the calcineurin-NFAT pathway is activated (Kipanyula et 
al., 2013). 
 
Activation of the zinc finger transcription factor Ying Yang 1 (YY1), a downstream 
effector of NRG1 has also been shown to be crucial for Schwann cell myelination 
(He et al., 2010). Conditional Schwann cell deletion of YYI in mice was shown to 
result in severe hypomyelination of the sciatic nerves and failure of Schwann cells to 
express high levels of Krox20 and myelin proteins. Nonetheless this myelin defect 
was shown to be rescued by the enforced expression of Krox20 in Schwann cells 
cultured from the sciatic nerves of YY1 null mice, as the percentage of P0
+ cells was 
restored to normal. Further experiments by He et al. (2010) revealed that soluble 
NRG1 stimulates MEK dependent phosphorylation of YY1 on serine118, serine184 and 
serine247, which in turn promotes the binding of YY1 to the Krox20 promoter and 
MSE (myelinating Schwann cell enhancer) region, where it drives Krox20 
transcriptional activation in cultured Schwann cells (Ogata et al., 2004) 
PI3kinase/Akt  
The phosphatidylinositol-3-kinase (PI3K) is composed of two subunits, the adaptor 
subunit p85 and the catalytic subunit p110, and has been shown to be robustly 
activated in Schwann cells upon NRG1 signalling via the ErbB2/3 receptors 
(Taveggia et al., 2005, Maurel and Salzer, 2000). The PI3 kinase signalling pathway, 
phosphorylates and actives the serine-threonine kinases Akt and mTOR, which go 
onto stimulate downstream molecules that drive myelination (Goebbels et al., 2012). 
Impairing the PI3K signalling pathways in Schwann cells, by either treating Schwann 
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cell/DRG co-cultures with a PI3K signalling inhibitor (LY294002) or infecting 
Schwann cells with an adenovirus carrying a dominant negative mutant of the 
regulatory subunit p85 (Ax-p85DN), was shown to block the initiation of Schwann cell 
myelination and reduce the expression of myelin associated glycoprotein (MAG) 
(Ogata et al., 2004, Maurel and Salzer, 2000). Further experiments also revealed 
that overexpression of PI3K or activated Akt signalling, significantly enhanced myelin 
protein expression in Schwann cell/DRG neuronal co-cultures, in addition to 
enhancing myelin sheath formation during regeneration in vivo (Ogata et al., 2004). 
Recent gain of function studies in vivo have extended earlier findings. Mice 
conditionally depleted of phosphatase and tensin homolog (Pten); a lipid 
phosphatase, which antagonises PI3K signalling, demonstrate increased activation 
of the PI3K signalling pathways. This was shown to result in Schwann cell 
hypermyelination and myelin abnormalities in non-compacted regions; focal myelin 
thickening in paranodal regions and Schmidt-lantermann incisures (Goebbels et al., 
2012). The PI3K-Akt pathway has thus been shown to be a driver of myelination and 
a direct target of NRG1 signalling. 
ERK 
Extracellular signal-related kinase (ERK) is a mitogen activated protein kinase 
(MAPK) signalling pathway capable of regulating both cell differentiation and 
proliferation. The classical activation of ERK 1/2 signalling is triggered by the 
sequential phosphorylation and activation of RAS-RAF-MEK 1/2. 
In Schwann cells the ERK 1/2 signalling pathway has been shown to exert two 
opposing functions in a context dependent manner; (1) to drive Schwann cell 
differentiation and myelination during development and (2) to promote demyelination 
and inhibit myelin formation following nerve injury [discussed in section 1.6.4].  
During Schwann cell development NRG1 dramatically increases the activation of the 
MAPK ERK 1/2 signalling pathway. While activation of this pathway was originally 
thought to be redundant during Schwann cell development (Maurel and Salzer, 
2000), recent in vivo studies using conditional ERK 1/2 double null mice have shown 
that ERK1/2 signalling is essential for the progression of immature Schwann cells to 
a myelinating state (Newbern et al., 2011). A significant decrease in the gene and 
protein expression of Krox20 was observed in the nerves of ERK 1/2 double null 
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mice, along with a striking reduction in the number of myelinated axons and an 
increase in the number of unmyelinated axons (Newbern et al., 2011). Furthermore, 
ERK 1/2 was shown to be a necessary downstream transducer of NRG1/ErbB 
signals, as loss of ERK 1/2 in glial progenitor cells blocks the survival effects of 
NRG1 in vitro (Newbern et al., 2011). 
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Figure 1. 4: Activated signalling pathways during Schwann cell myelination. Axonal 
Neuregulin1-type III (NRG1-III) binds to the ErbB3 receptor on Schwann cells. This leads to 
the activation of the ErbB2/3 receptor complex, which subsequently activates a variety of 
downstream pathways. These include activation of ERK 1/2 signalling, activation of YY1 
through phosphorylation by MEK 1/2, and the activation of NFATc3/4 via calcineurin induced 
dephosphorylation. G-coupled protein receptor (Gpr) 126, is activated by either collagen IV 
or laminin 211 (Monk et al., 2015), it thereon functions to elevated levels of cAMP, which 
activates its main target protein kinase A (PKA), in addition to directly activating Krox20 
expression. PKA can phosphorylate and activate both the cAMP response element binding 
protein (P-CREB) and NF-KB, both of which activate Oct6 (Monk et al., 2009, Svaren and 
Meijer, 2008). Oct6 is also enhanced by Sox10, which bind to the Oct6 SCE region. During 
embryonic development, Sox10 has been shown to be activated/upregulated in the neural 
crest cells by many proteins, including Slug, Snail, Notch, Pax3, FoxD3, cMyc and Sox9 
(Jacob, 2015), where it then continues to be expressed throughout Schwann cell 
development. Together YY1, NFATc3/4, Oct6 and Sox10 have been shown to promote 
Krox20 transcriptional expression by binding to the Krox20 MSE region. ERK 1/2 has been 
shown to influence Krox20 expression, however the mechanism is not known (Newbern et 
al., 2011). Activation of Krox20 is essential as it goes on to induce the expression of proteins 
and enzymes required for myelination (Nagarajan et al., 2001).   
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1.5 Positive myelin regulators during Schwann cell development 
Schwann cell myelination is tightly controlled by key positive and negative 
transcriptional regulators. Positive myelin regulators drive Schwann cells along the 
myelinating lineage, and activate the expression of myelin associated gene, whilst 
also acting to suppress the expression and activity of negative regulators [Section 
1.6]. Sox10, Oct6 and Krox20 have been identified as key positive transcriptional 
regulators and are discussed below (Jessen and Mirsky, 2008). 
1.5.1 Sox10 
Sox10 (SRY related box 10) is a high mobility group (HMG) domain transcription 
factor, and a member of the SoxE subgroup of Sox proteins. Sox proteins of the 
same group have at least 80% sequence similarly in their DNA-binding HMG domain 
(Wegner, 2010). The Sox10 protein contains a HMG domain, two activation domains 
(K2 and Transactivation (TA) domain) as well as a DNA dependent dimerization 
domain, which enables Sox10 to dimerize either side of a DNA sequence 
(Barrionuevo and Scherer, 2010). All Sox proteins have been shown to bind to a 
common 7 base pair (bp) consensus motif ‘(A/T)(A/T)CAA(A/T)G-3’ in DNA. To help 
ensure that specific Sox proteins bind to different gene sequences and are not 
competing for the same regions, flanking sequences located in front of and after the 
consensus motif have been show to aid binding specificity. In particular SoxE 
proteins bind preferentially to sequences with AG in the 5’ flank and G or GG in the 
3’ flank (Wegner, 2010). On recognition of the DNA sequence, Sox transcription 
factors bind to the minor grooves of the DNA, causing the grooves to widen and the 
DNA to bend. It is speculated that this DNA bending enables the Sox proteins to 
exert  their regulatory function (Kamachi and Kondoh, 2013).  
Sox10 is a major neural crest regulator and has been shown to be activated in a 
Sox9 dependent manner (Betancur et al., 2010). Its expression is critical for the 
specification of neural crest cells into peripheral glia and melanocytes (Britsch et al., 
2001, Schreiner et al., 2007). Following peripheral glia specification Sox10 continues 
to be expression in Schwann cells where it functions to regulated Schwann cell 
development, myelination and myelin maintenance (Kuhlbrodt et al., 1998, Finzsch 
et al., 2010). Loss of Sox10 in neural crest cells has been shown to block 
specification into Schwann cell precursors, resulting in a complete lack of Schwann 
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cells in the PNS (Britsch et al., 2001). Sox10 has also been shown to be essential for 
the normal expression of ErbB3 receptor in neural crest cells, as in Sox10 null mice 
erbB3 expression was reduced. As mentioned earlier in section 1.4, ErbB3 is 
essential for NRG1 signalling during Schwann cell development (Britisch et al., 
2001). Loss of Sox10 in developing embryonic Schwann cells was further shown to 
block Schwann cells from differentiating beyond the immature Schwann cell stage. 
Sox10 null mice failed to upregulate Oct6 (a key transcription factor required for 
driving the transition of immature Schwann cells to the promyelinating stage), Krox20 
(a master regulator of myelination) and the gene expression of P0 and MBP (Finzsch 
et al., 2010). More recent studies have confirmed that Sox10 plays an essential role 
in activating the expression of the two key Schwann cell transcription factor Oct6 
(Jagalur et al., 2011) and Krox20 (Reiprich et al., 2010), as well as the expression of 
myelin proteins P0, periaxin and PMP22 (Schreiner et al., 2007, Srinivasan et al., 
2012). Whilst Sox10 is essential for the progression of Schwann cells to the 
myelinating phenotype and the expression of myelin regulatory genes and proteins, 
its continued expression in Schwann cells is critical for myelin maintenance (Bremer 
et al., 2011). Depletion of Sox10 in adult myelinating Schwann cells was shown to 
result in Schwann cell myelin loss and dedifferentiation (Bremer et al., 2011).   
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Figure 1. 5: Sox proteins family homology and partner binding. (A) Diagram of the key 
functional domains of Sox10 (Class E), Sox9 (Class E) and Sox2 (Class B1). The functional 
domains consist of the dimerization domain (Db, green), the 79 amino acid high mobility 
group (HMG, blue), the weak activation domain (WA or K2, orange) and the transactivation 
domain (TA, yellow). The percentage figures demonstrate the similarities of the domains 
compared to Sox10. Numbers above the domains illustrate amino acid residue counting from 
the N-terminus. (B) Schematic representative of DNA binding and the requirement of Sox-
partner complex;  Sox proteins are important for the activation or repression of specific 
genes, in order for Sox proteins to exert gene regulatory functions, they are generally 
required to form complexes with partner transcription factors. Binding of Sox proteins to DNA 
alone does not usually lead to transcriptional activation or repression, thus functional Sox 
binding sites are commonly accompanied by a second binding site for partner proteins.  In 
Schwann cells Sox10, has been shown to partner with Oct6, Krox20 and NFATc3/4. Whilst 
Sox2 has been shown to partner with Oct4 in embryonic stem cells and Pax6 during lens 
development (Kamachi and Kondoh, 2013). Adapted from (Barrionuevo and Scherer, 2010, 
Kamachi and Kondoh, 2013).   
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1.5.2 Oct 6 
Oct6 (also known as suppressed cAMP inducible protein (SCIP)) is a class III POU 
domain transcription factor transiently expressed in Schwann cells. The POU domain 
(named after three transcription factors Pit, Oct, and Unc) is a conserved bipartite 
DNA binding domain composed of two subunits; the POU-specific domain and the 
POU-homeodomain, which catalyse high affinity site-specific DNA binding (Verrijzer 
and Van der Vliet, 1993).  
Oct6 is initially expressed in immature Schwann cells, its expression then peaks 
during the promyelin Schwann cell stage, where it acts to regulate the onset of 
myelination (Jaegle et al., 2003). Oct6 synergises with Sox10 and together they then 
bind to the Krox20 myelin specific enhancer (MSE), and drive the transcriptional 
activated expression of Krox20 (Ghislain and Charnay, 2006, Jagalur et al., 2011). In 
the absence of Oct6, Schwann cells are transiently arrested at the promyelin stage.  
Studies carried out in Oct6 null mice, revealed that Schwann cell myelination and 
myelin protein expression was delayed during development, however by P90 
myelination was revealed to be normal (Jaegle et al., 1996). Further experiments 
revealed that Brain-2 (Brn2), a POU domain transcription factor is able to substitute 
for Oct6, and  partially rescue the delay in Schwann cell development when highly 
expressed in Oct6 null mice (Jaegle et al., 2003). Double knockout of Oct6 and Brn2 
in mice, was shown to worsen the myelinating phenotype; the delay in myelination 
and time for which Schwann cells were arrested at the promyelination state was 
shown to be substantially longer then in Oct6 null mice (Jaegle et al., 2003). 
Although Oct6 acts to initiate Schwann cell myelination, its expression must be 
reduced following the onset of myelin formation. Continued expression of Oct6 in 
Schwann cells was shown to cause Schwann cell hypomyelination and prevented 
the upregulated expression of MBP, P0 and PMP22 in vivo (Ryu et al., 2007). 
1.5.3 Krox20 
Krox20, also known as early growth response 2 (Egr2) is a Cys2/His2 type zinc finger 
transcription factor, recognised as the master regulator of Schwann cell myelination. 
Krox20 is expressed from E15.5 (in mice), and continues to be expressed in 
Schwann cells during development and in adulthood, where it functions to regulate 
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the expression of many myelin components (Topilko et al., 1994, Nagarajan et al., 
2001, Decker et al., 2006). 
The expression of Krox20 is absolutely necessary for Schwann cell myelination. In 
Krox20 null mice, Schwann cells completely fail to myelinate axons and express very 
low levels of myelin proteins P0 and MBP (Topilko et al., 1994). Electron microscopy 
analysis confirmed that axons in the nerves of these animals are surrounded by 
Schwann cells that have made about one and a half turns, this suggested that in the 
absence of Krox20 Schwann cells are capable of making a 1:1 relationship with 
axons, however are unable to progress beyond the promyelinating stage (Topilko et 
al., 1994). Further studies carried out on mice homozygous for the hypomorphic 
Egr2 allele (Egr2lo/lo), confirmed that failure to sufficiently elevate Krox20 expression 
results in Schwann cells being retained at the immature/ promyelinating stage; this 
was marked by the sustained expression of Sox2 and Oct6 at P14. Furthermore, 
Egr2lo/lo mice had severely hypomyelinated axons and exhibited tremors and 
impaired coordination; phenotypically displaying characteristics of congenital 
hypomyelination neuropathy (Le et al., 2005a). Continued Krox20 expression in adult 
Schwann cells has also been shown to be essential for myelin maintenance (Decker 
et al., 2006). Conditional depletion of Krox20 in adult Schwann cells using a 
tamoxifen inducible Cre recombination system [see Section 1.6.4]  resulted in 
Schwann cells undergoing demyelination and dedifferentiation (Decker et al., 2006). 
After nerve injury, Krox20 expression is reduced as Schwann cells demyelinate and 
dedifferentiate. Nonetheless, indirect evidence suggests that following nerve repair, 
Krox20 must be re-expressed in Schwann cells, in order to downregulate the 
expression of negative myelin regulators and increase the expression of myelin-
associated genes, thus enabling Schwann cells to remyelinate regenerating axons 
(Nagarajan et al., 2001, Le et al., 2005a, Parkinson et al., 2008). 
Krox20 regulates the expression of many genes critical for the formation of myelin 
and myelin maintenance. These include myelin associated genes, P0, MBP, PMP22, 
MAG, connexin 32 and periaxin, as well as genes encoding enzymes involved in lipid 
and cholesterol biosynthesis such as 3-hydroxy-3-methyl glutaryl (HMG) CoA 
reductase and stearoyl CoA desaturase (Nagarajan et al., 2001). Studies have 
shown that Krox20 regulates the expression of genes associated with myelination by 
directly binding to regulatory DNA sequences. For example Krox20 induces the 
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transcriptional gene expression of P0 by binding to two regulatory sites located in 
intron 1 (LeBlanc et al., 2006). Krox20 has also been shown to regulate the 
transcriptional gene expression of MBP, by binding to two conserved sites in the 
Schwann cell enhancer (termed MbpSCE1) upstream of the MBP gene, and a 
potential third site in intron 1. The transcriptional gene expression of MAG has also 
been shown to be induced by Krox20 binding to sites in the second intron of the 
MAG gene (Jang et al., 2006).  Interestingly, Krox20 has been shown to co-localise 
with Sox10 in regulating many of the myelin genes mentioned above, and that many 
of these genes contain clustered binding site for Krox20 and Sox10 within their 
regulatory elements. 
For Krox20 to mediate successful myelination, it must interact with the NGF1-A/Egr 
binding protein (Nab) 1 and 2 transcriptional co-repressors  (Mager et al., 2008).  
This interaction has been shown to be important for the transcriptional repression of 
specific genes known to oppose myelination such as inhibitors of DNA 
binding/differentiation 2 (Id2) and Id4 [Section 1.6.7]. Furthermore, double knockout 
of Nab1 and Nab2 in mice, was shown to phenocopy Egr2lo/lo mice i.e. early lethality  
and Schwann cells being arrested at the immature/promyelin stage, thus supporting 
the notion that Krox20/Nab complexes are important for myelination (Le et al., 
2005b)  
In order for Krox20 to upregulate the expression of myelin associated components 
during Schwann cell development and following nerve repair, it must first 
downregulate the expression of gene associated with immature Schwann cells, 
these include cJun, Sox2 and Notch [discussed in Section 1.6]. In vitro experiments 
have shown that enforced Krox20 by adenoviral infection in Schwann cells 
suppresses cJun, Sox2 and Notch, while in the absence of Krox20, cJun, Sox2 and 
Notch levels remain high (Parkinson et al., 2004, Parkinson et al., 2008, Woodhoo et 
al., 2009). Furthermore, in vivo experiments have also confirmed that in the absence 
of Krox20 or when Krox20 expression is low, Notch and Sox2 remain highly 
expressed (Le et al., 2005a, Woodhoo et al., 2009) 
Some of the functional roles of Krox20 i.e. the upregulation of myelin-associated 
genes and the suppression of genes associated with immature Schwann cells,  have 
been suggested to be mediated through Dicer, a type-III ribonuclease responsible for 
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the regulating miRNA maturation. Inactivation of Dicer in Schwann cells was shown 
to impair the timely upregulated expression of PMP22 and MBP and the 
downregulated expression of Sox2 and Notch, thus blocking Schwann cells at the 
promyelinating stage and preventing myelination (Verrier et al., 2010, Pereira et al., 
2010).  
As Schwann cells transition from the immature/ promyelinating stage into the mature 
myelinating stage, they must cease proliferation. Krox20 has been show to block 
Schwann cell proliferation, by reducing their responsiveness to NRG1, and elevating 
the levels of the cell cycle inhibitor p27. At the immature Schwann cell stage, 
Schwann cells are also highly susceptible to TGF-β induced cell death. Both NRG1 
and TGF-β have been shown to mediate Schwann cell proliferation and cell death 
via the JNK-cJun signalling pathway (Parkinson et al., 2001, Parkinson et al., 2004). 
Remarkably Krox20 was revealed to arrest Schwann cell proliferation and inhibit cell 
death by directly targeting the JNK-cJun signalling pathway and preventing its 
activation by NRG1 and TGF-β (Parkinson et al., 2004). 
1.6 Negative myelin regulators during Schwann cell development 
and in the injury response.  
The cross inhibitory effects exerted between positive and negative myelin regulators 
enables Schwann cells to transition back and forth between the immature and 
myelinating phenotype. Schwann cells thus demonstrate a high degree of plasticity, 
which is essential for nerve repair following injury [discussed in Section 1.7]. 
Negative myelin regulators are characterised by their ability to oppose promyelin 
signals, and promote Schwann cell dedifferentiation and myelin loss following nerve 
injury (Jessen and Mirsky, 2008). Over the last decade a range of myelin regulators 
such as cJun, Notch, Sox2, Sox4, Pax3, Id2, Egr1 (Krox24) and Egr3 have either 
been characterised as negative regulator of Schwann cell myelination, or shown to 
exhibit features of a negative regulator (Bartesaghi et al., 2015, Jessen and Mirsky, 
2008). 
1.6.1 cJun 
The basic leucine zipper transcription factor cJun, is a key component of the AP1 
transcription complex, where it forms heterodimers with JunD, JunB/c-Fos and 
activating transcription factor (ATF) family members (Davis, 2000). cJun is a 
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downstream effector of the cJun N-terminal kinase (JNK) MAPK signalling pathways. 
Activation of cJun via phosphorylation of the NH2-terminal Serine 63 and 73 residues 
by JNK is important for many biological processes, including cell death and 
proliferation. Nonetheless, cJun is also able to exert functions independent of being 
phosphorylated. In Schwann cells the cJun protein has been show to exert many 
functional effects, which are discussed below (Parkinson et al., 2008). 
cJun is highly expressed in immature Schwann cells, however as Schwann cells 
differentiate and myelinate, its expression is suppressed by the master 
transcriptional myelin regulator Krox20 (Parkinson et al., 2004, Parkinson et al., 
2008). Downregulation of cJun was shown to be necessary for Schwann cell 
myelination, as enforced expression of both cJun and MAPK kinase 7 (MKK7); an 
upstream regulator of cJun, was shown to inhibit the induction of myelin proteins P0 
and periaxin in response to cAMP and Krox20 (Parkinson et al., 2008). After nerve 
injury, cJun was also shown to be re-expressed in Schwann cells, where it plays a 
central role in driving Schwann cell dedifferentiation and demyelination. Experiments 
carried out on cJun null mice, revealed that in the absence of cJun the rate of 
Schwann cell dedifferentiation and myelin loss was strongly delayed (Parkinson et 
al., 2008). 
More recent experiments have revealed that the re-expression of cJun in Schwann 
cells after injury is also required for axonal survival and the reprogramming of 
Schwann cells into a repair cell that supports nerve regeneration (Fontana et al., 
2012, Arthur-Farraj et al., 2012). Following nerve injury cJun null mice demonstrated 
a significant reduction in sensory and motor neuron survival after injury (Arthur-Farraj 
et al., 2012, Fontana et al., 2012). It was revealed that in the absence of cJun, the 
expression of genes required for axonal survival and growth were markedly reduced, 
these included GDNF (glial derived neurotrophic factor), Artn (artemin), BDNF (brain 
derived neurotropic factor) and LIF (leukemia inhibitory factor). In vitro experiments 
further confirmed that cJun was capable of directly regulating GDNF and Artn; the 
mRNA expression levels of these neurotrophic factors were dramatically increased in 
Schwann cells infected with an ectopic cJun expressing adenovirus. Moreover, 
administration of recombinant GDNF and Artn proteins to the injury site of cJun null 
mice for 28days improved motor neuron survival; supporting the notion that cJun 
regulates axonal survival following injury (Fontana et al., 2012).  
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cJun was also revealed to control the downregulation of myelin proteins and the 
upregulation of proteins associated with regeneration; N-cadherin, P75NTR and 
NCAM. In addition, cJun was shown to be required for Schwann cell myelin debris 
and lipid clearance, along with the formation of bands of Büngner and the promotion 
of axon growth. Consequently, in cJun null mice axon outgrowth was decreased and 
functional recovery were severely impaired even at 70 days post injury (Arthur-Faraj 
et al., 2012). 
1.6.2 Sox2 
Sox2 is a member of the SoxB1 subgroup of high mobility group box domain 
transcription factors, capable of acting as either a transcriptional activator or 
repressor depending on the partner protein that it co-operates with, when binding to 
a DNA domain (Kamachi and Kondoh, 2013). Sox2 is commonly known for its 
function in maintaining and inducing cellular  pluripotency, through interacting with 
three other factors; Oct3/4, c-Myc and Krüppel-like factor 4 (KLF4) (Takahashi and 
Yamanaka, 2006).  
In Schwann cells, Sox2 has been identified as a marker of the immature Schwann 
cell stage, it is highly expressed prior to the onset of myelination, but then rapidly 
declines as Schwann cells begin to myelinate. Following nerve injury Sox2 is again 
re-expressed (within 5 days), as mature Schwann cells dedifferentiate back to an 
immature state (Le et al., 2005a, Parkinson et al., 2008). In vitro studies have 
confirmed that Sox2 is suppressed upon the initiation of myelination by the master 
transcriptional regulator Krox20 (Parkinson et al., 2008). Furthermore, as seen in 
hypomorphic in Egr2Lo/Lo mice, failure to sufficiently upregulate Krox20 in Schwann 
cells results in maintenance/ failure to downregulate Sox2 (Le et al., 2005).  
Further experiments revealed that Sox2 functions as a negative regulator of 
Schwann cell myelination in vitro (Le et al., 2005a). Adenoviral expression of Sox2 in 
Schwann cells was shown to prevent the upregulated mRNA expression of myelin 
associated genes such as Krox20, P0, periaxin, in response to forskolin treatment. 
Sox2 lentiviral infection in Schwann cells also revealed that Sox2 blocks myelination, 
in Schwann cell/DRG neuronal co-cultures (Le et al., 2005a). 
52 
 
1.6.3 Notch 
The Notch signalling pathway is highly conserved and plays a central role in 
regulating cellular communication, development, proliferation and differentiation. 
Notch is a transmembrane heterodimer receptor, composed of four different 
members (Notch 1 to 4), and is activated by transmembrane proteins; Delta and 
Jagged (Bray, 2006). Binding of the Notch ligand to the Notch receptor, triggers 
proteolytic cleavage events; ADAM 17 metalloprotease catalyses the first cleavage 
of the extracellular domain, ʏ-secretase then mediates the second cleavage at the 
intracellular domain consequently releasing the Notch intracellular domain (NICD) 
from the Notch transmembrane receptor. The NICD then translocates into the 
nucleus where it interacts with the DNA binding protein CLS (or RBPJ) and its co-
activator Mastermind (MAM),  activating the transcription of Notch targets such as 
Hairy and enhancer of split 1 (Hes 1) and Hes 5 (Bray, 2006). 
Notch has been found to act at a number of stages during Schwann cell 
development where it exerts different functional roles. During Schwann cell 
development Notch drives the differentiation of Schwann cell precursors into 
immature Schwann cells, by enhancing the expression of the erbB2 receptor on 
Schwann cells and thus increasing SCP sensitivity to NRG1; this is required for SCP 
survival and Schwann cell lineage progression. At the immature Schwann cell stage 
Notch exerts a mitogenic effect and increases Schwann cell proliferation. 
Nonetheless, as Schwann cells begin to differentiate into the myelinating stage, 
Notch signalling is reduced (Woodhoo et al., 2009). This reduction in Notch 
signalling was shown to be mediated by Krox20, and proven to be important for the 
timely onset of myelination. Enforced Notch signalling in Schwann cells blocked the 
upregulated expression of myelin proteins in response to cAMP, in addition to 
blocking myelination in DRG/Schwann cells co-cultures (Woodhoo et al., 2009). In 
vivo, increased Notch signalling was shown to significantly decrease the number of 
myelinating Schwann cells at P2 and also decrease myelin thickness at P5 in the 
nerves of P0Cre+;CALSL-NICD mice, in which NICD levels are elevated in Schwann 
cells. In contrast, inactivation of Notch signalling significantly increased Schwann cell 
myelin thickness in the nerves of P0Cre+;Notch1fl/fl mice at P5 (Ibid).  
Notch has also been identified to be upregulated in Schwann cells following nerve 
injury, where it acts to drives Schwann cell demyelination. After sciatic nerve injury 
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the rate of Schwann cell demyelination was shown to be dramatically reduced in 
RBPJ null mice; where Notch signalling is reduced. In contrast increased Notch 
signalling was shown to accelerate Schwann cell myelin loss, as well as the 
reduction in MBP expression. Together this data confirmed that Notch acts to 
negatively regulate myelination during Schwann development and after nerve injury 
(Woodhoo et al., 2009).  
1.6.4 ERK 
As discussed in Section 1.4, the ERK 1/ 2 signalling pathways can exert two distinct 
functional roles in a context dependent manner. Following peripheral nerve injury, 
ERK 1/2 is rapidly phosphorylated within 15 minutes, in Schwann cells in the distal 
nerve stump. Its expression thereafter increases, peaking at days 3 and 7 after injury 
(Napoli et al., 2012, Zrouri et al., 2004, Yamazaki et al., 2009). ERK 1/2 activation in 
this context, has been shown to play a central role in driving Schwann cell 
dedifferentiation, regulating the inflammatory response, and preventing Schwann cell 
remyelination (Harrisingh et al., 2004, Napoli et al., 2012). Studies carried out in 
Schwann cells in vitro and in vivo have used a regulatory protein system to analyse 
the function of ERK. ERK is activated via the Ras/Raf/MEK 1/2 signalling pathways, 
thus to drive ERK signalling in vitro Schwann cells were infected with a retrovirus 
encoding an inducible Raf fusion protein; which contains the kinase domain of Raf 
fused to an oestrogen receptor hormone binding domain (ER). In normal baseline 
condition the Raf-ER construct is inactive, however the addition of tamoxifen (an ER 
ligand) rapidly activates the Raf/ERK pathway (Harrisingh et al., 2004). Tamoxifen 
binds to the oestrogen receptor, displacing inhibitory large heat shock proteins and 
therefore reversing the steric hindrance (Littlewood et al., 1995). A similar method 
was used to study the functional effects of ERK in vivo. Transgenic mice carrying a 
tamoxifen inducible Raf-kinase/oestrogen receptor fusion protein, expressed under 
the control of the P0 promoter (P0-RafTR) were generated. Only when tamoxifen is 
administrated to the mice, does the RafTR become activated, stimulating the ERK 
signalling pathway (Napoli et al., 2012). 
 Activation of Raf in cultured Schwann cells using the Raf-ER system prevented the 
upregulation of Oct6, Krox20, P0, periaxin and MBP in response to dibutyryl cAMP 
(db-cAMP), and drove Schwann cell dedifferentiation. Furthermore, the activation of 
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Raf in established myelinated Schwann cell/DRG co-cultures induced demyelination 
and the downregulation of P0, MBP, PMP22 and perixain gene expression. To 
determine whether the effects mentioned above were mediated through the Raf/ERK 
pathway, experiments using established myelinated Schwann cell/DRG co-cultured 
treated with tamoxifen (to induce Raf signalling) in the presence or absence of an 
ERK signalling inhibitor U0126 were carried out. In the presence of U0126, Raf/ERK 
signalling failed to drive myelin fragmentation and Schwann cell dedifferentiation. 
These experiments thus suggest that sustained activation of the Raf/ERK pathway 
acts to negatively regulate Schwann cell differentiation and myelination. 
Recent experiments carried out in vivo using P0-RafTR adult mice, have also 
confirmed that the Raf/ERK signalling pathways causes Schwann cells to 
downregulate the expression of myelin genes, degrade their myelin sheath and 
dedifferentiate back to an immature Schwann cell state.  Moreover, P0-RafTR adult 
mice display severe defects in motor function at 10 days after tamoxifen injection. 
This suggested that sustained Raf/ERK in Schwann cells can cause 
neuropathological effects. Further in vivo experiments identified that the Raf-ERK 
signalling pathway is also sufficient to drive the inflammatory response in myelinated 
Schwann cells.  P0-RafTR mice treated with tamoxifen showed complete blood 
nerve barrier breakdown within 5 days, and an influx of inflammatory cells into the 
nerve.  
To determine the functional role of ERK 1/2 in driving Schwann cell demyelination 
and the inflammatory response after nerve injury, wild type (WT) mice which had 
undergone nerve crush injury were treated with a MEK 1/ 2 inhibitor PD032501.  
Animals treated with PD032501 showed delays in Schwann cells downregulating the 
expression of myelin associated genes and to dedifferentiate. In addition mice 
displayed an inhibited inflammatory response (Napoli et al., 2012). Together these 
studies shown that the Raf/ MEK/ ERK 1/2 signalling pathway is sufficient to drive 
Schwann cell demyelination and initiate an inflammatory response. Activation of this 
pathway following nerve injury is thus fundamental for Schwann cell plasticity and 
Wallerian degeneration [discussed in Section 1.7]. 
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1.6.5 p38 MAPK 
The p38 MAPK (mitogen-activated protein kinase) signalling pathway plays a central 
role in regulating cellular proliferation, apoptosis, differentiation and inflammation in 
response to environmental stimuli such as external stress, inflammatory cytokines or 
UV radiation.  MAPK kinase 3 (MKK3) and MKK 6 pathway specifically activates p38 
MAPK by dual phosphorylation at threonine180 and tyrosine182 residues (Cuenda and 
Rousseau, 2007). MKK4, an activator of the JNK pathways, has also been identified 
to specifically activate p38α. Independent of the MAPK kinase pathway, TAB1 
(transforming growth factor β activated protein kinase 1 (TAK)-binding protein) can 
activate p38 MAPK; this method of activation involves TAB1 interacting with p38α, 
which in turn causes p38α to undergo auto-phosphorylation (Ge et al., 2002, Cuenda 
and Rousseau, 2007). 
There are four isoforms of p38 kinase, p38α, p38β, p38ʏ (ERK6/ SAPK3) and p38δ 
(SAPK4), although all four isoforms are widely expressed, p38ʏ is most highly 
expressed in skeletal muscle, while p38δ is most highly expressed in the testis, 
pancreas, kidneys and small intestine (Yang et al., 2014b). Out of all four isoforms, 
p38α has been shown to be the most highly expressed and functional isoform in 
Schwann cells [discussed further in Chapter 5].  
p38 MAPK is highly expressed in immature Schwann cells at E17 (in rats), its 
expression thereafter declines from P1, as immature Schwann cells differentiate into 
myelinating Schwann cells. This suggests that p38 MAPK is not involved in the 
regulation of myelin formation (Yang et al., 2012). Following nerve injury, p38 MAPK 
is rapidly activated within 15 minutes in the distal nerve segment, where it acts to 
drive Schwann cell demyelination (Zrouri et al., 2004, Yang et al., 2012). Studies by 
Yang et al. (2012) identified that blocking the re-activation of p38 MAPK following 
nerve injury, using a specific p38 MAPK inhibitor SB203580 delayed Schwann cell 
demyelination. At 3 days post injury no significant difference in the MBP positive 
area was observed in nerves treated with SB203580 compared to uncut nerves. In 
contrast, nerves not treated with SB203580 were reported to exhibit a significant 
54% reduction in the MBP positive area. Further experiments by Yang et al. (2012) 
also showed that activation of the p38 MAPK signalling pathway in myelinated 
DRG/Schwann cell co-cultures, caused Schwann cell to demyelinate and reduce the 
expression of Krox20 and MAG, in the absence of trauma [discussed in more detail 
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in Chapter 5] (Yang et al., 2012). This study highlights that the p38 MAPK signalling 
pathway plays an important role in the injury response, and acts as a negative 
regulator of Schwann cell myelination.  
1.6.6 Sox4 
Sox4 is a class C Sox family transcription factor, recently identified to be expressed 
during the early postnatal stages of Schwann cell development (P2-P10). Its 
expression thereafter declines, but has been shown to be high in three different 
neuropathic mutant mouse models; Sh3tc2-/- (a model of CMT type-4C) (Arnaud et 
al., 2009), Pmp22-/- (a mouse model of CMT type-1A) and  Lpin1-/- (Lpini encodes for 
the phosphatidate phosphatase enzyme, which is required for triacylglycerol 
biosynthesis) (Nadra et al., 2008). To elucidate the functional role of Sox4 in 
Schwann cells, Bartesaghi et al. (2015) generated mice that overexpressed Sox4 
specifically within Schwann cells (Sox4 tg). While the Sox4 mRNA expression was 
shown to be elevated in the Sox4 tg mice into adulthood, increased Sox4 protein 
expression was only detected at postnatal day 0. Analysis of Sox4 tg nerves at P2 
revealed that Sox4 overexpression reduced MBP, P0, Krox20 and Oct6 expression 
and caused Schwann cell hypomyelination. Nonetheless, this effect was only 
temporary as myelin thickness returned to normal and the expression of MBP, P0, 
Krox20 and Oct6 was shown to be upregulated by P5 (Bartesaghi et al., 2015). 
Schwann cells were reported to tightly regulate the protein expression of Sox4, by 
targeting it for degradation, thus making it impossible to significantly increase Sox4 
protein levels. As Sox4 protein expression is elevated in Sh3tc2-/- mice and not 
degraded, these mice were crossed with Sox4 tg mice to generate Sh3tc2-/-, Sox4 tg 
mice; this enabled the functional effects of Sox4 to be determined, by seeing 
whether increasing Sox4 expression would worsen the phenotype of sh3tc2-/- mice. 
Indeed Sh3tc2-/-,Sox4 tg mice demonstrated a worse phenotype and increased g-
ratio compared to Sh3tc2-/- mice (Bartesaghi et al., 2015). Together this data 
suggests that Sox4 is capable of negatively regulating Schwann cell myelination. 
1.6.7 Pax3, Id2, Egr1 and Egr3 
The transcription factors Pax3, Egr1 (Krox24) and Egr3 and the transcriptional 
regulator Id2 have also be identified to be expressed at the immature Schwann cell 
stage and/or to negatively regulate Schwann cell myelination (Jessen and Mirsky, 
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2008). Pax3 is a paired domain transcription factor expressed in Schwann cell 
precursors, and maintained in non-myelinating Schwann cells (Kioussi et al., 1995). 
Schwann cells infected with a Pax3 expressing adenovirus, showed that Pax3 
regulates Schwann cell proliferation and survival, and is able to completely block the 
upregulated expression of myelin components; Oct6, P0, MBP and periaxin in 
response to cAMP and Krox20 (Doddrell et al., 2012, Kioussi et al., 1995).  Id2 is a 
member of the Id helix domain transcription factors and is expressed in immature 
Schwann cells, its expression thereafter declines as Schwann cells myelinate; where 
it is repressed by Krox20 in conjunction with Nab 1/2 (Mager et al., 2008). Following 
nerve injury, Id2 has been shown to be re-expressed (Le et al., 2005a). Depletion of 
Id2 by RNA interference in cultured Schwann cells, was shown to augment P0 
expression in response to cAMP, thus suggesting that Id2 may exert inhibitory 
effects on myelination (Mager et al., 2008). No further studies have been carried out 
to elucidate the functional role of Id2 in Schwann cells during development and after 
injury, this is therefore yet to be determined. Egr1 (Krox24) and Egr3 are zinc finger 
transcription factors, closely related to Krox20 and of which bind to the same DNA 
target sequences. In Schwann cells Egr1 and Krox20 are never co-expressed; 
Krox20 is solely expressed in myelinating Schwann cells, whereas Egr1 is expressed 
in Schwann cell precursors, immature Schwann cells and non-myelinating Schwann 
cells, it is also re-expressed in dedifferentiating Schwann cells within 24 hours of 
nerve injury (Topilko et al., 1997). As Krox20 and Egr1 are expressed at different 
times during Schwann cell development, it is suggests that they exert opposite 
functions (Topilko et al., 1997). Further studies have identified that Egr1 and Egr3 
regulate the expression of P75NTR in Schwann cells, by binding directly to the P75NTR 
promoter and inducing transactivation (Gao et al., 2007). P75NTR is a low affinity 
neurotrophin receptor expressed in immature Schwann cells, and is important for 
regulating axon growth and survival, as well as axon myelin thickness (Gao et al., 
2007, Jessen and Mirsky, 2008). Double knockout of Egr1 and Egr3 in mice was 
shown to reduce the expression of P75NTR by 82.5%, which consequently resulted in 
a decrease in myelin thickness (Gao et al., 2007). Surprisingly Krox20 expression 
was not altered in Egr1/Egr3 double knockout mice, which suggests that Krox20 and 
Egr1/Egr3 do not antagonise one another. Unfortunately to date no analysis has 
been carried out in Egr1/Egr3 double knockout mice to determine with the role of 
58 
 
Egr1/Egr3 in Schwann cell myelination during development or dedifferentiation after 
injury.  
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Figure 1. 6: Signals that drive demyelination. The proteins extracellular signal-regulated-
kinase (ERK) 1/2, p38, cJun, Sox2 and NICD act to oppose Schwann cell myelination and 
drive demyelination. ERK 1/2 also functions as a positive regulator of myelination, during 
early Schwann cell development. ERK is activated by MAPK ERK Kinase (MEK) and Raf. 
p38 is phosphorylated by MAP kinase kinase 3/6 (MKK3/6) which is phosphorylated by the 
upstream MAPKK kinase (MAPKKK). cJun is upregulated and phosphorylated by cJun N-
terminal kinase (JNK), which is downstream of MKK4/7. The regulator of Sox2 in Schwann 
cells remains unknown, however Notch1 has been suggested to regulate Sox2 in the PNS 
(Wakamatsu et al., 2004). The Notch receptor is cleaves by the metalloprotease ADAM17 
and ʏ-secretase, enabling the release of the Notch intracellular domain (NICD). All four of 
these signalling proteins have been shown to block myelination during Schwann cell 
development by impairing Krox20 expression. Furthermore, following peripheral nerve injury 
the re-expression of these proteins have been confirmed to drive Schwann cell 
demyelination, by suppression Krox20 expression. Adapted from (Napoli et al., 2012, Yang 
et al., 2012, Le et al., 2005, Woodhoo et al., 2009).   
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1.7 Schwann cell demyelination, remyelination and repair 
Schwann cells demonstrate remarkable plasticity, where they are able to freely 
transition between the immature Schwann cell (also known as a repair cell after 
injury) state and the mature myelinating state. This is a key feature in peripheral 
nerves following injury, making nerve repair in the PNS more effective than in the 
CNS (Stoll et al., 2002). 
Damage to peripheral nerve triggers an injury related response, whereby nerves 
distal to the site of injury degenerate through a process termed Wallerian 
degeneration. The nerve proximal to the injury sites regenerate with the aid of 
Schwann cells, to re-innervate target tissues. Wallerian degeneration is a sequence 
of events that includes; axonal degeneration, Schwann cell demyelination, 
dedifferentiation and proliferation, axon/myelin debris clearance, breakdown of the 
blood nerve barrier and activation of the inflammatory response (Jessen and Mirsky, 
2008).  
During Wallerian degeneration, Schwann cells degrade their myelin and differentiate 
into repair/Büngner cells. Repair Schwann cells function to support axonal survival 
and growth through the production of trophic factors; to support axon guidance by 
forming bands of Büngner, as well as to promote functional recovery by 
remyelinating regenerating axons (Fontana et al., 2012, Arthur-Farraj et al., 2012). 
Repair Schwann cells also assist with myelin debris clearance through a process 
termed myelinophagy, which is essential to enable axon regrowth through the injury 
site [discussed in Chapter 4] (Gomez-Sanchez et al., 2015).  
Successful nerve regeneration also requires activation of the inflammatory response. 
Repair Schwann cells secrete inflammatory cytokines such as tumour necrosis factor 
alpha (TNFα), interleukin 1β (IL1β), IL6, IL10 and leukaemia inhibitory factor (LIF), 
as well as chemoattractant proteins such as monocyte chemoattractant protein 
(MCP-1). The expression of these inflammatory cytokines and chemokines at the 
site of injury encourages the recruitment of immune cells, in particular macrophages, 
to assist with myelin/axon debris clearance and promote neurite outgrowth 
(Svennigsen and Dahlin, 2013). 
The transition of Schwann cells into a repair competent phenotype is associated with 
the rapid suppression of key myelin regulators such as Krox20 and myelin proteins 
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such as P0 and MBP. In addition, repair Schwann cells also rapidly upregulate the 
expression of negative myelin regulators; cJun, Sox2, Notch signalling, and activate 
the ERK 1/2 and p38 MAPK signalling pathways, all of which drive Schwann cell 
demyelination and dedifferentiation [see Section 1.6]. Repair cells display a similar 
protein expression profile to immature Schwann cells, as they re-express the cell 
adhesion (calcium independent) molecules L1 and neuronal cell adhesion molecule 
(NCAM), in addition to the tyrosine kinase neurotrophin receptor p75NTR. Interestingly 
repair cells also re-express the cell adhesion (calcium dependent) molecule N-
cadherin and membrane receptor integrin α1β1, but at much higher levels than that 
observed in immature Schwann cells (Jessen and Mirsky, 2008, Thornton et al., 
2005, Arthur-Farraj et al., 2012). Following N-cadherin re-expression in repair cells, it 
re-localises to the cell-cell contact junction’s where it mediates Schwann cell 
clustering and the formation of cord like structures, which help to guide axons across 
the nerve bridge. Once axons are fully regenerated, repair Schwann cells 
downregulate the expression of negative myelin regulators, redifferentiate back into 
myelinating Schwann cells and remyelinate axons; this process is essential for 
complete nerve repair [discussed in Chapter 4 and 5] [see Figure 1.7].  
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Figure 1. 7: Peripheral nerve regeneration. Following peripheral nerve injury (A) axons 
(blue) distal to the injury site degenerate and Schwann cells (SC) (yellow) demyelinate, 
unwrapping axons and dedifferentiate into an immature/repair Schwann cell in a process 
termed Wallerian degeneration (B). Repair Schwann cells then proliferate and produce 
chemokines that recruit macrophages to the injury site, where together they clear myelin 
debris (brown) (C). Repair Schwann cells then clump together forming bands of Bϋngner, 
which help to guide axons (D) back to their target tissue for re-innervation (E). Once axons 
are fully regenerated, repair Schwann cells redifferentiate backing into myelinating Schwann 
cells and remyelinate axons.  
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1.8 Differences between the PNS and CNS in nerve repair after 
injury 
Unlike the PNS, the CNS is less effective in nerve repair and regeneration following 
injury. This is mainly due to the unfavourable environment within the CNS following 
injury, which consequently impedes regeneration of axons in the CNS.  
In the PNS, Schwann cells and macrophages rapidly clear myelin debris, which 
contains the myelin associated inhibitor (MAI) MAG; known to inhibit axonal 
outgrowth and regeneration. In contrast, in CNS oligodendrocytes and microglia 
(macrophage like cells) are less effective at myelin debris clearing (Stoll et al., 2002). 
What makes matters worse is that myelin debris in the CNS is more enriched in 
MAI’s than in the PNS. Known MAI’s in the CNS include MAG, oligodendrocyte 
myelin glycoprotein (OMGp) and NogoA all of which bind to the same receptor 
complex, Nogo-66 receptor (Ngr)-p75NTR expressed on neurons; causing nerve 
growth cone collapse (Filbin, 2003). In the absence of the Ngr receptor, studies have 
revealed that OMGp fails to inhibit neurite outgrowth (Filbin, 2003). 
Astrocytes in the CNS are also renowned for forming glial scars (comprised of 
astrocytes, microglial and oligodendrocyte precursors) after injury, which acts as a 
physical barrier blocking axonal regeneration and contains inhibitory molecules such 
chondroitin sulfate proteoglycans (CSPGs) (Huebner and Strittmatter, 2009). The 
expression of CSPGs is upregulated by astrocytes, they are the main inhibitory 
molecule expressed in the glial scar and act to inhibit axon regeneration. CSPGs 
may be membrane bound or secreted and include neurocan, vesican, brevican, 
phosphacan, aggrecan and NG2 (Huebner and Strittmatter, 2009). 
1.9 Schwann cells in disease 
Schwann cells have been shown to cause a range of diseases in human patients. 
Loss of healthy Schwann cell function commonly results in peripheral neuropathies, 
whereas Schwann cell transformation has been reported to cause the formation of 
Schwann cell derived tumours.  
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1.9.1  Peripheral neuropathies  
Peripheral neuropathies are often caused by damage or disease affecting the 
peripheral nerves; they can be extremely disabling and even fatal. Direct peripheral 
nerve injuries which cause local damage or systemic illnesses such as diabetes 
(diabetic neuropathy), cancer and infection (leading to an increased inflammatory 
response, for e.g. as seen in Guillain-Barre syndrome) are common causes of 
peripheral neuropathies. Other causes included genetic mutations which directly 
affect the function of Schwann cells and/ or neurons.   
1.9.1.1 Charcot-Marie-Tooth disease 
Charcot-Marie-Tooth diseases (CMT), also referred to as hereditary motor and 
sensory neuropathy (HMSN) is the most common inherited peripheral neuropathy in 
patients, and has an incidence rate of 1:2500 individuals. CMT is caused by 
mutations in various genes responsible for the development of the peripheral nerves, 
currently over 40 gene mutations have been identified in Schwann cells and/or 
neurons. CMT disease has been classified into four groups, CMT1, CMT2, CMT3 
and CMT4; these groups have then been further divided into subgroups due to the 
numerous different gene mutations [See Table 1 for subgroups of CMT1, CMT2, 
CMT3 and CMT4]. 
CMT type 1 (CMT1) is an autosomal dominant demyelinating neuropathy caused by 
Schwann cell defects. It has an early onset, occurring in the first or second decade of 
life and results in slow nerve conduction velocities. Nerve biopsies taken from 
patients with CMT1 often show signals of demyelination, remyelination, onion 
bulbing, and eventually axon loss (Suter and Scherer, 2003) . Reports estimated that 
approximately 80% of diagnosed CMT patients are classified as CMT1. Moreover 
CMT1 type A (CMT1A) is the most common form of CMT1, and is caused due to a 
1.4Mb duplication of the PMP22 gene on chromosome 17p11.2 (Patzkó and Shy, 
2011). 
CMT type 2 is an autosomal dominant axonal neuropathy, patients tends to have 
normal nerve conduction velocities, but reduced amplitudes of the compound muscle 
action potential, with an onset occurrence mainly during adulthood. While clinical 
symptoms of CMT2 tend to overlap extensively with CMT1, CMT2 is often less 
disabling and causes less sensory loss [symptoms discussed in Chapter 3]. CMT2 
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type A (CMT2A) is the most common subtype of CMT2, accounting for 
approximately 20% of CMT2 cases (Patzkó and Shy, 2011). CMT2A is caused due 
to mutations in the mitofusin 2 genes (MFN2) located on chromosome 1p36 (Suter 
and Scherer, 2003, Patzkó and Shy, 2011).  
CMT type 3, most commonly known as congenital hypomyelinating neuropathy 
(diagnosed at birth) or Dejerine-Sottas syndrome (diagnosed in infancy), can be 
either dominant or recessive. CMT3 is a demyelinating neuropathy classified by 
severe early onset in infants (Suter and Scherer, 2003). 
CMT4 is an autosomal recessive severe axonal and demyelinating neuropathy, 
which is very rare. CMT4 is mostly associated with early onset, where is it often 
diagnosed at birth or during infancy (Suter and Scherer, 2003).  
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CMT subtypes Genetic mutation Onset  
CMT1: Autosomal dominant demyelination neuropathy  
CMT type 1A PMP22 Onset between 1st and 2nd decade. 
CMT type 1B P0 Onset between 1
st and 2nd decade. 
CMT type 1C SIMPLE Onset between 1st and 2nd decade. 
CMT type 1D/ 4E Krox20/Egr2 Onset between 1st and 2nd decade 
CMT type 1X Cx32 Occurs at all ages.  
CMT2: Autosomal dominant  axonal neuropathy   
CMT type 2A MFN2 Onset by 10 years of age. 
CMT type 2B RAB74 Onset between 2nd and 3rd decade. 
CMT type 2C Unknown Onset between 2nd and 3rd decade. 
CMT type 2D GARS Onset between 2nd and 3rd decade. 
CMT type 2E NEFL Late onset (30 years of age +). 
CMT3: Autosomal dominant/recessive severe demyelinating neuropathy   
DSS AD (PMP22, MBP, Cx32, 
Krox20, NEFL) ; AR 
(MTMR2 and PRX) 
Delayed motor development before 3 
years of age.  
CHN AD (PMP22, MBP, 
Krox20); AR (Krox20) 
Onset occurs at birth  
CMT4: Autosomal recessive severe demyelinating neuropathy   
CMT type 4A GDAP1 Early childhood onset. 
CMT type 4B1 MTMR2 Early childhood onset 
CMT type 4B2 MTMR13 Childhood onset 
CMT type 4C KIAA1985 (SH3TC2)  
CMT type 4D NDRG1 Childhood onset 
CMT type 4E Krox20/Egr2 Infantile onset. Progression to 
wheelchair dependency 
CMT type 4F PRX Childhood onset. Severe disability by 
50 years of age 
CMT type 4G FGD4  
CMT type 4J FIG4  
Table 1: An overview of Charcot-Marie-Tooth type 1, type 2, type 3 and type 4 
subgroups and genes. AD, autosomal dominant; AR, autosomal recessive; DSS, 
Dejerine-Sottas syndrome; CHN, congenital hypomyelinating neuropathy; PMP22, peripheral 
myelin protein 22; P0, myelin protein zero; SIMPLE, small integral membrane protein of late 
endosome; Egr2, Early growth response 2; Cx32, connexin32; MFN2, mitochondrial protein 
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mitsofusin 2; RAB7A, small GTPase late endosomal protein gene 7; GARS, glycyl-tRNA 
synthetase; NEFL, Neurofilament light polypeptide proteins; GDAP1, ganglioside induced 
differentiation associated protein 1; MTMR, Myotubularin related protein; SH3TC2, SH3 
domain and tetratricopeptide repeats 2; NDRG1, N-myc downstream regulated gene 1; 
FGD4, FYVE, RhoGEF and PH domain containing 4; FIG4, FIG4 homologue. Adapted from 
(Suter and Scherer, 2003, Reilly and Shy, 2009)  
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1.9.2 Neurofibromatosis type 1 
Neurofibromatosis type 1 (NF1), formally known as von Recklinghausen’s disease, is 
an autosomal dominant disorder affecting roughly 1:3500 individuals worldwide 
(Jouhilahti et al., 2011). NF1 is a tumour condition caused by mutations (50% of 
which are sporadic) or loss of the NF1 gene that encodes the tumour suppressor 
proteins neurofibromin. Common clinical hallmarks of NF1 include numerous benign 
cutaneous or plexiform neurofibromas, café-au-lait macules (flat brown pigmented 
marks), learning difficulties and speech disorders (Jouhilahti et al., 2011). 
Neurofibromas are complex tumours comprising Schwann cells, axons, perineural 
cells, mast cells and blood vessels and are classified as either cutaneous or 
plexiform (Zhu et al., 2002, Jouhilahti et al., 2011). 
Neurofibromas are thought to originate from Schwann cells, as studies have shown 
that mice with NF1 null Schwann cells develop neurofibromas (Zhu et al., 2002). 
Nonetheless, biallelic inactivation of NF1 (NF1-/-) in Schwann cells alone is not 
permissive for plexiform neurofibroma formation; in order for plexiform neurofibromas 
to develop NF1-/- Schwann cells must also interact with surrounding heterozygous 
NF1+/- cells in a tumour microenvironment (Zhu et al., 2002). Further studies have 
also identified that NF1+/- mast cells are an essential component of the tumour 
microenvironment, permitting neurofibroma growth and maintenance; mice failed to 
develop plexiform neurofibomas when their NF1+/- bone marrow was replaced with 
NF1+/+ bone marrow (Jouhilahti et al., 2011).  
While adult myelinating Schwann cells depleted of NF1-/- do not form neurofibromas 
in an NF1+/+ environment, they are able to form neurofibromas in an NF1+/+ 
environment following nerve injury. It is suggested that nerve injury results in a 
protumorigenic microenvironment at the wounded site, which is permissive for 
tumours to form specifically at that region (Ribeiro et al., 2013). 
1.9.3 Neurofibromatosis type 2 
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder, that affects 
approximately 1:25000-30000 births (Hanemann, 2008). NF2 results from mutations 
in the NF2 gene on chromosome 22q 11.2, which encodes for the tumour 
suppressor protein Merlin (Moesin/ezrin/radixin like protein); as a result Merlin 
function is lost (Ferner, 2007). Merlin is thought to interact with multiple intracellular 
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signalling pathways such as PI3K-Akt, to maintain growth suppression. Thus in the 
absence of merlin unregulated cellular proliferation occurs (Ferner, 2007).  
NF2 results in the formation of many benign tumours; these include schwannomas, 
meningiomas and ependymomas (detailed below), as well as retinal hamartomas, 
tumours of the eye and lens opacities (Hanemann, 2008, Ferner, 2007). 
Schwannomas are pure Schwann cells derived tumours that rarely become 
malignant and often occur in the vestibular 8th cranial nerve (which is the most 
frequent, resulting in hearing loss, tinnitus and vertigo), the spinal roots and along 
the peripheral nerves (Hanemann, 2008). Meningiomas are encapsulated tumours 
which are most often benign (90% of the time), they occur intracranially or within the 
spinal canal and arise from arachnoid “cap” (meningothelial) cells that form 
membranous layers that cover the brain and the spinal cord (Rockhill et al., 2007). 
Ependymoma account for 2-5% of intracranial tumours and arise from ependymal 
cells (Hanemann, 2008). These cells line the ventricles of the brain and the central 
canal of the spinal cord, where they are responsible for the production of cerebral 
spinal fluid (CSF) (O’Shaughnessy and Bussières, 2006). 
 
1.10 Studying Schwann cell biology in vivo  
To study Schwann cell biology in vivo, a range of molecular techniques are available 
which allow for specific genetic modifications. Methods to achieve insertion, deletion 
or alteration of specific genes include lentiviral vector transfections which allow for 
the introduction of new genes, lentiviral gene transfer vectors expressing short-
hairpin RNA which target specific genes for the deletion (Cotter et al., 2010), the 
inducible tetracycline-dependent regulatory (tet)-on and tet-off system (Gossen and 
Bujard, 1992), as well as recombineering which is based on homologous 
recombination in embryonic stem cells (Sharan et al., 2009). Nonetheless, one of the 
most commonly used techniques in Schwann cell biology is the Cre/LoxP system, a 
technique which allows for the quick and precise ablation or modifications of genes 
in any tissue at any definite time (Sauer, 1998). 
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1.10.1 Cre-LoxP mediated recombination 
The Cre-LoxP system is a DNA recombination tool, widely used to specifically target 
the expression of genes or carry out DNA deletions or insertions at specific DNA 
sites. When combined to a specific promoter to drive Cre expression, the Cre-LoxP 
system can induce conditional gene modification in a particular tissue or cell type, 
and at specific developmental time-points (Sauer, 1998). It is therefore the most 
commonly used tool for studying the functional role of particular genes in Schwann 
cells during development and after nerve injury, in order to understand how 
alterations in their expression levels may contribute to health or disease in vivo. 
The Cre recombinase protein is an enzyme found in bacteriophage P1 that mediates 
site specific recombination, at a 34 base pair site called loxP. The loxP sites consist 
of two 13bp inverted repeats flanking an 8bp asymmetric core sequence. When two 
loxP sites are placed either side of an endogenous target DNA sequence, Cre is able 
to mediate recombination and thus the excision of the targeted DNA sequence; this 
particular method can be used to conditionally knockout a particular gene [see 
Figure 1.8] (Sauer, 1998). Alternatively this method can also be used to switch on 
the expression of a particular gene at a specific time-point. This is beneficial for 
turning on a gene that may cause morbidity or reduced viability in the transgenic 
mouse line. In this second case, a STOP cassette floxed by loxP sites could be 
inserted between the gene of interest and the promoter, thus only upon Cre 
mediated excision of the STOP signal will the gene be expressed [See Figure 1.9]. 
(Sauer,1998). A reporter gene such as green fluorescent protein (GFP) can be 
added either after the second loxP site (when wanting to achieve gene deletion) or 
after the target gene (when wanting to activate gene expression), this will only be 
expressed upon Cre-mediated recombination. Cre recombinases can be supplied to 
a system by either crossing a mouse stain containing the Cre recombinase gene 
(usually under the control of a specific promoter) in vivo, or by infection with a virus 
containing the gene in vitro.  
Cre expression can be selectively enforced in Schwann cells when regulated under 
the control of a Schwan cell specific promotor element. The most common promoter 
used is the P0 promoter, which has been shown to successfully drive the expression 
of Cre. The P0 Cre transgene (as known as mP0TOTA Cre) contains the complete 
mouse P0 gene (all exons and introns), with 6 kilobases (6 kb) of promoter and the 
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natural polyadenylation site, which has a mutated ATG start sequence that has been 
substituted with the Cre recombinase enzyme (Feltri et al., 1999a). As P0 is 
expressed in Schwann cells from approximately E13.5-15, Cre driven recombination 
also occurs at this time. The desert hedgehog (DHH) promoter sequence can also 
be used to drive Cre (DHH Cre), this gene is expressed in Schwann cell precursors 
from E12 and therefore causes Cre-recombination at earlier time-points than P0-Cre 
(Lindeboom et al., 2003, Jaegle et al., 2003). Alternatively, the 3.9kb periostin 
promoter sequence (Postn Cre) can be used in order to drive Cre recombination in 
Schwann cell precursors at an even earlier time-point, E11 (Lindsley et al., 2007). 
Nonetheless unlike P0, DHH and periostin are not specific to Schwann cells and are 
expressed in other cells types. DHH is expressed in the skin of the snout and parts 
of the vasculature (blood vessel wall endothelial cells) at E12 and in Sertoli cells 
found in the testis at postnatal day 15 (P15) (Lindeboom et al., 2003). Periostin is 
found in endocardial cushion cells, and suggested to cause recombination in some 
PNS neurons.    
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Figure 1. 8: Cre-mediated excisive recombination to achieve target gene deletion in 
mice. In the F0 generation mice carrying the Cre transgene (Cre
+) are crossed with mice 
carrying the target gene, flanked by two loxP sites. In the F1 generation, Cre-loxP mediated 
gene excision will occur in mice positive for the Cre transgene and therefore gene function 
will be altered. In mice negative for the Cre transgene, the loxP flanked target gene will not 
be excised and therefore the gene function will remain unaltered.   
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Figure 1. 9: Cre-mediated excisive recombination to achieve target gene expression in 
mice. In the F0 generation mice carrying the Cre transgene (Cre
+) are crossed with mice 
carrying the stop cassette, flanked by two loxP sites. In the F1 generation, Cre-loxP 
mediated excision of the STOP cassette will occur in mice positive for the Cre transgene and 
the target gene will be expressed. In mice negative for the Cre transgene, the loxP flanked 
STOP cassette will not be excised and therefore the target gene will not be expressed. 
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1.10.2 The use of P0 Cre-loxP recombination in the generation 
of Sox2 overexpressing mice 
Gene trapping is an approach used to introduce insertional mutations across the 
mammalian genome. The method requires mutation to be inserting into an intronic or 
coding region of genomic DNA, using a specific gene trap vector containing a 
reporter gene (to identify cell lines where the vector has successfully be inserted). 
Trap vectors are composed of DNA sequences derived from cDNA or genomic DNA 
of the trap locus. The Rosa26 gene trap cassette containing a β-galactosidase 
reporter gene inserted into the Rosa26 locus where it has been shown to be 
ubiquitously expressed across a wide range of mouse tissue types, including the 
brain, bone marrow, spleen and muscle from embryonic development (Zambrowicz 
et al., 1997). The Rosa26 locus (located on mouse chromosome 6) and the Rosa26 
gene trap cassette are therefore commonly used for the integration of transgenes. 
Furthermore, gene insertions into the Rosa26 locus do not cause any adverse 
effects (for e.g. animal viability or cell phenotype is not affected) and the inserted 
gene is not subjected to gene silencing (Zambrowicz et al., 1997).  
In order to achieve Sox2 overexpression at the Rosa26 locus, a conditional allele of 
the Rosa26 locus was created by Lu et al. (2010) and referred to as Rosa26R-Sox2-
IRES-GFP [See Figure 1.10]. To prevent Sox2 from being expressed under normal 
conditions by the Rosa26 locus, a neo-STOP sequences flanked by two loxP sites 
was inserted upstream of the Sox2 gene. Only upon removal of the neo-STOP 
sequence by Cre-loxP mediated recombination will Sox2 be expressed.  
The pRosa26 promoter expresses the gene of interest at low levels, therefore to 
increase the levels of Sox2 transcription factor after recombination, a synthetic 
cytomegalovirus early enhancer/ chicken beta actin (CAG) promoter was inserted 
upstream of the Sox2 gene. The CAG promoter is a hybrid promoter generated by 
combining the human CMV immediate-early enhancer/promoter (hCMV) and the 
chicken β-actin promoter, in order to drive gene expression at high levels (Garg et 
al., 2004).  
The human CMV immediate-early enhancer/promoter (hCMV) is able to increase the 
target gene expression, however in the presence of interferon γ (IFNγ), gene 
expression levels are reduced. Studies have also shown that the activity of hCMV 
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promoter varies in different tissues and cell lines, for e.g. it is not transcriptionally 
active in most cells in the mouse skin (Garg et al., 2004). The chicken β-actin 
promoter is highly active across a wide range of cell types and modified versions 
were initially used to efficiently drive the expression of interleukin 5 (IL5) in BMT10 
cells (Jun-ichi et al., 1989). When these two individual promoters are coupled 
together (CAG promoter), they have been shown to be more effective at promoting 
higher levels of transgene expression, than when used separately. Furthermore, the 
CAG promoter has been shown to be more effective at driving gene expression 
across many more cell and tissue types (Alexopoulou et al., 2008, Garg et al., 2004). 
In order to easily identify the cells in which Cre-mediated recombination has taken 
place, an IRES-EGFP (internal ribosomal entry site-enhanced green fluorescent 
protein) cassette was inserted downstream of the Sox2 gene. Thus in all cells where 
recombination has taken place and Sox2 is expressed, GFP will also be expressed.  
In order to obtain transgenic mice that conditionally overexpress Sox2, mice 
homozygous for the Rosa26R-Sox2-IRES-EGFP allele were crossed with mice 
carrying the mTOTA-P0 Cre transgene [described in section 1.10.1]. P0 is expressed 
in Schwann cells at embryonic day 13.5-15 and therefore recombination should 
occur at this time-point (Feltri et al., 1999a, Lu et al., 2010a).  The expected outcome 
of this cross is that all of the offspring will be heterozygous for the Sox2-IRES-EGFP 
transgene, with 50% being P0 Cre positive (
+) or P0 Cre negative (
-). In order to 
generate mice that are also homozygous for the Sox2-IRES-EGFP transgene and 
Cre+ / Cre-, selected heterozygous Sox2-IRES-EGFP Cre+ mice were then crossed 
back with homozygous Sox2-IRES-EGFP mice [See Figure 1.11].  
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Figure 1. 10 schematic diagram of the Rosa26R-Sox2-IRES-EGFP allele targeting 
scheme. The Rosa26R-Sox2-IRES-EGFP allele was created by inserting a CAG–loxP-
STOP-loxP-Sox2-IRESGFP-polyA cassette into an accepting Rosa-targeting plasmid. GFP 
is only detected upon Cre mediated recombination and removal of the Neo stop sequence is 
floxed by the loxP sides. Adapted from (Lu et al., 2010a).  
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Figure 1. 11 Mouse breeding scheme to generate Sox2 overexpressing mice. Diagram 
shows the sequences of crosses that were made with transgenic mice during this research. 
Homozygous Sox2-IRES-EGFP mice were crossed with P0 Cre
+ mice in order to create 
generation N1 (A). The resulting offspring were either heterozygous Sox2-IRES-EGFP Cre– 
or heterozygous Sox2-IRES-EGFP Cre+ (B).  Heterozygous Sox2-IRES-EGFP Cre+ mice 
were then crossed back with homozygous Sox2-IRES-EGFP to generate N2 (C). The 
resulting offspring were either heterozygous Sox2-IRES-EGFP Cre– (Het control), 
heterozygous Sox2-IRES-EGFP Cre+ (Sox2HetOE), homozygous Sox2-IRES-EGFP Cre– 
(Homo control) or homozygous Sox2-IRES-EGFP Cre+ (Sox2HomoOE) (D).   
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1.10.3 The use of P0 Cre-LoxP recombination in the generation 
of p38α knockout mice. 
To obtain Schwann cell specific p38α conditional knockout mice, mice that are 
homozygous for the p38α transgene, containing loxP sites surrounding exon 2 and 3 
[see Figure 1.12], were crossed with mice containing the mTOTA-P0 Cre transgene 
[described in section 1.10.1] and are homozygous for the p38α transgene. As 
discussed in section 1.10.1, recognition of the loxP sites by Cre will result in Cre 
recombination and thus removal of exons 2 and 3 from the p38α transgene. As 
reported by Heinrichsdorff et al. (2008), removal of exons 2 and 3 results in p38α 
becoming inactivated and not being expressed (Heinrichsdorff et al., 2008). 
The resulting offspring from the cross mentioned above will be either heterozygous 
for the p38α transgene and Cre- or heterozygous for the p38α transgene and Cre+. In 
order of obtain mice that are homozygous for the p38α transgene and Cre+ 
(conditional p38α knockout), an additional cross is required: mice heterozygous for 
the p38α transgene and Cre+ are backcrossed with mice homozygous for the p38α 
transgene. The resulting offspring from this final cross will be one of 4 genotypes; 
heterozygous for the p38α transgene and Cre-, heterozygous for the p38α transgene 
and Cre+, homozygous for the p38α transgene and Cre- (controls) or homozygous for 
the p38α transgene and Cre+ (p38α knockout) [See Figure 1.13].  
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Figure 1. 12: A schematic description of the p38α targeting strategy to generate mice 
with loxP-flanked p38α alleles. (A) p38α wild type allele containing exons 2 and 3 and the 
ATP binding site of the kinase domain. (B) p38α transgene containing an inserted neomycin 
(Neo) resistant cassette, as a selectable marker. The Neo cassette is flanked by two short 
flippase (FLP) recognition target (Frt) sites: white arrows indicate Frt sites; black arrows 
indicate loxP sites. (C) Using FLP target recombination the Frt flanked Neo cassette was 
removed from the p38α transgene. (D) Cre recombination in p38αfl/fl:P0Cre
+ mice [see Figure 
1.13] results in deletion of exon 2 and 3 and the generation of a p38α conditional knockout 
allele. BamHI (B); HindIII (H) restriction endonucleases. Adapted from (Heinrichsdorff et al., 
2008).  
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Figure 1. 13: Mouse breeding scheme to generate p38α knockout mice. Diagram shows 
the sequences of crosses that were made with transgenic mice during this research. (A) 
p38α flox/flox (fl/fl) mice were crossed with P0 Cre
+ wild type/wild type mice in order to create 
generation N1. (B) The resulting offspring were either heterozygous p38α flox/wild type Cre– 
or heterozygous p38α flox/wild type Cre+. (C) In order to generate N2, the selected p38α 
flox/wild type Cre+ offspring were then crossed with p38α flox/flox mice. (D) This resulted in 
p38α flox/flox Cre+ (p38α conditional knockout mice) offspring which are born at an expected 
Mendelain ratio of 3:1. p38α flox/flox Cre-  were used as controls in this study.   
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Chapter 2 Materials and Methods 
 
2.1 Cell culture  
2.1.1. Primary Rat Schwann cell preparation  
Pure rat Schwann cell cultures were prepared, through serum purification (Brockes 
et al., 1979). The sciatic nerve and brachial plexus were removed from post-natal 
day 3 (P3) rodents and placed in L15 medium [Sigma]. Having removed the 
epineurial sheath, the nerves were placed into a digestion solution containing 50:50 
2.5mg/ml trypsin [Invitrogen] and 4mg/ml collagenase [Worthington enzymes, 
Lakewood, USA] (both dissolved in Earle’s balanced salt solution [Sigma]). Nerves 
were incubated for 45 minutes at 37°C, 5% CO2 in a Hera cell 240 incubator 
[Heraeus] and then triturated up to 10 times with a blue pipette tip (maximum volume 
1ml) and 20 times with a yellow tip (maximum volume 200μl). The cell suspension 
was centrifuged at 200xg for 5 minutes in a 5702 centrifuge [Eppendorf, Cambridge, 
UK], the pellet was resuspended in 2ml of 10% FCS/DMEM containing 10-5M of the 
anti-mitotic cytosine arabinoside C (Ara C) [Sigma] and the cells plated on to pre-
coated 35mm dished [Greiner, Stonehouse, UK] [Table 2.1]. Plates were coated with 
100μg/ml poly-L-lysine (PLL) [Sigma, Poole, UK] diluted in 1x phosphate buffered 
saline (PBS) for 60 minutes at room temperature, washed with 1x PBS and then 
coated with 4μg/ml laminin [Invitrogen, Paisley, UK] diluted in DMEM for 60 minutes 
at room temperature (note, the cells were plated without washing the laminin). Cells 
were incubated for 3 days at 37°C, 5% CO2 and then changed into growth medium 
[Table 2.1].  The medium on the cells was changed every 3 days.  
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Rat Schwann cells  
1g/L Glucose 
DMEM 
3%  Fetal bovine serum 
2µM forskolin 
10ng/ml Neuregulin 
500U/ml P/S 
Table 2. 1: Growth medium used for Schwann cells. Lists the culture medium used to 
expand primary cells used in this study. The Dulbecco’s Modified Eagle Medium (DMEM), 
serum, growth factors and antibiotics used are all listed. The bottom row indicates the 
proteins used to coat cell culture plates. 
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 2.1.2. Passaging Cells 
Growth medium was removed and cells were washed in PBS, then incubated with 
trypsin/ethylenediamine tetraacetic acid (EDTA) solution [PAA] (0.5mg/ml trypsin and 
0.22mg/ml EDTA dissolved in 1x PBS) for 2 minutes at 37°C. The volume of 
trypsin/EDTA used for each culture dish is listed in Table 2.2. Approximately 5ml of 
10%FCS/DMEM solution was added to suspended cells and centrifuged at 200xg for 
5 minutes. The cell pellet was resuspended in growth medium and replated onto 
fresh PLL/laminin coated plates. 
 
2.2. Cell culture experiments  
2.2.1.  Plating cells 
Cells were cultured for immunocytochemistry and western blotting experiments. For 
immunocytochemistry, 5000 rat Schwann cells were plated onto coated coverslips in 
the 15μl droplet onto 100μg/ml poly-D-lysine [Sigma] (diluted in water, 2 hours at 
room temperature) and 20μg/ml laminin (diluted in defined medium, 30 minutes at 
37°C) coated 13mm glass coverslips [Scientific laboratory supplies (SLS), 
Nottingham, UK] placed in a 24 well plate. After 2 hours each well was topped up 
with 500μl of defined medium (DM) [For DM composition see Table 2.3].  
 
To harvest cells for protein experiments, 100,000 cells were plated per well of a 6 
well plate in growth medium. After cells had grown to confluency, medium was 
removed and replaced with 3ml/well defined medium. For some experiments 
300,000 rat Schwann cells were plated onto 90mm cell culture dishes instead. All 
culture dishes were coated as required [Table 2.2].  
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Table 2. 2: Volume of growth medium and trypsination solution. The volume of solution 
needed for each size cell culture plate. All plates supplied by Greiner.  
  
Culture dish Growth medium 
volume 
Trypsin/EDTA volume 
35mm 2ml 0.5ml 
90mm 10ml 1.5ml 
6 well plate 3ml per well 1ml per well 
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Table 2. 3: Composition of defined medium. Table lists all the components of the defined 
medium used in this study and their respective final concentration. 
  
Components Concentration 
Hams F12 Medium [Invitrogen] 48% 
DMEM Medium [Invitrogen] 48% 
Bovine serum albumin (BSA) [Sigma] 350µg/ml 
Putrescine [Sigma] 16µg/ml 
Transferrin [Sigma] 100µg/ml 
Thyroxine (T4) [Sigma] 400ng/ml 
Progesterone [Sigma] 60ng/ml 
Dexamethasone [Sigma] 38ng/ml 
Glutamine [Sigma] 2mM 
Penicillin /Streptomycin (P/S) [Invitrogen] 100 U/ ml 
Selenium [Sigma] 160ng/ml 
Insulin [Sigma] 10-6 M 
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2.2.2.  Defined medium (DM) 
The composition of defined medium, which is designed to maintain Schwann cells in 
a quiescent non-proliferative state, is detailed in Table 2.3 (Jessen et al., 1994, 
Parkinson et al., 2008).  All cells were incubated for 1 hour in defined medium before 
adenoviral infection. Basal conditions were determined by incubation of cells for 48 
hours in DM alone. 
2.2.3.  Adenoviral infections 
Rat Schwann cells were infected with 4μl/ml adenovirus (equivalent to a multiplicity 
of infection of ~1500) in DM supplemented with 2μM forskolin [For the list of all 
adenoviruses used in this study see Table 2.4] (Parkinson et al., 2001). After 24 
hours, infected media was aspirated and replaced with fresh DM (with no forskolin) 
for a further 24 hour incubation before fixing or lysing of cells for analysis.  
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Adenovirus Expressed 
protein 
Tag GFP Backbone Source [Reference] 
 
Ad GFP Green 
fluorescent 
protein (GFP) 
alone. 
- Yes AdEasy-1 Gift from Prof. J 
Milbrandt [Washington 
Uni.School of Medicine, 
St Louis, USA] 
(Nagarajan et al., 2001) 
Ad Sox2 Sox2 Flag Yes AdEasy-1 Gift from Prof. J. 
Milbrandt. 
(Le et al., 2005a) 
Table 2. 4: Adenoviral vectors. Table lists the adenovirus names, expressed protein, 
antibody tag (Flag or none), co-expression of green fluorescent protein (GFP), adenoviral 
backbone, vector source and original reference. Ad Easy-1 is based on the adenovirus 
serotype 5 (Ad5) with deletions in E1 and E3 viral regions to render them replication 
incompetent (He et al., 1998).  
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2.3. Transgenic animals 
2.3.1. Transgenic animal crossing 
Transgenic mouse breeding and experiments were carried out according to Home 
Office regulations under the UK Animals (Scientific Procedures) Act 1986. Ethical 
approval for all experiments was granted by Plymouth University Animal Welfare and 
Ethical Review Board (AWERB).  
To identify the effect of Sox2 overexpression in Schwann cells in vivo, we crossed 
homozygous Rosa26R-Sox2-IRES-GFP mice which were a gift from Dr Mark Onaitis 
(Duke University Medical Centre, Durham, USA) (Lu et al., 2010b) with P0-CRE 
(mTOTA P0-Cre) mice (Feltri et al., 1999).  This allowed us to generated 
heterozygous Rosa26-Sox2-IRES-EGFP CRE positive (+) and CRE negative (-) 
offspring. Heterozygous Rosa26-Sox2-IRES-EGFP CRE+ offspring were then 
crossed with homozygous Rosa26-Sox2-IRES-EGFP mice to generate heterozygous 
and homozygous Rosa26R-Sox2-IRES-GFP CRE- and CRE+ mice [For genetic 
crossing see Figure 1.11]. CRE+ animals carrying one copy of the Rosa26-Sox2-
IRES-EGFP transgene are referred to as Sox2HetOE; CRE+ animals carrying two 
copies of the Rosa26-Sox2-IRES-EGFP transgene are referred to as Sox2HomoOE. 
For analysis of both Sox2HetOE and Sox2HomoOE mice, age and sex-matched 
heterozygous and homozygous Rosa26-Sox2-IRES-EGFP CRE- animals were used 
as control animals: Neither heterozygous nor homozygous Rosa26-Sox2-IRES-
EGFP CRE- animals express P0-Cre and therefore do not underdo Cre 
recombination, which would allow for the overexpression of Sox2.  Thus both 
heterozygous and homozygous Rosa26-Sox2-IRES-EGFP CRE- animals are 
suitable to be used as controls against both Sox2HetOE and Sox2HomoOE animals.  
2.3.2. Transgenic animal genotyping 
Genotyping is carried out in order to determine the genetic make-up of a transgenic 
animal by examining its DNA. The procedure will reveal the alleles that the individual 
animal has inherited from its parents. In the case of the Sox2 overexpressing mice, 
we wanted to determine whether the animals had inherited one or two copies of the 
Rosa26R-Sox2-IRES-GFP allele which contains LoxP sites, to identify if they were 
heterozygous or homozygous for the Rosa26R-Sox2-IRES-GFP transgene. We also 
wanted to determine if the animals were P0-CRE+, as heterozygous and 
89 
 
homozygous Sox2-IRES-GFP CRE- mice were used as controls [See Figure 1.11 for 
crosses]. In the case of the p38α knockout mice, we were looking for animals that 
had inherited LoxP sites on both alleles and were P0-CRE+. Mice which were 
p38αflox/flox CRE- were used as controls [see Figure 1.13 for crosses]. 
Genomic DNA was extracted from ear notch or tail samples using the hot sodium 
hydroxide and tris (HotSHOT) method (Truett et al., 2000): 75μl of alkaline lysis 
reagent [Table 2.12] was added to the tissue samples, either ear notches or tail 
snips. Using a PTC-100 Peltier Thermal Cycler [M.J. Research, Waltham, USA] the 
samples were heated to 95°C for 1 hour and 30 minutes and then cooled to 4°C. 
75μl of neutralisation reagent [Table 2.12] was added to the lysed sample, the 
sample was then vortexed and stored at -20 ˚C.  
In order to check the genotype of the Rosa26R-Sox2-IRES-GFP animals, three 25μl 
PCR master mix reactions were prepared per lysed tissue sample [For master mix 
components see Table 2.5]:  
(1) In order to determine the P0-CRE status of the animals, 1μl of P0-CRE forward 
and reverse primers [see Table 2.6] was added to 1 reaction [see Figure 2.1 for an 
example of the agarose gel];  
(2) to identify if whether the Sox2-IRES-GFP mice were carrying one or two copies of 
the Rosa26R-Sox2IRES-GFP transgene, 1μl of R26 wild type forward and reverse 
primers [Table 2.6] was added to second reaction [see Figure 2.1 for an example of 
the agarose gel];  
(3) to confirm the presence of the Rosa26R-Sox2-IRES-GFP transgene in the 
homozygous Sox2-IRES-GFP animals, 1μl of Sox2-IRES-GFP forward and reverse 
primers [see Table 2.6] was added to a third reaction [see Figure 2.1 for an example 
of the agarose gel].  
In order to determine the check the genotype of the p38α animals, two 25μl PCR 
master mix reactions were prepared per lysed tissue sample [see Table 2.5]: (1) To 
determine the P0-CRE status of the animals, 1μl of P0-CRE forward and reverse 
primers [see Table 2.6] was added to 1 reaction; (2) to determine the p38α LoxP 
status of the animals, 1μl of p38α LoxP forward and reverse primers [see Table 2.6] 
was added to another reaction [see Figure 2.2 for an example of the agarose gel]. 
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PCR was carried out using a PTC-100 Peltier thermocycler [for standard PCR 
programme see Table 2.7 and for variations to the standard programme see table 
2.6]. 15μl of each PCR reaction was electrophoresed in 1x tris-acetate-EDTA (TAE) 
solution, on a 1.5% (w/v) agarose gel [Invitrogen] (diluted in TAE), at 90-100V for 45-
60 minutes using a Power Pac 300 [Biorad] and a SubCell® GT tank [Biorad] [For 
TAE see Table 2.13]. DNA bands were visualised with GelRed Nucleic Acid Gel 
Stain (10,000x) (1:10,000 in the agarose gel) [Biotium, California, USA]  and images 
captured on a BiodocIt™ Imaging system [UVP, Cambridge, UK] [for variations to 
standard protocol see Table 2.6 
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Component concentrations Volume 
DNA or cDNA  
 
 2µl 
ddH20  14.9µl 
 
5 x Green GoTaq® Buffer  
[Promega] 
 5 µl 
MgCl2  
[Promega] 
1.5mM 1.5 µl 
Forward and reverse primers 
[MWG, Ebersburgh, Germany] 
0.5 picomoles 1 µl 
Deoxynucleotide triphosphate 
(dNTP) [Promega] 
200µM 0.5 µl 
Taq Polymerase 
[Promega] 
1.25U 0.1 µl 
Table 2. 5 : Components of polymerase chain reaction master mix used for both 
genotyping and semi-quantitative RT-PCR. Table lists all the components used in a PCR 
mastermix per 25µl reaction.  
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Gene Forward primer 
sequence 5’- 3’ 
Reverse primer 
sequence 5’- 3’ 
Anneal 
temp 
(˚C) 
No. of 
Cycles 
MgCl2 
Conc. 
(mM) 
Size 
(bp) 
P0-CRE 
(M) 
 
CCACCACCTCT
CCATTGCAC 
GCTGGCCCAAA
TGTTGCTGG 
57 35 1.5 492 
R26 WT 
(M) 
GGAGCGGAGA
AATGGATATG    
              
AAAGTCGCTCT
GAGTTGTTAT  
50 38 1.5 550 
Sox2-IRES-
GFP (M) 
 
CTACCTGAGCA
CCCAGTCCG 
ATAACACCTAC
TCAGACAATGC 
62 30 1.5 309 
p38  
(M) 
 
CTACAGAATGC
ACCTCGGATG 
AGAAGGCTGGA
TTTGCACAAG 
62 35 1.5 1) 121 
2) 188 
Neuroserpin 
(M) 
 
ATCCAATGAGG
CTGGTGGTA 
CTTCGATCAGC
TGTGCTTTG 
51.7 35 1.5 140 
Krox20  
(M) 
 
GCCAAGGCCGT
AGACAAA 
 
TTGCCCATGTA
AGTGAAGGTC  
53 35 1.5 154 
Necl 4 
(M) 
TGCAGTGGTAG
AGGCTCAGA 
 
GCCTCATGGGT
CAGATAGGA 
54 35 1.5 144 
Sox2  
(M)  
 
CAGCTCGCAGA
CCTACATGA 
TGGAGTGGGA
GGAAGAGGTA 
55 35 
 
1.5 152 
18S 
(M) 
 
GAGAAACGGCT
ACCACATCC 
GGACACTCAGC
TAAGAGCATCG 
55 39 1.5 
 
339 
Table 2. 6: Polymerase chain reaction conditions for each primer pair. Table lists the 
target gene transcript to be amplified (Gene), the sequence of the forward and reverse 
primer, the annealing temperature (Anneal. Temp), number of cycles, magnesium chloride 
concentration and the fragment size in base pairs (bp) for each reaction. In some cases as 
seen when analysing the p38 gene, two PCR fragments of different sizes (bp) are produced 
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in mice heterozygous for the transgene; the wild type p38 fragment (121bp) and the p38 
floxed “transgene” fragment (188bp)  [see Figure 2.2]. (M) denotes a mouse target transcript.  
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Step Number Conditions 
Step 1 95˚C for 5 minutes 
Step 2 95˚C for 45 seconds 
Step 3 55˚C for 45 seconds 
Step 4 72˚C for 1 minute 
Step 5 Back to steps 2-4, 29 times 
Step 6 72˚C for 10 minutes 
Step 7 4˚C  
Table 2. 7: Standard polymerase chain reaction program. For variations to the annealing 
temperature and number of cycles for individual primers see Table 2.6. 
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Figure 2. 1: Example of an agarose gel showing P0-CRE, R26 and Rosa26R-Sox2-
IRES-GFP genotypes. (A) Samples with a large band at 492bp indicate that these animals 
inherited the P0-CRE allele e.g. 2, 3, 4, 5. (B) Samples with a large upper band at 550bp 
indicate that these animals carry the wild type Rosa26 allele e.g. 2, 5, 7, 8. (C) Samples with 
a band at 309bp indicate that these animals have inherited the Rosa26R-Sox2-IRES-GFP 
transgene e.g.1, 2, 3, 4, 5, 6, 7, 8. Animals which are heterozygous for the R26 WT allele 
and the Rosa26R-Sox2-IRES-GFP transgene and are P0-CRE positive will be Sox2 
heterozygous over-expressors (Sox2HetOE) e.g. 2 and 5. Animals which are homozygous for 
the Rosa26R-Sox2-IRES-GFP transgene and are P0-CRE positive will be Sox2 
homozygous over-expressors (Sox2HomoOE) e.g. 3 and 4. Animals which are heterozygous for 
the R26 WT allele and the Rosa26R-Sox2-IRES-GFP transgene and are P0-CRE negative 
will be Sox2 heterozygous controls (Het Control) e.g. 7 and 8. Animals which are 
homozygous for the Rosa26R-Sox2-IRES-GFP transgene and are P0-CRE negative will be 
Sox2 Homozygous Controls (Homo Control) e.g. 1 and 6.  
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Figure 2. 2: Example of an agarose gel showing p38α LoxP genotypes. (A) p38 loxP 
heterozygous samples are represented by double bands, one at 121bp (p38α wild type 
band) and one at 188bp (p38α floxed band) indicating that these animals have a p38α loxP 
site on only one allele (wt/fl) e.g. 1, 3, 4, 5, 8. p38α loxP homozygous samples are 
represented by a single band at 188bp, indicating that these animals have P38α loxP sites 
on both alleles (fl/fl) e.g. 2, 6, 7, 9.   
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2.3.3. Nerve dissection for analysis 
The sciatic nerve and brachial plexus was removed from mice ranging in age from 
postnatal day 2 (P2) to adult, and snap frozen immediately in liquid nitrogen, then 
stored at -80°C for future western blotting analysis. For immunohistochemistry  
nerves were fixed in 4% w/v paraformaldehyde (PFA) [Sigma] pH 7.4, diluted in 1x 
PBS [for PBS see Table 2.12], overnight at 4ºC,  then washed 3 times for 5 minutes 
in 1xPBS before being immersed in 30% w/v sucrose [Sigma] diluted in 1x PBS 
overnight at 4ºC, to allow for  cryoprotection.  For electron microscopy nerves were 
fixed in 2.5% (w/v) glutaraldehyde diluted in 0.1M sodium cacodylate buffer [for 
sodium cacodylate buffer see Section 2.12] overnight at 4°C.  
2.3.4. Sciatic nerve injury 
Transgenic mice were anaesthetized with isoflurane, the right sciatic nerves were 
exposed and either crushed or cut approximately 1cm distal to the sciatic notch. For 
nerve crush, the sciatic nerve was compressed using a pair of round end forceps, as 
previously described (Dun and Parkinson, 2015). The left contralateral sciatic nerve 
was left uninjured. Mice were euthanized at the indicated time and both the uninjured 
and injured distal sciatic nerves were collected for analysis.  
2.3.5 Cryosectioning of sciatic nerve  
Sciatic nerve samples were placed into a plastic embedding mould [Agar Scientific], 
filled with Tissue-Tek® optimum cutting temperature (OCT) compound [Sakura 
Finetek Europe B.V. Netherlands] and frozen slowly in liquid nitrogen. The frozen 
blocks were then sectioned into 10μm slices using an OTF 5000 Cryostat [Bright 
Instrument Co. Ltd, UK] and each section was placed on a positively charged 
SuperFrost® Plus microscope slide [VWR] and allowed to dry before staining.
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2.4. Analytical techniques  
2.4.1. Reverse transcription polymerase chain reaction (RT-   
  PCR) 
RT-PCR is used as a semi-quantitative method to detect the rate of transcription of a 
target gene by measuring the abundance of the corresponding mRNA. Reverse 
transcription is used to convert isolated mRNA into cDNA, which can then be 
amplified by PCR and detected by agarose gel electrophoresis. 
 
Total RNA was harvested from the sciatic nerves of 21 day old mice, using an 
RNeasy Plus® Mini Kit [Qiagen,Crawley, UK] following the manufacturer’s protocol. 
Briefly sciatic nerves were lysed, DNA removed by passage over a gDNA eliminator 
column, RNA bound to an RNeasy spin column, washed and RNA eluted in 30μl of 
RNase free water. RNA concentration (260nm or absorbance at A260) and purity 
(A260/A280) were measured using a Nanodrop 2000 spectrophotometer [Thermo-
Scientific]. For each sample 1μg of RNA was reverse transcribed into cDNA using M-
MLV Reverse Transcriptase enzyme [Promega] and random hexamer primers 
[Promega] following the manufacturer’s protocol. Gene expression was then 
measured by PCR. Each 25μl PCR reaction was made up of 2µl cDNA and 23µl of 
master mix (For master mix components see Table 2.5). PCR was performed in a 
PTC-100 or PTC-200 thermocycler [MJ Research,Waltham, USA] [for standard 
program see Table 2.7 and for variations to the standard protocol see Table 2.6]. 
15μl of each PCR reaction was electrophoresed in 1x Tris-acetate-EDTA (TAE) 
solution, on a 2% (w/v) agarose gel [Invitrogen] (diluted in TAE), at 120V for 45-60 
minutes using a Power Pac 300 [Biorad] and a SubCell® GT tank [Biorad] [For TAE 
see Table 2.12]. DNA bands were visualised with GelRed nucleic acid gel stain 
(10,000x) (diluted 1:10,000 in the agarose gel) [Biotium, California, USA]  and 
images captured on a BiodocIt™ Imaging system [UVP, Cambridge, UK] [for 
variations to standard protocol see Table 2.6]. 
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2.4.2. Immunofluorescent staining 
Immunofluorescent staining is a technique used to visualise the expression and 
localisation of a protein within a cell. Primary antibodies are raised against epitopes 
from proteins of interest and bound by secondary antibodies conjugated with 
fluorescent chromophores. Chromophores are excited by specific wavelengths of 
light, and fluoresce; releasing light of a lower frequency/longer wavelength. This can 
be detected and recorded using a digital camera on a fluorescent microscope. 
2.4.2.1. Immunocytochemistry 
Culture medium was aspirated and cells were fixed with 500μl/well 4% w/v 
paraformaldehyde (PFA) [Sigma] pH 7.4, diluted in 1x PBS, for 10 minutes [for PBS 
see Table 2.12]. 4% PFA was removed and cells washed twice with nonsterile 1x 
PBS. Coverslips were placed on staining platforms and blocked / permeabilised with 
antibody diluting solution (ADS) containing 0.2% (v/v) Triton X-100 [Sigma] (ADST) 
for 30 minutes at room temperature [for ADS see Table 2.12]. Primary (1°) antibody 
was diluted in ADST and 50μl of primary antibody solution added to each coverslip 
and incubated overnight at 4°C [for concentrations of specific 1° antibodies see 
Table 2.8]. The next day coverslips were washed six times in 1x PBS and secondary 
(2°) antibody diluted in ADS, including Hoechst [Sigma] at a final concentration of 
4μg/ml, was applied for 30 minutes at room temperature [for specific 2° antibodies 
see Table 2.10]. Coverslips were then washed 6 times in 1x PBS, mounted on 
frosted glass slides [VWR] using 10μl Citifluor antifade glycerol/PBS mounting 
medium [Agar Scientific, Stansted, UK] and sealed with nail varnish. 
2.4.2.2. Immunohistochemistry  
Sciatic nerve samples were fixed in 4% w/v paraformaldehyde overnight, washed 3 
time for 5 minutes in 1x PBS and then dehydrated in 30% sucrose overnight; all 
overnight steps were done at 4°C. Sciatic nerve samples were placed into a plastic 
embedding mould [Agar Scientific], coated with Tissue-Tek® OCT compound [Agar 
Scientific] and frozen slowly in liquid nitrogen. 8μm thick sciatic nerve sections were 
cut from the frozen blocks using an OTF 5000 Cryostat [Bright Instrument Co. Ltd, 
UK], placed onto positively charged SuperFrost® Plus microscope slide [VWR], and 
allowed to dry before staining.  
 
100 
 
Slides mounted with tissue samples were washed once for 5 minutes in 1x PBS and 
a hydrophobic barrier was drawn around the sample using a PAP pen [Fisher 
Scientific, Loughborough, UK]. If required, samples were fixed with -20˚C methanol 
(MeOH) for 10 minutes at room temperature. Tissue samples were permeabilised / 
blocked with either ADST or ADS for 60-90 minutes at room temperature then 
washed once for 5 minutes in 1x PBS. 1˚ antibodies diluted in either ADS or ADST 
were added overnight at 4ºC [for concentrations of specific 1° antibodies see Table 
2.8]. The next day tissue samples were washed 3 times for 5 minutes in 1x PBS and 
2° antibodies (1:250), including Hoechst dye (1/1000) [Sigma]  diluted in ADS were 
applied for 45 minutes at room temperature [for specific 2° antibodies see Table 2.8]. 
Tissue sections were then washed 3 times in 1x PBS, mounted in Citifluor antifade 
glycerol/PBS mounting medium and a glass cover slip was sealed over the top of the 
tissue section with nail varnish.  
2.4.2.3. 3-layer protocol 
In some instances to increase staining intensity a 3-layer staining protocol was used 
[Table 2. 8]. Tissue samples were permeabilised / blocked and incubated with 1° 
antibody following the standard protocol. The 2° antibody was replaced with a 
biotinylated secondary antibody, raised against the primary antibody species, diluted 
1:250 in ADS and incubated for 60 minutes at room temperature. Samples were then 
washed 3 times for 5 minutes in 1x PBS before incubating with either Alexa Fluor® 
streptavidin 568 (1:1000) [Invitrogen] or Alexa Fluor® streptavidin 633 (1:1000) 
[Invitrogen] tertiary layer and Hoechst dye (1/1000) diluted in ADS for 45 minutes at 
room temperature. Tissue samples were washed 3 time for 5 minutes in 1x PBS, 
mounted and sealed as standard protocol. 
2.4.2.4. Imaging and quantification 
Stained slides were visualised under a fluorescence microscope. For counting 
experiments, all specific antibody staining in cells and across nerve tissue samples 
were scored as positive and counted. Photos were taken using a Nikon Eclipse 80i 
Fluorescence microscope [Nikon, Kingston upon Thames, Surrey], an intensilight C-
HGF1E lightbox [Nikon] and the NIS Elements software package [Nikon]. Photos 
were taken using the x10, x20 or x40 objective lenses. 
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Antibody Dilution Fix Block / 1˚ 
diluent 
2˚antibody Source 
Sox2 1/200 4% PFA ADST Anti-rabbit Millipore [Watford, 
UK] 
Krox20 1/100 4% PFA ADST Anti-rabbit Covance [Princeton, 
New Jersey, USA] 
MBP 1/100 4% PFA ADS Biotinylated 
Anti-goat 
[Vector 
Laboratories] 
Santa Cruz 
Biotechnology 
[Texas, USA] 
P0 1/100 First 4% 
PFA, then 
MeOH 
fixation 
ADS Biotinylated 
anti-mouse 
[Vector 
Laboratories, 
Peterborough, 
UK] 
Gift from Prof. J. 
Archelos 
[Uni. of Graz, Graz, 
Austria] 
Ki-67 1/200 4% PFA ADST Anti-rabbit Abcam 
 
cJun 1/200 4% PFA ADST Anti-rabbit Cell Signalling 
 
F4/80 1/250 First 4% 
PFA, then 
MeOH 
fixation 
ADS Anti-rat Abcam 
IBA1 1/300 First 4% 
PFA, then 
MeOH 
fixation 
ADS Biotinylated 
Anti-rabbit 
[Vector 
Laboratories] 
Wako Pure 
Chemical industry 
CD3e 
 
1/200 First 4% 
PFA, then 
MeOH 
fixation 
ADS Anti-Hampster BD Pharmingen 
NIMP 1/200 First 4% 
PFA, then 
MeOH 
fixation 
ADS Biotinylated 
Anti-rat 
[Vector 
Laboratories] 
Abcam 
Survivin  1//100 4% PFA ADST Biotinylated 
anti-Goat 
[Vector 
Laboratories] 
Santa Cruz 
Biotechnology 
[Texas, USA] 
 
Sox10 1/1000 4% PFA ADST Biotinylated 
Anti-rabbit 
[Vector 
Laboratories] 
Gift from Prof. M. 
Wegner 
[Erlangen 
University, 
Erlangen,Germany] 
N-cadherin 
 
1/400 4% PFA ADST Biotinylated 
Anti-rabbit 
[Vector 
Laboratories] 
Becton Dickinson 
Β-catenin 
 
1/200 4% PFA ADST Anti-Mouse Becton Dickinson 
Neurofilament 
 
1/500 4% PFA ADST Anti-Chicken Abam 
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Table 2. 8: Primary antibodies used for immunoflourescent staining. Table lists the 
primary antibodies alongside the 1° antibody dilution, fix, block / permeabilisation / 1° 
antibody diluent solution and source. Secondary antibodies used were Alexa Fluor® goat 
anti-rabbit 568, goat anti-hamster 568 and goat anti-chicken 568, goat anti-rat 568 
[Invitrogen]. A biotinylated secondary antibody indicates a 3-layer staining protocol was 
used. 
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2.4.3. Western blotting  
Western blotting is used to identify the expression levels of different proteins within 
tissue or cell preparations. Proteins are extracted from tissues or cells using a cell 
lysis buffer and separated according to their molecular weight through sodium 
dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE). Proteins are 
transferred to membranes and probed with primary and secondary antibodies; the 
latter conjugated with horseradish peroxidase (HRP). Membranes are then coated 
with chemiluminescent substrate reagent, which interacts with the HRP enzyme, 
resulting in an enzymatic reaction which releases light. This can be detected using 
photographic film and an X-ray film developer.   
Cells were lysed in 1x dilution of radio-immunoprecipitation assay (RIPA) buffer 
containing 1:20 Complete™ Mini EDTA free protease inhibitor cocktail [Roche, 
Lewes, UK], 1:100 phosphatase inhibitor cocktail II [Sigma] and 1:50 phosphatase 
inhibitor cocktail C [Santa Cruz] [For RIPA buffer see Table 2.12]. Cell lysate was 
collected on ice using a cell scraper, heated to 95°C for 5 minutes, cooled on ice, 
centrifuged at 13 400xg for 15 minutes in a MicroCentaur centrifuge [MSE, London, 
UK] and the supernatant stored at -80°C.  
 
Sciatic nerve tissue samples were lysed in 1x SDS lysis buffer [for SDS buffer see 
table 2.12], sonicated for 10 seconds, heated to 95°C for 5 minutes, cooled on ice, 
centrifuged at 13,400 x g for 5 minutes in a MicroCentaur centrifuge [MSE, London, 
UK] and the supernatant stored at -80°C. 
 
Protein concentrations were estimated using a BCA™ protein assay [Thermo 
Scientific, Epsom, UK] following the manufacturer’s instructions and absorbance at 
562nm measured on a GENIos microplate reader [Tecan, Reading, UK] using the 
XFluor software add-in [Tecan]. Prior to electrophoresis, 4x reducing sample buffer 
was added to the lysate, the samples were then boiled at 95°C for 5 minutes [for 
sample buffer see table 2.12]. 
 
Samples were loaded onto either a 10% or 12% w/v polyacrylamide gels (depending 
on the size of the proteins of interest) alongside 10μl of Precision Plus Protein All 
Blue Standard [Bio-Rad].  SDS PAGE was performed in 1x running buffer at 
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constant 150V for 1.5 hour in a Mini Protean® 3 Cell [Bio-Rad]. Protein was 
transferred to Immuno-Blot™ polyvinylidene fluoride membranes [Bio-Rad] in 1x 
transfer buffer at constant 250mA for 1.5 hours at room temperature or constant 
85mA overnight at 4°C. Membranes were blocked in either 5% (w/v) milk powder 
[Marvel, Coolock, Republic of Ireland] or 5% (w/v) bovine serum albumin (BSA) 
[Fisher Scientific] dissolved in 1x Tris buffered saline (TBS) for 2 hours at room 
temperature [For gels, buffers and solutions see Table 2.12]. Primary antibodies 
were diluted in the blocking solution and incubated on a roller at 4°C overnight [For 
specific primary antibody dilutions see Table 2.9]. Following primary antibody 
incubation, membranes were washed 3 times for 5 minutes in 1x TBS and incubated 
with HRP conjugated secondary antibodies [Promega], diluted 1:5,000 in 2.5% (w/v) 
milk powder 1x TBS, for 1 hour at room temperature. Membranes were then washed 
3 times for 10 minutes in 1x TBS then incubated with SuperSignalTM West Pico 
chemiluminescent substrate [Thermo-Scientific] for 5 minutes in the dark. 
Photographic film, Hyperfilm™ [GE Healthcare, Amersham, UK] was exposed to the 
membranes for between 5 seconds and 5 minutes, as required, in a Hypercassette™ 
[GE Healthcare]. Exposed film was developed using a Compact X4 automatic X-Ray 
film processor [XoGraph Imaging Systems Ltd, Tetbury, UK] following the 
manufacturer’s instructions. Films were scanned using a Fluor-S TM Multi-imager 
[BioRad].   
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Antibody 
[Source] 
Dilution Block 2˚Antibody Molecular weight 
(kDa) 
Sox2  
[Novus Biological] 
1:1000 5% Milk Anti- Rabbit 
HRP 
37  
c-Jun  
[BD Biological] 
1:1000 5% Milk Anti- Mouse 
HRP  
37-40  
MBP 
[Santa Cruz 
Biotechnology] 
1:2000 5% Milk/  Anti- Goat 
HRP 
17 
Protein Zero (P0) 
Gift from Prof. J. 
Archelos 
1/20000 5% Milk/ 
 
Anti- Mouse 
HRP 
25  
β-tubulin 
[Santa Cruz 
Biotechnology 
1/2500 
 
5%  Milk Anti- Mouse 
HRP 
50 
Sox10 
Gift from Michael 
Wegner 
1/5000 5% Milk/ BSA Anti-Guinea 
pig HRP 
58  
Krox-20 
[Covance] 
1:1000 5% BSA Anti- Rabbit 
HRP 
65  
 
Necl 4 (cadm4) 
[Origene]  
1:5000 5% BSA Anti- Goat 
HRP 
65  
p38α 
[Cell signaling] 
1:500 5% BSA Anti- Mouse 
HRP 
38  
p-p38  
[Cell signaling] 
1:500 5% BSA Anti- Rabbit 
HRP 
38 
P-Erk1/2  
[Cell signaling] 
1:500 5% BSA Anti- Rabbit 
HRP 
42-44 
Sox10 
[Abcam] 
1:1000 5% Milk Anti-Rabbit 
HRP 
55-60 
Table 2. 9: Primary antibodies for western blotting. Table lists the primary antibodies 
used in this study, the source and corresponding dilutions, blocking solutions and secondary 
antibodies.  
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2.4.4. Electrophysiology 
Electrophysiology is the study of electrical activity of excitable cells. The suction 
electrode method was used to analyse the extracellular electrophysiology of mouse 
sciatic nerves. In this technique, glass electrodes are used to record the summation 
of all the action potentials produced by all the individual axons within a nerve bundle; 
the compound action potential (CAP). Nerves are placed into saline-filled electrodes, 
the proximal end connected to an amplifier and the distal end connected to a 
stimulus recording unit (recordings are usually orthodromically), thus upon 
stimulation the extracellular compound response can be recorded. 
2.4.4.1. Electrophysiological recording of compound action 
potentials using suction electrodes 
Sciatic nerve samples were placed onto an interface perfusion chamber [Harvard 
Apparatus Inc] for 30-45 minutes and allowed to equilibrate before measurements 
were initiated.  This was done to allow the sciatic nerve to recover from the trauma of 
the dissection and to regain homeostatic control over its ionic environment. The 
sciatic nerves were kept at 37ºC at all times, perfused with artificial cerebrospinal 
fluid (aCSF) [For aCSF buffer see Table 2.12] and oxygenated with 95% O2, 5% CO2, 
which was passed through a water chamber for warming and humidification (Fern et 
al., 1998, Alix and Fern, 2009).  
Upon experimentation, compound action potentials (CAP) were evoked via square-
wave constant-voltage current pulses of 150 to 600 µsecs delivered by an isolated 
stimulus unit (Iso Stim A320; World Precision Instruments, Stevenage, UK) at 30 
second intervals. The proximal end of the sciatic nerve was placed into an aCSF 
filled glass stimulating electrode, containing a chloride silver wire in the lumen and 
another wrapped around the barrel, near the end of the electrode to provide the 
current return. The distal end of the sciatic nerve was placed into an aCSF filled 
recording glass electrode, with a chloride silver wire running through the lumen. A 
third electrode, the subtraction electrode, was placed next to the recording electrode 
to suppress the stimulus artefact and electrical noise. All electrodes were connected 
via a high impedance head stage (Axon Instruments) to an amplifier (Axon 
Instruments, Cyber Amp 320; Union City, CA), which subtracted the signal from the 
subtraction electrode, from the signal originating from the recording electrode. The 
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resulting signal was amplified 10 times, filtered (low-pass1000 Hertz) and digitized 
(25,000Hz, 1401 mini; Cambridge Electronic Design).  The resulting signal was 
displayed on a computer using Signal software (Cambridge Electronic Design).  
2.4.4.2. Electrophysiology data analysis 
Nerve conduction velocity (NCV) is the speed at which an electrochemical impulse is 
propagated down a neural pathway. Conduction velocity speeds largely depend on 
axon diameter and the level of axon myelination. In this experiment, CAP recordings 
were used to calculate the NCV of sciatic nerves taken from P20 mice and adult 
mice which had undergone sciatic nerve crush (21 days post injury). NCV was 
calculated from two parameters: (1) Conduction distance (nerve length), and (2) 
latency to peak of compound action potential (the time difference between the peak 
of the CAP and the start of the stimulus artefact) (Alix and Fern, 2009) [For 
mathematical formula see Table 2.10]   
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Mathematical formulas 
 
Nerve conduction 
velocity (NCV) 
(m/s) = 
Conduction distance (Nerve Length) 
 
Latency of the Peak CAP (Peak of the CAP − Start of the 
stimulus artefact) 
 
Static sciatic 
index (SSI) = 
 
(118.9 x TSF ) – (52.2 x PLF) -7.5 
 
TSF = TS experimental – TS normal / TS normal 
PLF = PL experimental – PL normal / PL normal 
 
Table 2. 10: Mathematical formulas. Table lists the formulas used to calculate NCV and 
SSI from the given parameters. (TSF) denotes toe spread factor, (TS) denotes toe spread, 
(PLF) print length factor, and (PL) denotes print length.   
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2.4.5. Motor-Sensory functional testing 
2.4.5.1. Rotarod performance testing 
Rotarod performance testing is used to measure motor function, co-ordination and 
balance. In this experiment rotarod performance testing was used to analyse the 
motor function of control and Sox2OE mice ages 6 and 8 weeks old. The apparatus 
was set up in an environment with minimal stimuli (such as noise, movement or light 
changes). Mice underwent three training trials; they were placed onto a rotating rod 
which accelerated from 2 to 30 rotations per minute in 250 seconds. The mice were 
given a 1 hour rest in-between each training trial, it was considered a valid test if the 
mice ran forward on the rod. The next day mice were re-tested the animals following 
the above mentioned protocol and the latency to fall off was recorded. The average 
latency time was used as the outcome value.  
2.4.5.2. Static sciatic index 
Static sciatic index (SSI) is a method for assessing functional loss and recovery after 
peripheral nerve injury in mice over a duration of time. Using video analysis of 
standing animals, parameters (1-5 toes spread and print length) taken from the 
normal and experimental hindpaw are compared by a mathematic formula [For SSI 
mathematical formula see Table 2.10] and provide information related to the degree 
of sensory-motor functional changes (Baptista et al., 2007, Bervar, 2000). 
SSI analysis was carried out on mice which had undergone sciatic nerve crush 
injury. Mice were placed into a clear perspex box and paw print measurements were 
taken using a video camera, from each mouse before surgery (0 days), 2 hours after 
surgery (0.1 days) and thereafter at 2-3 day intervals for 21 days following injury. 
The degree of functional loss and recovery post-surgery was calculated as described 
above.  
2.4.5.3. Toe spread reflex 
Toes spread reflex is used to assess the degree of functional recovery following 
nerve injury. Normally when rodents are lifted by their tail, the legs extend laterally 
and the toe digits spread, maximising the distance between them. Following nerve 
injury, the ability to carry out this toe spread reflex is impaired, however in time 
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improves in relation to the degree of nerve regeneration and functional recovery in 
animals.   
In this experiment, mice which had undergone sciatic nerve crush injury were lifted 
gently by the tail and toe spread reflex was assessed at 12, 14, 17, 19 and 21 days 
post injury. A score of 0 was given when there was no leg extension or toe 
spreading, a score of 1 was given when there was partial leg extension and partial 
toe spreading and a score of 2 was given when there was full leg extension and full 
toe spreading (Siconolfi and Seeds, 2001). The total score per genotype (a minimum 
of 3) at each time-point was given as the toe spread reflex score. 
2.4.5.4. Von Frey filament threshold testing 
Von Frey filaments are commonly used to measure sensory function. The method 
involves the application of varying pressures to the mid-plantar surface of the 
hindpaw in order to determine the mechanical withdrawal threshold.  
In the experiment, Von Frey filament threshold testing was carried out on 6 week old 
mice and mice which had undergone sciatic nerve crush injury at 7, 10, 12, 14, 17, 
19 and 21 days post injury. Mice were placed into a plastic cage on a metal mesh 
floor and Von Frey filaments ranging from 180g to 0.008g were applied to the mid-
plantar surface of the right hindpaw (when in contact with the floor) for 5-8 seconds. 
Filaments were applied in ascending order and the smallest filament to induce a foot 
withdrawal response was considered the threshold stimulus (Vogelaar et al., 2004).  
2.4.5.5. Toe Pinch test 
Toe pinch testing is commonly used as a method for measuring sensory function and 
peripheral nerve regeneration after nerve injury. This technique involves using a pair 
of fine smooth forceps to lightly pinch the most distal part of the toes in order to 
generate a response.  
In this experiment, pressure and sensitivity tests were carried out on 6 week old mice 
and mice which had undergone sciatic nerve crush injury at 7, 10, 12, 14, 17, 19 and 
21 days post injury. Animals were gently scruffed and the most distal part of toe 3, 4 
and 5 on both hindlimbs (normal and experimental) were lightly pinched. A response 
was considered upon reflex withdrawal or the animal making a sound (Siconolfi and 
Seeds, 2001).   
111 
 
2.4.6. Electron microscopy 
Electron microscopy is a viewing technique used to visualise the ultrastructure of a 
specimen under high magnification with high resolution. The technique is operated 
under a vacuum and works by using an electromagnetic lens to focus beams of 
electron on to a specimen to generate an image. There are two basic types of 
electron microscopes, the scanning electron microscope (SEM) [For details see 
section 2.4.6.2] and the transmission electron microscope (TEM) [For details see 
section 2.4.6.3]. 
2.4.6.1. Nerve tissue preparation for SEM and TEM 
Sciatic nerve samples were dissected and fixed using 2.5% (w/v) glutaraldehyde 
diluted in 0.1M sodium cacodylate buffer for at least 1 hour. Nerves were rinsed 
twice in 0.1M sodium cacodylate buffer at room temperature for 1 hour [see Section 
2.12], then secondary fixed with osmium tetroxide (1% in sodium cacodylate buffer) 
for 1 hour. After rinsing twice with sodium cacodylate buffer, the tissue was then 
dehydrated through an alcohol series, starting with 30% ethanol, then 50%, 70%, 
90% and finally 100% ethanol. The rinse with 100% ethanol was repeated twice, and 
each rinse was left for 15 minutes to ensure adequate exchange of liquids. Once the 
alcohol dehydration was complete, the 100% ethanol was replaced with Agar low 
viscosity resin. Tissues were placed into increasing concentrations of resin, 30% 
(30% resin: 70% ethanol), 50% (50% resin: 50% ethanol), 70% (70% resin: 30% 
ethanol) and finally 100% resin. The 100% resin change was repeated twice, and 
each change was left for at least 12 hours to allow the resin to completely infiltrate 
into the tissue. Tissue samples were then placed into a mould embedding Beem 
capsules and transferred into a Taab embedding oven [Agar Scientific, UK], where 
the resin was polymerised at 60oC overnight (12 hours) to form a solid matrix that 
thoroughly permeates the tissue.  
2.4.6.2 Scanning electron microscopy 
Scanning electron microscopy (SEM) can be used to take high resolution and 
magnification images of cell surface morphology. Within the scanning electron 
microscope, a focused beam of electrons are scanned along the surface of the 
sample under low vacuum. The electrons interacting with the sample, then produce 
various signals that can be detected and provide information about the sample 
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surface topography. In this experiment, the polished surface of a nerve was exposed 
to a beam of electrons. Backscattered electrons (electrons which come into contact 
with the specimen and are reflected back) were then detected with a backscatter 
electron detector and used to form an image. The image formed related to the 
chemical composition of the specimen, through atomic number contrast; bright 
intensities correlate with parts of the sample with a high atomic number, and dark 
areas correlates with parts of the sample with low atomic number. SEM was 
conducted in the Plymouth Electron Microscopy Centre [PEMC, Plymouth, UK].  
Following nerve tissue preparation and resin embedding [see section 2.4.6.1], the 
resulting hard blocks were removed from the Beem capsule and trimmed with a 
Leica Ultracut E ultramicrotome using a glass knife, to expose the surface of the 
tissue specimen. Samples were imaged on a JEOL 6610 LV scanning electron 
microscope [JEOL, Welwyn Garden City, UK] at 15kV, with a 12mm working 
distance and at x700 and x1500 magnifications. 
2.4.6.3. Transmission electron microscopy 
Transmission electron microscopy (TEM) can be used to take high resolution and 
magnification images of the cellular structures of a specimen. Within the 
transmission electron microscope, a beam of electrons is transmitted through an 
ultrathin stained section under a high vacuum. The beam of electrons is then either 
transmitted through the specimen, absorbed or scattered by internal structures of the 
specimen. An image is formed from the transmitted electrons below the specimen 
and is detected by a charge-coupled device (CCD) camera [GATAN Orius]. The 
image detected by the camera is then displayed on a computer. TEM was conducted 
in the Plymouth Electron Microscopy Centre [PEMC, Plymouth, UK]. 
 
Following nerve tissue preparation and resin embedding [see section 2.4.6.1], the 
resulting hard blocks were removed from the Beem capsule and sectioned with a 
Leica Ultracut E ultra-microtome using a diatome diamond knife [Agar Scientific]. 
The resulting sections (80nm thick) were then places onto supporting 200 mesh thin 
bar copper grids [Agar Scientific]. The copper grids with the sections were then 
stained using a saturated solution of uranyl acetate for 15 minutes, washed in double 
distilled water for 30 seconds, then stained with a solution of Reynold’s lead citrate 
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for 15 minutes [for staining solutions see Table 2.11]. Samples were imaged on a 
JEOL 1400 transmission electron microscope [Jeol, Welwyn Garden City, UK] at 
120kV, using a variety of magnifications.         xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
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Solutions Components [sources] 
Uranyl acetate 1g uranyl acetate powder [ Agar Scientific]  
dissolved in 1.5ml of 70% ethanol 
 
Reynolds lead citrate 1pellet (0.1-0.2g) of sodium hydroxide [Agar Scientific] 
0.25g lead citrate powder [Agar scientific] 
dissolved in 50ml double distilled water 
 
Table 2. 11: TEM staining solution. Details of the components used to make up the 
staining solutions for TEM.  
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2.5 Statistical testing 
All numerical data are presented as mean ± 1 standard error of the mean. Unless 
otherwise stated, n=3 was used for all experiments. Statistical significance was 
assessed using Student’s t-Test, one way ANOVA with Bonferroni post-hoc or 
Kruskal-Wallis with Dunn’s post-hoc test and a significance threshold of p value (p) 
<0.05. Statistical significance on graphs was shown as follows P<0.05 as *, P<0.01 
as **, P<0.001 as *** and non-significant (NS). 
2.6 General laboratory solutions 
Composition of all general laboratory solutions shown in Table 2.12. 
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Solutions Components [source] 
10x phosphate buffered saline 
(PBS) 
80.0g sodium chloride [Sigma] 
2.0g potassium chloride [Sigma] 
2.0g mono-potassium phosphate [Sigma] 
11.5g sodium phosphate [Sigma] 
dissolved in 1L water 
 
1x antibody diluting solution 
(ADS) 
20.0ml donor calf serum [Sigma] 
3.6g lysine monohydrochloride [Sigma] 
400μl 10% sodium azide 
dissolved in 180ml 1x PBS 
 
Alkaline lysis reagent  25 mM NaOH [Sigma]  
0.2 mM disodium EDTA  
(pH12- dissolve in H2O without adjusting pH)  
 
Neutralising reagent  40 mM Tris-HCl [Sigma] 
(pH5- dissolve in H2O without adjusting pH)  
 
10x tris buffered saline (TBS) 160.0g sodium chloride [Sigma] 
48.8g Trizma® base [Sigma] 
dissolved in 2L water 
 
10% polyacrylamide running 
gel 
4.8ml water 
2.5ml Trizma®-HCl 1.5M (pH 8.8) [Sigma] 
2.5ml 40% acrylamide/bis [Bio-Rad] 
100μl 10% SDS [Sigma] 
75μl ammonium persulphate (APS) 
10μl Temed [Sigma] 
 
12% polyacrylamide running 
gel 
4.5ml water  
2.3ml Trizma®-HCl 1.5M (pH 8.8) [Sigma]  
3ml 40% acrylamide/bis [Bio-Rad]  
100μl 10% SDS [Sigma]  
75μl ammonium persulphate (APS) [Sigma]  
10μl Temed [Sigma]  
 
10 x Western running buffer 45.5g Trizma® base [Sigma] 
216g Glycine [Sigma]  
15g SDS  
Dissolved in 1.5 litres of water  
 
10 x Western transfer buffer 45.5g Trizma® base  
216.0g glycine  
dissolved in 1.5L water  
 
1 x Western transfer buffer 100.0ml 10x western transfer buffer 
200.0ml methanol [Rathburn Chemicals, 
Walkerburn, UK] 
700.0ml water 
3.8ml 10% SDS 
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Solutions Components [source] 
1x western stripping buffer 1.5g glycine [Sigma] 
0.1g SDS [Sigma] 
1.0ml Tween20 [Sigma] 
dissolve in 100ml ultrapure water 
adjust to pH2.2 
 
2x SDS lysis buffer 
 
4% (w/v) SDS  
20% (v/v) glycerol [Sigma]  
60mM Trizma®-HCl (pH 6.8)  
0.001% (w/v) Bromophenol Blue [Sigma]  
4% (w/v) β-mercaptoethanol [Sigma]  
 
4x reducing loading buffer 8% (w/v) SDS  
40% (v/v) glycerol   
250mM Tris-HCL(pH 6.8)  
200mM dithiothreitol (DTT) [Sigma]  
0.4% (w/v) Bromophenol Blue 
 
RIPA buffer 50mM Tris (pH 7.5)  
150mM Sodium chloride (NaCl)  
1mM Ethylene glycol-bis (2 aminoethylether) 
tetraacetic acid (EGTA) [Sigma)  
1mM Ethylenediaminetetraacetic acid (EDTA) [Sigma] 
1% (v/v) Triton x-100 [Sigma] 
0.5% (w/v) Deoxycholic acid [Sigma]  
0.1% (w/v) SDS [Sigma] 
1mM Sodium orthovanadate [Sigma]  
10μg/ml Leupeptin [Sigma]  
Dissolved in 100ml water 
 
50x tris-acetate-EDTA (TAE) 
solution 
242.0g Trizma® 
57.1ml glacial acetic acid 
100.0ml 0.5M EDTA (pH 8.0) 
dissolve in 1L water 
 
0.1M sodium cacodylate buffer  
 
2.15g sodium cacodylate 
dissolve in 100ml water 
 
Artificial cerebral spinal fluid 
(aCSF)  
126 mM NaCl [Sigma] 
3 mM KCl [Sigma] 
2 mM NaH2PO4 [Sigma] 
2 mM MgCl2 [Sigma] 
26 mM NaHCO3 [Sigma] 
10 mM Glucose [Sigma] 
2 mM CaCl2  [Sigma] 
pH 7.45 and  bubbled with 95% O2, 5% CO2  
 
Table 2. 12: Composition of general laboratory solutions. Details of the components and 
a brief protocol for preparation of general laboratory solutions used in this study.  
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Chapter 3 Schwann cell myelination and sensory-motor function is 
impaired by Sox2 overexpression during development in vivo 
 
3.1 Introduction 
Schwann cells in the peripheral nervous system are renowned for their remarkable 
plasticity, which is regulated by the transcriptional activation of both positive and 
negative myelin regulators. Many positive regulators such as Krox20 (Egr2), Oct6 
(SCIP or Tst1), Sox10, NFkB and NFATc4 have been identified by both in vitro and 
in vivo analysis, but there is relatively little data on potential negative regulators of 
myelination that may be as important in both regulating the correctly timed onset of 
myelination and potentially in the pathology of demyelinating neuropathies of the 
PNS (Parkinson et al., 2004, Finzsch et al., 2010, Bremer et al., 2011, Kao et al., 
2009, Salzer, 2008).  
While the transcription factors Pax3, cJun, Id2 and Sox2, activation of the Notch 
pathway, as well as signalling through the ERK1/2 and p38 mitogen activated protein 
(MAP) kinases, have been shown to inhibit myelination of Schwann cells in vitro, 
there is only direct genetic evidence that increased activation of the Notch or ERK1/2 
signalling pathway in Schwann cells inhibits or is sufficient to drive the de-
myelination of Schwann cells in vivo (Doddrell et al., 2012, Harrisingh et al., 2004, Le 
et al., 2005a, Parkinson et al., 2008, Woodhoo et al., 2009, Yang et al., 2012, 
Jessen and Mirsky, 2008, Mager et al., 2008). The high mobility group (HMG) 
domain transcription factor Sox2 has been shown using an in vitro assay, Schwann 
cell/dorsal root ganglion co-cultures and adenoviral overexpression of Sox2 in 
Schwann cells, to inhibit the induction of Krox20 and myelination of axons but an in 
vivo demonstration of the potential inhibitory role of Sox2 in vivo within the intact 
nerve has not been shown. 
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3.2 Results 
3.2.1 Sox2 overexpressing mice exhibit a phenotype of a peripheral 
neuropathy 
Patients suffering with Charcot Marie Tooth (CMT) disease such as congenital 
hypomyelinating neuropathy (CHN) and CMT-type 1 (CMT-1) disease, clinically 
present symptoms such as muscle weakness, muscular atrophy of the hands, 
sensory loss, characteristic foot abnormalities, tremors, ataxia and areflexia (Jani-
Acsadi et al., 2008). Mouse models of CMT disease have also been shown to mimic 
some of the phenomena that occur in human CMT (Kinter et al., 2013, Saporta et al., 
2012, Wrabetz et al., 2006). CMT mouse models can therefore provide us with a 
good reference to the disease and the ability to gain a deeper understanding of the 
mechanisms that cause and/or enhance disease progression (Sereda et al., 1996, 
Sereda and Nave, 2006, Tanaka and Hirokawa, 2002).    
Sox2 has been previously shown to be upregulated in mouse models of CHN and to 
impair Schwann cell myelination in vitro (Le et al., 2005a). In order to determine 
whether Sox2 was capable of blocking myelination and inducing a phenotype similar 
to that of CMT in vivo, we generated mice which conditionally overexpressed Sox2 in 
Schwann cells. To achieve this we crossed P0 Cre+ mice with mice homozygous for 
the Sox2-IRES-EGFP transgene. This allowed us to generate heterozygous Rosa26 
Sox2IRES-EGFP CRE positive (+) and CRE negative (-) offspring. Heterozygous 
Rosa26 Sox2IRES-EGFP CRE+ animals were then backcrossed with homozygous 
Rosa26 Sox2IRES-EGFP mice to generate heterozygous and homozygous 
Rosa26R-Sox2IRES-GFP CRE– (hereafter referred to either Sox2 Het or Homo 
control mice) and CRE+ mice. CRE+ animals carrying one copy of the Rosa26 
Sox2IRES-EGFP transgene are referred to as Sox2HetOE; CRE+ animals carrying two 
copies of the Rosa26 Sox2IRES-EGFP transgene are referred to as Sox2HomoOE 
mice [See Figure 1.11] (Feltri et al., 1999a, Lu et al., 2010a). In these experiments 
both heterozygous and homozygous Rosa26 Sox2IRES-EGFP CRE- animals are 
suitably used as controls against Sox2HetOE and Sox2HomoOE animals [see section 
2.3.1 for details]. 
During development from postnatal day 21 (P21), we observed that Sox2HomoOE mice 
appeared to be slightly smaller compared to age matched control litter mates, this 
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became even more obvious as Sox2HomoOE mice reached adulthood. By P60, we 
observed that Sox2HomoOE mice displayed typical characteristic of a peripheral 
neuropathy such as hindlimb clasping when lifted by the tail, foot abnormalities, 
ataxia and muscle weakness [Figure 3.1]. These observations suggested that 
overexpression of Sox2 within Schwann cells resulted in the onset of a peripheral 
neuropathy within these mice (Sereda et al., 1996, Sereda and Nave, 2006).   
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Figure 3. 1: Sox2HomoOE mice display characteristics of CMT disease. P60 Sox2HomoOE 
mice were smaller and showed signs of hindlimb clasping(B and D), whilst Sox2 control 
(Homo and Het) littermates were normal in size and displayed normal hindlimb spreading 
when lifted by the tail (A and C).  
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3.2.2 Sox2 overexpression impairs Schwann cell myelination  
In the PNS mature Schwann cells myelinate motor axons in a 1:1 ratio by extending 
their plasma membrane and spirally ensheathing the axonal segment. Multiple 
spirals formed around an individual axon condense into a multilamellar compact 
sheath, enabling axonal protection and saltatory conduction. Nonetheless, in many 
peripheral neuropathies such as CHN and CMT-1 disease, Schwann cells fail to 
sufficiently myelinate axons resulting in severe axonal hypomyelination (Decker et 
al., 2006, Le et al., 2005a, Jessen and Mirsky, 2005).   
As mentioned previously, Sox2 has been shown to be upregulated in mouse models 
of CHN and to impair Schwann cell myelination in vitro (Le et al., 2005a). To 
determine whether Sox2 was capable of blocking myelination in vivo, sciatic nerves 
were removed from Sox2 control (Het and Homo), Sox2HetOE and Sox2HomoOE mice 
and the morphology of the nerves was examined at postnatal day 7, 21 and 60 by 
electron microscopy.  
In the sciatic nerves of Sox2HetOE mice at P7, axons were significantly shifted 
towards having thinner myelin, compared to axons in the sciatic nerves of Sox2 Het 
control mice [Figure 3.2]. In Sox2 Het control mice the average myelin thickness was 
at 0.33 ± 0.005 µm (mean ± 1 standard error of the mean), whereas in Sox2HetOE 
mice the average myelin thickness was significantly lower at 0.28 ± 0.004 µm 
(P<0.001, n=3). Similarly, in the sciatic nerves of Sox2HomoOE mice at P7, axons 
shifted towards having thinner myelin, compared to Sox2 Homo control mice; the 
average myelin thickness of Sox2 Homo control nerves 0.38 ± 0.008 µm, whereas 
the average myelin thickness of Sox2HomoOE nerves was significantly lower at 0.27 ± 
0.01 µm (P<0.001, n=3) [data not shown]. Counts made on the total percentage of 
unmyelinated axons in a 1:1 relationship with Schwann cells showed that there was 
a significant increase in the percentage of unmyelinated axons in the sciatic nerves 
of Sox2HetOE mice (27.6 ± 3.4 %) (P<0.05) and Sox2HomoOE mice (28 ± 2.09 %) 
(P<0.001) compared to Sox2 (Het and Homo) control mice (7.5 ± 0.56 %) at P7 
[Figure 3.2] (n=3 Sox2HetOE, n=3 Sox2HomoOE, n=6 Sox2 control).  Further analysis at 
P21 revealed that overexpression of Sox2 resulted in a significant shift in the 
population of axons towards having a higher g-ratio.  The average  g-ratio observed 
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in Sox2HetOE mice was 0.71 ± 0.003, whereas the average g-ratio observed in Sox2 
Het control mice was 0.68 ± 0.002 (P<0.001, n=3) [Figure 3.3]. The percentage of 
unmyelinated axons in a 1:1 relationship with Schwann cells was also significantly 
increased in the sciatic nerves of Sox2HetOE mice (15.3 ± 1.34 %) at P21 compared to 
Sox2 Het control mice (1.13 ±  0.17%) (P = 0.001, n=3) [Figure 3.3]. Myelin 
thickness was not analysed in the nerves of Sox2HomoOE and Sox2 Homo control 
animals at P21.  
We next wanted to determine whether overexpression of Sox2 resulted in Schwann 
cell hypomyelination in adult mice.  We therefore analyse the sciatic nerves of Sox2 
Het control, Sox2HetOE and Sox2HomoOE mice at P60.  Surprisingly, at P60 there was 
no longer a significant difference in myelin thickness between Sox2 Het control and 
Sox2HetOE mice (P>0.05, n=3); the average g-ratio for Sox2 Het control mice was 
0.66 ± 0.02 and the average g-ratio for Sox2HetOE mice was 0.65 ± 0.02. Further 
analysis also revealed that no significant difference in the total population of 
unmyelinated axons was observed between Sox2 Het control mice (0.17 ± 0.17%) 
and Sox2HetOE mice (0%) at P60 (P>0.05, n=3) [Figure 3.4]. We therefore analysed 
the expression of the Sox2-IRES-EGFP transgene in the Sox2HetOE animals and 
found that expression of both Sox2 and GFP declined from P21 onwards and was 
undetectable at later time-points, either by western blot of by immunocytochemistry 
[data not shown & unpublished data by Dr Xin-Peng Dun in our group]. We were 
unable to conclude at this time why expression levels of Sox2 and GFP decline in 
these Sox2HetOE mice, but it does show that loss of Sox2 expression in a 
hypomyelinated nerve will allow myelination to proceed and complete by P60 in the 
mouse peripheral nervous system.  
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Figure 3. 2: Inhibition of myelination by Sox2 overexpression at P7. Transmission 
electron micrographs of sciatic nerve sections taken from Sox2 Het control (A), Sox2HetOE (B) 
and Sox2HomoOE mice (C) at P7. Graph (D) showing the percentage distribution of axons in 
relation to their myelin thickness; note a shift in the population of axons towards having 
thinner myelin in the sciatic nerves of Sox2HetOE mice. (E) Graph showing a significant 
increase in the population of unmyelinated axons in the sciatic nerves of Sox2HetOE (P=0.026) 
and Sox2HomoOE mice (P=0.007), compared to control P7 mice (n=3 Sox2HetOE, n=3 
Sox2HomoOE, n=6 Sox2 (het and homo) control). 
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Figure 3. 3: Inhibition of myelination by Sox2 overexpression at P21. (A & B) 
Transmission electron micrographs of sciatic nerve sections taken from Sox2 Het control (A) 
and Sox2HetOE mice (B) at P21. Graph (C) showing the percentage distribution of axons in 
relation to their g-ratio; note a shift in the population of axons towards having an increased g-
ratio (i.e. thinner myelin), in the sciatic nerves of Sox2HetOE mice. (D) Graph showing a 
significant increase in the population of unmyelinated axons in the sciatic nerves of 
Sox2HetOE mice compared to Sox2 Het control mice P21 (P = 0.001, n=3 per genotype). 
 
5µm 5µm 
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Figure 3. 4: Inhibition of myelination seen in Sox2HomoOE at P60. (A, B, C) Transmission 
electron micrographs of sciatic nerve sections taken from Sox2 Het control (A), Sox2HetOE (B) 
and Sox2HomoOE mice (C) at P60. (D) Graph showing the average g-ratio of axons; note there 
is significant increase in the g-ratio of Sox2HomoOE mice, compared to control mice (P <0.001, 
n=3 per genotype). (E) Graph showing the population of unmyelinated axons in the sciatic 
nerves of Sox2 Het control, Sox2HetOE and Sox2HomoOE mice; note there is a significant 
increase in the number of unmyelinated axons in Sox2HomoOE mice compared to control mice 
(P<0.01, n=3 per genotype).  
  
5µm 5µm 5µm 
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We next compared myelin thickness in the nerves of Sox2 Het control and 
Sox2HomoOE nerve mice at P60. We revealed that myelin thickness was significantly 
reduced in the nerves of Sox2HomoOE mice, compared to Sox2 Het control mice at 
P60 (P<0.001, n=3); in Sox2 Het control mice the average g-ratio was 0.66 ± 0.2, 
whereas in Sox2HomoOE mice the average g-ratio was significantly higher at 0.87 ± 
0.08 [Figure 3.4]. A significant increase in the total population of unmyelinated axons 
was also observed in the sciatic nerves of Sox2HomoOE mice (46.5 ± 8.04%) at P60 
compared to sciatic nerves of Sox2 Het control mice (0.17 ± 0.17%) (P<0.01, n=3) 
[Figure 3.4]. As nerves taken from Sox2HomoOE mice remained severely 
hypomyelinated we carried out further analysis to determine the expression of the 
Sox2-IRES-EGFP transgene in the animals. In contrast to what was observed in 
Sox2HetOE mice, Sox2 and GFP were both highly expressed within the nerves of 
Sox2HomoOE mice at P60 [Figure 3.7 A-F] and P90 [Figure 3.8 A-F]. Thus having two 
copies of the Sox2-IRES-EGFP transgene appears to retains the expression of Sox2 
and GFP past P21, although we cannot confirm why this is. 
In summary, overexpression of Sox2 is able to alter peripheral myelination during 
development. This was determined by an overall reduction in myelin thickness 
observed at P7 in both Sox2HetOE and Sox2HomoOE mice, at P21 in Sox2HetOE mice and 
at P60 in Sox2HomoOE mice. In addition, overexpression of Sox2 also increased the 
total number of unmyelinatinated axons in a 1:1 relationship with Schwann cells 
during development, and in adult Sox2HomoOE mice.  
To confirm whether the increased number of unmyelinated axons was due to a block 
in Schwann cell development and radial sorting at the immature phase (prior to 
Schwann cells forming a 1:1 ratio with axons), further analysis looking at 
unmyelinated axons was carried out on nerves taken from P7 and P21 Sox2HetOE 
sciatic nerves and P7 and P60 Sox2HomoOE sciatic nerves. EM analysis revealed that 
all axons in the sciatic nerves of Sox2HetOE mice at P7 and P21 were ensheathed by 
either an individual Schwann cell forming a 1:1 ratio with axons >1µm, or a non-
myelinating Schwann cell which groups axons <1µm into structures known as 
Remak bundles; no naked axons (unassociated) were observed [data not shown]. 
Similarly at P7 and P60 all axons in the sciatic nerves of Sox2HomoOE mice were 
ensheathed by either individual Schwann cells forming a 1:1 ratio or non-myelinating 
Schwann cells [Figure 3.5].   
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These observations show that Sox2 overexpression does not affect the early stages 
of axon radial sorting by immature Schwann cells, as clear Schwann cell basal 
laminae can be observed surrounding individual Schwann cells. However, as seen in 
Figure 3.5, panel A (asterisks) there does appear to be some delay in the sorting of 
some large diameter axons in the sciatic nerves of P7 Sox2HomoOE nerves. 
Nonetheless, this appears to be corrected by P60, as all large diameter axons 
appear to be sorted into a 1:1 ratio. Thus, Sox2 expression does not result in any 
long term defects in the segregation of axons; by P60 all large calibre axons (axons 
>1µm) are sorted into a 1:1 relationship with promyelinating Schwann cell and 
smaller calibre axons (axons <1µm) are sorted into Remak bundles. We therefore 
conclude that Schwann cells which overexpress Sox2 are capable of radial sorting 
and normal development up until the promyelinating stage, which is when Sox2 
appears to affect Schwann cell myelination.   
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Figure 3. 5: Sox2 overexpression does not affect axonal sorting. Transmission electron 
micrographs of sciatic nerve sections taken from P7 (A-B) and P60 (C-D) Sox2HomoOE mice.  
Morphological analysis of unmyelinated axons reveal that all axons are sorted into a 1:1 ratio 
with Schwann cells at both P7 (A & B), and P60 (C & D). a, Axon; SC, Schwann cell; Re, 
Remak bundle, *, asterisks identifying a large diameter axon (axon >1µm) in a Remak 
bundle, panel A.  
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3.2.3 Sox2 overexpression impairs myelin protein expression 
Sox2 is initially expressed during Schwann cell development, and is a marker of 
immature Schwann cells. More recently Sox2 has been shown to be re-expressed 
upon nerve injury and following demyelination both in vitro and in vivo (Woodhoo et 
al., 2009, Lee et al. 2005, Decker et al., 2006). Furthermore, Sox2 has been shown 
to negatively regulate the expression of myelin associated genes, including Krox20, 
Protein Zero (P0), Gap junction beta-1 protein (GJB1) and N-myc downstream 
regulated gene 1 (NDRG1) in vitro, consequently blocking the ability of Schwann 
cells to myelinate axons (Le et al., 2005a) 
The zinc finger transcription factor Krox20 (also known as Egr2), is a known master 
regulator of myelination and plays an essential role in activating the expression of 
myelin associated genes; myelin basic protein (MBP), P0, peripheral myelin protein 
22 (PMP22), as well as the induction of lipid and cholesterol synthesizing enzymes 
(Topilko et al., 1994, Nagarajan et al., 2001, Parkinson et al., 2004). The expression 
of Krox20 is critical for Schwann cell myelination and myelin maintenance, as Krox20 
null and mutant mice with a hypomorphic Krox20 allele demonstrate severe 
hypomyelination of the peripheral nerves and impaired expression of myelin 
associated genes (Topilko et al., 1994, Nagarajan et al., 2001, Le et al., 2005a, 
Decker et al., 2006). P0 has also been shown to play a critical role in Schwann cell 
myelination, as it is involved in the adhesion and compaction of the multi-layered 
myelin sheath. Reduced expression, mutations and complete loss of P0 function 
does not affect Schwann cells forming a 1:1 relationship with large diameter axons 
(>1µm in diameter). However, the absence of P0, reduced P0 expression and 
heterozygous P0 mutations in mice, have all been shown to result in the formation of 
abnormal and unstable myelination, which begins to degenerate at approximately 
P21, resulting in reduced motor function and the development CMT-1B (Giese et al., 
1992, Hayasaka et al., 1993, Saporta et al., 2012). P0 is therefore essential for stable 
compact myelin formation and myelin maintenance. As both Krox20 and P0 play 
critical roles in myelination, it was thus essential to determine whether Sox2 was 
capable of negatively regulating their protein expression, in addition to the 
expression of other myelin proteins such as MBP, as a mechanism for Sox2 induced 
hypomyelination [observed in Section 3.2.1].  
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Sciatic nerves taken from Sox2 Homo control and Sox2HomoOE mice at P7, P21, P60 
and P90 were analysed for changes in the expression of myelin proteins by 
immunohistochemical analysis and western blotting. 
At P7, immunohistochemical analysis revealed that Sox2 and green fluorescent 
protein (GFP) (which is coexpressed with Sox2) [see Section 1.9.2] were highly 
expressed within the sciatic nerves of Sox2HomoOE mice, whereas no Sox2 or GFP 
expression was detected in the sciatic nerves of Sox2 Homo control mice (n=3) 
[Figure 3.6]. Immunolabelling of sciatic nerve sections with antibodies for MBP 
further revealed that Sox2 reduced the expression of MBP and the number of MBP 
positive myelin rings in the sciatic nerves of Sox2HomoOE mice, compared to Sox2 
Homo control mice (n=3) [Figure 3.6]. These experiments were repeated by western 
blot, which further revealed that high levels of Sox2 reduced the expression of MBP, 
as well as Krox20 and P0 in the sciatic nerves of Sox2
HomoOE mice, compared to Sox2 
Homo control mice (n=3) [Figure 3.6]. Again at P21, western blot analysis revealed a 
similar effect; high levels of Sox2 dramatically reduced the expression of Krox20 and 
MBP within the sciatic nerves of Sox2HomoOE mice, compared to Sox2 Homo control 
mice (n=3) [data not shown]. An Affymetrix gene array experiment carried out by Dr 
R.Doddrell, using RNA harvested from rat Schwann cells infected with Sox2/GFP or 
GFP expressing adenovirus, revealed that β-tubulin 2A expression remains 
unaltered in the presence of Sox2 overexpression (unpublished data in our group 
from Dr R.Doddrell and Dr Xin-Peng Dun). β-tubulin 2A was therefore used as a 
loading control for all experiments. 
At P60, immunohistochemical analysis revealed high levels of Sox2 and GFP 
expression within the sciatic nerves of Sox2HomoOE mice, whereas no Sox2 or GFP 
expression was detected in the sciatic nerves of Sox2 Homo control mice (n=8 
Sox2HomoOE, n=6 Sox2 Homo control). Immunolabelling of sciatic nerves with 
antibodies for Krox20, revealed that Krox20 was clearly reduced in Sox2HomoOE mice, 
compared to Sox2 Homo control mice (n=4). Accordingly, a reduction in the 
expression of MBP and the number of MBP positive myelin rings was observed in 
the sciatic nerves of Sox2HomoOE mice, as well as a reduction in the expression of P0 
and the number of P0 positive myelin rings, compared to Sox2 Homo control mice 
(n=4) [Figure 3.7]. These experiments were repeated by western blot which showed 
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that Sox2 decreased the expression of Krox20 and myelin proteins P0 and MBP 
(n=4) [Figure 3.7].  
At P90, immunohistochemical analysis revealed that Sox2 and GFP was still highly 
expressed within the sciatic nerves of Sox2HomoOE mice, whereas no Sox2 or GFP 
expression was detected in the sciatic nerves of Sox2 Homo control mice (n=3). 
Similarly, the expression of MBP and the number of MBP positive myelin rings were 
both reduced within the sciatic nerves of Sox2HomoOE mice, compared to Sox2 Homo 
control nerves (n=3) [Figure 3.8]. Western blot analysis at P90 further revealed that 
Sox2 expression remained high the sciatic nerves of Sox2HomoOE mice and was able 
to reduce both Krox20 and MBP protein expression (n=3) [Figure 3.8].  
We therefore confirm that Sox2 is able to inhibit the expression of myelin associated 
proteins, in both early developing (P7 and P21) and adult (P60 and P90) Schwann 
cells. This adds to the increasing evidence that Sox2 is a true negative regulator of 
Schwann cell myelination in vivo.   
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Figure 3. 6: Sox2 impairs myelin protein expression during development. 
Immunofluorescent staining for Sox2 (A-D) shows that control nerves do not express Sox2 
(B), whilst Sox2HomoOE nerves show high expression of Sox2 (D) at P7. Note, control nerves 
do not express GFP (A), whereas GFP is expressed in the nerves of Sox2HomoOE mice (C). 
Immunofluorescent staining for MBP (E-H) shows that control nerves express high levels of 
MBP and more frequent myelin ring structures (F), compared to Sox2HomoOE nerves, which 
express reduced levels of MBP and have fewer myelin rings structures (H) at P7. Western 
blot (I) showing reduced expression of Krox20, P0 and MBP in Sox2
HomoOE nerves compared 
to control nerves at P7 (n=3). Images taken using 40x objective, scale bar is 20µm.   
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Figure 3. 7: Sox2 impairs Schwann cell myelin protein expression at P60. 
Immunofluorescent staining using antibodies against Sox2 (A-F) shows that Sox2 Homo 
control nerves do not express Sox2 (B & C), whereas Sox2HomoOE nerves show high 
expression of Sox2 (E & F) at P60 . Note, control nerves do not express GFP (A), whereas 
Sox2HomoOE nerves highly express GFP (D). Immunofluorescent staining using antibodies 
against Krox20 (G-J) shows that Sox2 Homo control nerves have a high abundance of 
Krox20 positive nuclei (G & H), whereas Sox2HomoOE nerves have few Krox20 positive nuclei 
(I-J). Immunofluorescent staining using antibodies against MBP (K-N) shows that Sox2 
Homo control nerves express high levels of MBP and numerous MBP positive myelin ring 
structures (K & L), whereas Sox2HomoOE nerves express reduced levels of MBP and have 
fewer myelin rings structures (M & N) at P60. Immunoflurescent staining using antibodies 
against P0   (O-R) shows that Sox2 Homo control nerves have thicker and more numerous 
P0 positive myelin ring structures (O & P) compared to Sox2
HomoOE nerves (Q & R). Western 
blot (S) showing reduced expression of Krox20, P0 and MBP and high expression of Sox2 in 
the sciatic nerves of Sox2HomoOE mice, compared to Sox2 Homo controls at P60 (n=4). 
Images taken using 40x objective, scale bar is 20µm. 
 
 
 136 
 
  
 137 
 
Figure 3. 8: Sox2 impairs myelin protein expression at P90. Immunofluorescent staining 
for Sox2 (A-F) shows that control nerves do not express Sox2 (B & C), whereas Sox2HomoOE 
nerves show high expression of Sox2 (E & F) at P90. Immunofluorescent staining for MBP 
(G-J) shows that control nerves express high levels of MBP and numerous MBP positive 
myelin ring structures (H), whereas Sox2HomoOE nerves express reduced levels of MBP and 
have fewer myelin rings structures (J) at P90. Western blot (K) showing overexpression of 
Sox2 leads to reduced Krox20 and MBP expression in the sciatic nerves of Sox2HomoOE mice, 
compared to controls at P90 (n=3). Images taken using 40x objective, scale bar is 20µm. 
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3.2.4 cJun expression is maintained in the sciatic nerves of Sox2 
overexpressing mice 
Like Sox2, cJun has been identified as a marker of immature Schwann cells and a 
negative regulator of myelination (Parkinson et al., 2008, Parkinson et al., 2004). 
Furthermore, Parkinson et al. (2008) identified that cJun and Sox2 are co-expressed 
in Schwann cells after sciatic nerve injury, however it is unclear whether these two 
transcription factors co-regulate one another.  We therefore wanted to identify 
whether cJun levels were also elevated within the sciatic nerves of Sox2 
overexpressing mice. 
Sciatic nerve sections taken from P7 and P60 Sox2 Homo control and Sox2HomoOE 
mice were immunolabelled with antibodies against cJun.  At P7 a minimal difference 
in cJun expression was observed between Sox2 Homo control and Sox2HomoOE 
nerves (n=3). However at P60 a more striking difference in the number of cJun 
positive nuclei was observed; whilst minimal cJun expression was detected in the 
sciatic nerves of Sox2 Homo control mice, clearly elevated nuclear cJun expression 
was detected in the sciatic nerves of Sox2HomoOE mice (n=3) [Figure 3.9].  
These results further support our previous findings that Sox2 maintains Schwann 
cells at the immature Schwann cells state, marked by the expression of an additional 
immature Schwann cell marker, cJun. Furthermore, our results support previous 
studies show that Sox2 and cJun are co-expressed in immature Schwann cells. 
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Figure 3. 9: cJun expression is elevated in Sox2 overexpressing nerves. Sciatic nerve 
sections taken from P7 and P60 Sox2 Homo control and Sox2HomoOE mice were 
immunolabelled with antibodies against cJun. Immunofluorescent staining for cJun at P7 (A-
F) shows that Sox2HomoOE nerves express slightly higher levels of cJun (D-F) compared to 
Sox2 Homo controls (A-C). At P60 Sox2HomoOE nerves showed strong nuclear expression of 
cJun (J-L), whereas only minor levels of cJun was detected in Sox2 Homo control nerves   
(G-I) (n=3). Images taken using 20x objective, (D,E,F, J, K, L  inset 200x), scale bar is 20µm.   
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3.2.5 Sox2 maintains N-cadherin expression in vivo 
Enforced expression of Sox2 in Schwann cells, has been shown to directly drive the 
re-localisation of N-cadherin, a transmembrane protein which mediates cell-cell 
adhesion in a calcium dependent manner, and thus cause the clumping of Schwann 
cells into clusters (Parrinello et al., 2010, unpublished observation by Dun et al., 
submitted: under review). Like Sox2, N-cadherin is highly expressed in Schwann cell 
precursors and immature Schwann cells, but its expression begins to reduce as 
Schwann cells differentiate into myelinating cells (Wanner et al., 2006, Crawford et 
al., 2008). Furthermore, N-cadherin is re-expressed in dedifferentiated Schwann 
cells following nerve injury and is re-localized to the cell contact junctions under the 
regulation of Sox2, allowing for Schwann cell sorting (Parrinello et al., 2010). As 
these studies have all confirmed that Sox2 is able to influence N-cadherin 
localisation, and that N-cadherin is a marker of undifferentiated Schwann cells in 
vitro, we wanted to examine whether the localisation and expression of N-cadherin is 
altered in the sciatic nerves of Sox2 Homo control and Sox2HomoOE mice at P60 by 
immunofluorescent staining. 
Sox2 Homo control nerve sections stained with antibodies for N-cadherin showed 
weak N-cadherin expression. In contrast, N-cadherin was up regulated in the sciatic 
nerves of Sox2HomoOE mice and formed a clear honeycomb like structure (n=3) 
[Figure 3.10]. These results suggest that Sox2 is able to directly increase the 
expression of N-cadherin in Schwann cells in vivo; making this the first study to 
confirm that Sox2 is able to regulate N-cadherin expression in an intact nerve. As N-
cadherin is a marker of immature Schwann cells, these results provide additional 
evidence that Sox2 maintains Schwann cells in an undifferentiated state.  
β-catenin is a known binding partner of N-cadherin and has been shown to co-
localise with N-cadherin at the Schwann cell-Schwann cell interface, as well as the 
Schwann cell-axon interface during Schwann cell development (Lewallen et al., 
2011). Further studies also confirmed that both N-cadherin and β-catenin are 
necessary for axonal induced Schwann cell proliferation and may also play a role in 
establishing Schwann cell polarity and the initiation of myelination (Gess et al., 2008, 
Lewallen et al., 2011). We therefore wanted to test whether Sox2 overexpression in 
vivo would also cause relocalisation of β-catenin.  
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Experiments carried out in vitro revealed that β-catenin expression was increased in 
Sox2 adenoviral infected Schwann cells, in contrast only faint β-catenin expression 
was detected in GFP adenoviral infected Schwann cells (unpublished observation by 
Dun et al., submitted: under review). Furthermore, immunofluorescent staining for β-
catenin in vivo revealed weak cell membrane staining in the sciatic nerves of Sox2 
Homo control mice, however strong cell membrane staining was detected in the 
sciatic nerves of Sox2HomoOE mice at P60 (n=3) [Figure 3.11]. 
These findings further supports the evidence that continued Sox2 expression 
maintains Schwann cells in an immature state and is able to either maintain or up 
regulate the protein expression of both N-cadherin and β-catenin in vivo.  
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Figure 3. 10: N-cadherin expression is elevated in Sox2 overexpressing nerves. 
Immunofluorescent staining for neurofilament and N-cadherin (A-F) revealed weak 
expression of N-cadherin in the sciatic nerves of Sox2 Homo control mice (A-C),  whereas 
strong expression of N-cadherin was observed in the sciatic nerves of Sox2HomoOE mice at 
P60 (D-F) (n=3). Images taken using 40x objective, (B, C, E, F, inset 80x), scale bar is 
20µm. 
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Figure 3. 11: β-catenin expression is elevated in Sox2 overexpressing nerves. 
Immunofluorescent staining for β-catenin (A-F) revealed weak expression of β-catenin in the 
sciatic nerves of Sox2 Homo control mice (B-C),  whereas strong expression of β-catenin 
was observed in the sciatic nerves of Sox2HomoOE mice at P60 (E-F) (n=3). Images taken 
using 40x objective, scale bar is 20µm. 
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3.2.6 Sox2 reduces the expression of Sox10 in vitro and in vivo  
Sox2 has previously been shown to block the induction of Krox20 in vitro by cAMP 
(Le et al., 2005a). More recently, it was further identified that Sox2 is able to block 
the ability of Sox10 and NFATc4 to synergistically bind and activate the Krox20 
Myelin Specific Enhancer (MSE) region, as well as the P0 promoter, thus preventing 
the transcriptional activation of Krox20 and P0 (Kao et al., 2009). However, the effect 
of Sox2 on the induction of transcription factors upstream of Krox20 and P0, such as 
Sox10 is still unknown. We therefore sough to identify whether Sox2 overexpression 
would impair Sox10 expression in vitro and in vivo.  
 
To test this in vitro, Schwann cells were infected with either control GFP or 
Sox2/GFP expressing adenovirus for 24 hours in defined medium supplemented with 
2μM forskolin, which was then removed and replace with defined medium without 
forskolin for a further 24hours. The expression of Sox2 and Sox10 was then 
examined by immunofluorescent staining. 
 
Schwann cells infected with control GFP-expressing adenovirus showed pronounced 
expression of GFP and low levels of Sox2 expression, whereas Schwann cells 
infected with Sox2/GFP-expressing adenovirus showed clear expression of GFP and 
marked expression of Sox2 (n=3) [Figure 3.12 A-D]. Analysis of Sox10 expression 
revealed that Schwann cells infected with control GFP-expressing adenovirus 
showed pronounced expression of Sox10 within their nucleus, whereas Schwann 
cells infected with Sox2/GFP-expressing adenovirus showed very faint Sox10 
expression (n=3) [Figure 3.12 E-H].  
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Figure 3. 12 :Sox2 blocks Sox10 expression in vitro. Rat Schwann cells were infected 
with control GFP (A, B, E, F) or Sox2/GFP (C, D, G, H) expressing adenovirus. 
Immunofluorescent staining for Sox2 (A-D) shows high express of Sox2 in the cells infected 
with Sox2/GFP (D), whereas only faint Sox2 expression could be detected in control cells 
(B). Immunofluorescent staining for Sox10 (E-H) shows high expression of Sox10 in control 
cells (F), whereas Sox10 expression was undetectable in Sox2 infected cells (H) (n=3). 
Western blot (I) shows reduced expression of Sox10 in the presence of high Sox2 
expression (n=1). Images taken using 40x objective, scale bar is 20µm. 
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Further analysis by western blot, showed that the expression of Sox10 was blocked 
in Schwann cells infected with Sox2/GFP-expressing adenovirus compared to 
Schwann cells infected with control GFP-expressing adenovirus (n=1) [Figure 3.12 I]. 
These results identify that Sox2 is able to block the expression of Sox10 by Schwann 
cells in vitro which could explain the mechanisms by which Sox2 impairs the 
expression of Krox20 and myelin proteins P0  and MBP.  
 
As enforced Sox2 expression was sufficient to block Sox10 expression in vitro, the 
next most important question was whether Sox2 was able to block Sox10 expression 
in vivo. To test this we followed up these experiments by analysing the expression of 
Sox10 in the sciatic nerves of Sox2 Homo control and Sox2HomoOE mice by 
immunohistochemistry and western blotting. At P7 and P14, western blot analysis 
revealed that Sox10 expression was quite similar in the sciatic nerves of Sox2HomoOE 
mice and Sox2 Homo control mice (n=3 at P7, n=2 at P14). Nonetheless, 
immunohistochemical analysis revealed that Sox10 expression was slightly reduced 
within the sciatic nerves of P7 Sox2HomoOE mice compared to Sox2 Homo control 
mice at P7 (n=3) [Figure 3.13]. Lastly we analysed the expression of Sox10 in P60 
Sox2HomoOE mice, where the phenotype of the mice appears to be much more 
severe. We observed a more dramatic reduction in the expression of Sox10 at this 
time-point, as well as an shift in the expression of Sox10 towards being more 
cytoplasmic, rather than nuclear in the nerves of Sox2HomoOE mice, compared to Sox2 
Homo control mice at P60 (n=3) [Figure 3.13].  
 
Our preliminary data suggests that maintained overexpression of Sox2 leads to 
reduced Sox10 expression and affects Sox10 nuclear localisation. As Sox10 is an 
essential transcription factor required for Schwann cell myelination and myelin 
maintenance, antagonising Sox10 expression could be a mechanism by which Sox2 
reduces myelination during development, and progressively enhances 
hypomyelination in adult Sox2HomoOE Schwann cells (Bremer et al., 2011).  
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Figure 3. 13: Sox10 expression is slightly altered in vivo by Sox2 overexpression. 
Sciatic nerves taken from P7 (A-F) and P60 (G-L) Sox2 Homo control and Sox2HomoOE mice 
were immunolabelled with antibodies against Sox10. Immunofluorescent staining showed 
weaker Sox10 expression within the sciatic nerves of Sox2HomoOE mice (D-F), compared to 
Sox2 Homo control (A-C) at P7 (n=3). Immunofluorescent staining at P60 again showed 
weaker and less nuclear localised Sox10 expression within the sciatic nerves of Sox2HomoOE 
mice (J-L) compared to Sox2 Homo control mice (G-I) (n=3). Western blots (M-N) showing 
similar levels of Sox10 expression in response to elevated Sox2 levels at P7 (M) (n=3) and 
P14 (N) (n=2). Images taken using 40x objective, scale bar is 20µm. 
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3.2.7 Sox2 reduces the expression of myelin associated genes, in 
addition to upregulating the expression of serine protease 
inhibitor neuroserpin 
Sox2 overexpression has been shown to suppress the expression of myelin related 
genes, including Krox20, MBP and periaxin, as well as the expression of Nectin like 
4 (Necl4), an adhesion molecule essential for normal Schwann cell myelination (Le 
et al., 2005a, Maurel et al., 2007, Spiegel et al., 2007) (unpublished data in our 
group by Dr R.Doddrell). We therefore wanted to confirm whether Sox2 was also 
capable of suppressing the gene expression of Krox20 and Necl4 in vivo.  
 
RNA was extracted from the sciatic nerves of Sox2 Het control and Sox2HetOE nerves 
at P20, reverse transcribed and analysed using semi quantitative RT-PCR. We were 
able to identify that both Krox20 and Necl4 gene expression was reduced in the 
sciatic nerves of Sox2HomoOE mice compared to Sox2 Homo control mice at P20 
[Figure 3.14] (n=1 per genotype). 
 
An Affymetrix gene array experiment carried out by Dr R.Doddrell, using RNA 
harvested from rat Schwann cells infected with Sox2/GFP or GFP expressing 
adenovirus, identified that overexpression of Sox2 massively up regulates the mRNA 
expression of Neuroserpin (55 fold increase). Neuroserpin is a secreted serine 
protease inhibitor which has previously been identified to regulate the expression 
and localization of N-cadherin in PC12 cells (Lee et al., 2008). As we have observed 
that Sox2 appears to increase the expression of N-cadherin in the nerves of 
Sox2HomoOE nerves, we wanted to follow this up and determine whether Sox2 also 
influenced the gene expression of Neuroserpin in vivo. Using semi-quantitative PCR 
we were able to reveal that overexpression of Sox2 resulted in a 1.7 fold increase in 
the expression of Neuroserpin in the sciatic nerves of Sox2HetOE mice at P20; 
however this data is preliminary and more repeats need to be carried out [Figure 
3.14] (n=1 per genotype).  
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Figure 3. 14: Sox2 alters the gene expression of Krox20, Necl4 and Neuroserpin. 
Agarose gel electrophoresis of reverse transcription PCR reactions (A), using RNA prepared 
from the sciatic nerves of Sox2 Het control and Sox2HetOE  mice to analyse the expression of 
Krox20, Neuroserpin and Necl4. Graph (B) showing Sox2 overexpression represses the 
gene expression of Krox20 (n=1). Graph (C) showing Sox2 overexpression up-regulates the 
gene expression of Neuroserpin (n=1). Graph (D) showing Sox2 overexpression represses 
the gene expression of Necl4 (n=1).  
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3.2.8 Sox2 enhances Schwann cell proliferation 
When previously analysing the sciatic nerves of Sox2 Homo control and Sox2HomoOE 
mice for changes in myelin proteins by immunohistochemical analysis, we observed 
an increased number of nuclei in the sciatic nerves of Sox2HomoOE mice. To 
determine whether Sox2 overexpression did in fact alter the number of nuclei within 
these nerves compared to Sox2 Homo control nerves, sciatic nerve sections were 
stained with Hoechst dye and nuclei counts were made at P3, P7 and P60. 
At P3, Sox2HomoOE nerves showed a 7 ± 5% increased number of nuclei per nerve 
section (610.5 ± 31 nuclei per nerve section) compared to Sox2 Homo control nerves 
(565 ± 39.8 nuclei per nerve section), although this was not significant (P=0.4, n=4) 
[Figure 3.15]. At P7, the number of nuclei present in the sciatic nerves of Sox2HomoOE 
(693 ± 67 nuclei per nerve section) was increased by 35 ± 12%, compared to Sox2 
Homo control nerves (512.2 ± 70 nuclei per nerve section), although again this was 
not yet significant (P=0.068, n=5) [Figure 3.16]. Nonetheless, at P60 the number of 
nuclei present in the sciatic nerves of Sox2HomoOE mice (870.3 ± 66 nuclei per nerve 
section), was significantly increase by 70 ±13% compared to Sox2 Homo control 
nerves (511.3±62 nuclei per nerve section) (P<0.01, n=3) [Figure 3.17]. Overall 
these results confirm that Sox2 increases the number of nuclei within the sciatic 
nerves of Sox2HomoOE mice, however at this stage it was not clear if this is due to an 
increase in Schwann cell proliferation, a reduction in Schwann cell apoptosis or an 
increased infiltration of other cells. 
To confirm whether Sox2 enhances the number of nuclei in the nerves of Sox2HomoOE 
mice, by increasing Schwann cell proliferation, sciatic nerve sections taken from 
Sox2 Homo control and Sox2HomoOE mice at P3, P7 and P60 were stained with 
antibodies for Ki67, a cellular marker of proliferation. It has previously been 
published that Sox2 enhances proliferation in stem cells and different cancer cell 
types, but more specifically that Sox2 is capable of enhancing the proliferative 
capacity of Schwann cells in response to the mitogen β-neuregulin (Chen et al., 
2008, Le et al., 2005a, Lu et al., 2010a). 
At P3, no significant change in Schwann cell proliferation was observed in the sciatic 
nerves of Sox2HomoOE mice (106.25 ± 21 Ki67 positive nuclei per nerve section) 
compared to Sox2 Homo control nerves (108 ± 57 Ki67 positive nuclei per nerve 
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section) (P>0.05, n=4) [data not shown]. However, at P7 a significant increase in 
Schwann cell proliferation (1.9 fold increase) was observed in the sciatic nerves of 
Sox2HomoOE mice compared to Sox2 Homo controls; in the sciatic nerves of 
Sox2HomoOE mice there was an average total of 43.6 ± 6.62 Ki67 positive nuclei per 
nerve section, whereas in the sciatic nerves of Sox2 Homo control mice there was 
an average total of 22.83 ± 5.7 Ki67 positive nuclei per nerve section (P<0.05, n=5 
Sox2HomoOE, n=6 Sox2 Homo control) [Figure 3.18]. Similarly, at P60 a significant 
increase in Schwann cell proliferation (3.3 fold increase) was observed in the sciatic 
nerves of Sox2HomoOE mice compared to Sox2 Homo controls; in the sciatic nerves of 
Sox2HomoOE mice there was an average total of 10.75 ± 1.65 Ki67 positive nuclei per 
nerve section, whereas in the sciatic nerves of Sox2 Homo control mice there was 
an average total 3.25 ± 1.1 Ki67 positive nuclei per nerve section (P<0.01, n=4) 
[Figure 3.19]. These results show clearly for the first time that Sox2 is able to directly 
enhance Schwann cell proliferation in vivo.   
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Figure 3. 15: Number of nuclei in the nerves of P3 control and Sox2 overexpressing 
mice. P3 Sox2 Homo control (A and B) and Sox2HomoOE nerve sections (C and D) stained 
with Hoechst nuclear dye. Graph (E) showing a slight increase in the average number of 
nuclei per transverse nerve section taken from Sox2HomoOE mice, compared to Sox2 Homo 
controls at P3: note this change was not significant (P>0.05, n=4 per genotype). Images 
taken using 20x objective, scale bar is 20µm. 
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Figure 3. 16: Number of nuclei in the nerves of P7 control and Sox2 overexpressing 
mice. P7 Sox2 Homo control (A and B) and Sox2HomoOE nerve sections (C and D) stained 
with Hoechst nuclear dye. Graph (E) showing the number of nuclei per Sox2 Homo control 
and Sox2HomoOE transverse nerve section at P7: note an increased number of nuclei in the 
nerves of Sox2HomoOE mice, compared to Sox2 Homo controls, although this was not 
significant (P>0.05, n=5 per genotype). Images taken using 20x objective, scale bar is 20µm. 
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Figure 3. 17: Increased number of nuclei in the nerves of P60 Sox2 overexpressing 
mice. P60 Sox2 Homo control (A and B) and Sox2HomoOE nerves sections (C and D) stained 
with Hoechst nuclear dye. Graph (E) showing a significant increase in the number of nuclei 
per transverse nerve in Sox2HomoOE mice, compared to Sox2 Homo controls at P60 (P<0.01, 
n=3 per genotype). Images taken using 20x objective, scale bar is 20µm. 
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Figure 3. 18: Sox2 increases Schwann cell proliferation at P7. Sciatic nerves taken from P7 (A-F) Sox2 Homo control and Sox2HomoOE mice 
were immunolabelled with antibodies against Ki67. Immunofluorescent staining shows fewer Ki67 positive nuclei in the sciatic nerves of Sox2 
Homo control mice (A-C) compared to Sox2HomoOE mice (D-F) at P7. Graph (G) showing the total number of Ki67 positive nuclei in the sciatic 
nerve section of Sox2 Homo control and Sox2HomoOE mice at P7 (P<0.05, n=5 Sox2HomoOE, n=6 Sox2 Homo control). Images taken using 20x 
objective, (D,E,F, inset 100x),  scale bar is 20µm.
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Figure 3. 19: Sox2 increases Schwann cell proliferation at P60. Sciatic nerves taken from P60 Sox2 Homo control and Sox2HomoOE mice 
were immunolabelled with antibodies against Ki67 (A-F). Immunofluorescent staining shows fewer Ki67 positive nuclei in the sciatic nerves of 
Sox2 Homo control mice (A-C) compared to Sox2HomoOE mice (D-F) at P60. Graph (G) showing the total number of Ki67 positive nuclei in the 
sciatic nerve section of Sox2 Homo control and Sox2HomoOE mice at P60 (P<0.01, n=4 per genotype). Images taken using 20x objective, (D,E,F, 
inset 100x), scale bar is 20µm   
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3.2.9 Sox2HomoOE nerves show an increased influx of immune cells 
Across many slow progressive demyelinating neuropathies such as CMT1-A, B and 
X an elevated number of immune cells such as T-lymphocytes and F4/80 positive 
macrophages appears to be a striking feature, with numbers of immune cells 
increasing with age and disease progression (Mäurer et al., 2002, Kohl et al., 2010a, 
Groh et al., 2010, Groh et al., 2015). Schwann cells in CMT mouse models have 
been shown to mediate macrophage recruitment and activation through the elevated 
expression of chemokines such as MCP1/CCL2 (Kohl et al., 2010a, Groh et al., 
2010). These activated macrophages then go on to secrete cytokines which lead to 
the recruitment of T-lymphocytes, which thereon attract more macrophages and T-
lymphocytes, resulting in a progressive inflammatory/pathogenic environment, with 
axonal damage and Schwann cell demyelination (Mäurer et al., 2002, Kiefer et al., 
2001, Kobsar et al., 2003).  
To assess whether Sox2HomoOE mice also exhibit an increased number of immune 
cells, we immunolabelled sciatic nerve sections taken from Sox2 Homo control and 
Sox2HomoOE mice with antibodies for both macrophages (F4/80 and Iba1) and T-cells 
(CD3).   
Double immunolabelling of sciatic nerve sections with antibodies for both F4/80 and 
Iba1 revealed that at P7, there was an increased number of macrophages present in 
the sciatic nerves of Sox2HomoOE mice (29.6 ± 14.4), compared to Sox2 Homo control 
nerves (15.5 ± 13.2), however this was not significant (P=0.17, n=5 Sox2HomoOE, n=4 
Sox2 Homo control) [Figure 3.20]. Nonetheless, there appeared to be a significant 
increase in the number of macrophages present in the sciatic nerves of P60 
Sox2HomoOE mice (48.5 ± 9.9) compared to control mice (6.3 ± 2.2) (P<0.05, n=4 
Sox2HomoOE, n=3 Sox2 Homo control) [Figure 3.20]. Immunolabelling of sciatic nerve 
sections with antibodies for CD3 (a T cell receptor complex marker) revealed that at 
P7, no T-lymphocytes were present in the sciatic nerves of either Sox2 Homo control 
or Sox2HomoOE mice (n=4) [data not shown]. However at P60, a slight increase in the 
number of CD3 positive T-lymphocytes was observed in the sciatic nerves of 
Sox2HomoOE mice (3.75 ± 1.8), compared to Sox2 homo control mice (0.7 ± 0.3), 
although this was not significant (P=0.13, n=4 Sox2HomoOE, n=3 Sox2 Homo control) 
[Figure 3.21]. These results suggest that like many other demyelinating neuropathy 
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mouse models, Sox2 overexpressing mice also exhibit an increased number of 
immune cells, which progressively increases with age.  
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Figure 3. 20: Sox2 overexpressing nerves have an increased number of macrophages. 
Immunofluorescent staining for F4/80 and Iba1 shows that P7 Sox2 Homo control nerves 
have fewer F4/80 and Iba1 positive cells (B-C) compared to Sox2HomoOE nerves (E-F). Graph 
(G) displaying the total number of macrophages present in the sciatic nerves of Sox2 Homo 
control and Sox2HomoOE mice at P7 (n=4 control, n=5 Sox2HomoOE). (H-M). Immunofluorescent 
staining for F4/80 and Iba1 at P60 show fewer F4/80 and Iba1 positive cells in the sciatic 
nerves of Sox2 Homo control mice (I-J), compared to Sox2HomoOE mice (L-M). Graph (N) 
displaying the total number of macrophages present in the sciatic nerves of Sox2 Homo 
control and Sox2HomoOE mice at P60 (n=3 control, n=4 Sox2HomoOE). Images taken using 20x 
objective, (D,E,F, K, L, M inset 50x), scale bars are 20µm   
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Figure 3. 21: Sox2 overexpressing nerves have an increased number of T-cells. 
Immunofluorescent staining for CD3 shows that P60 Sox2HomoOE mice have more numerous 
CD3 positive T-cells within the sciatic nerve (D-E), compared to Sox2 Homo control nerves 
(A-C). Graph (G) illustrating the total number of T-cells in the sciatic nerves of Sox2 Homo 
control and Sox2HomoOE mice at P60 (n= 3 Sox2 Homo control, n= 4 Sox2HomoOE). Images 
taken using 20x objective, (E,F inset 50x),  scale bar is 20µm.  
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3.2.10 Sox2 overexpression leads to reduced motor and 
sensory function 
To further characterise the phenotype of the Sox2 overexpressing mice, 
electrophysiological, functional and sensory testing was carried out.  
Nerve conduction studies are commonly used in neurological diagnosis and are the 
primary tests used to classify CMT disease, as they provide clues as to whether the 
neuropathy is demyelinating or axonal. In most cases demyelinating neuropathies 
are distinguishable by uniformly slower nerve conduction velocities (Jani-Acsadi et 
al., 2008, Sereda and Nave, 2006). To determine if Sox2 overexpression in Schwann 
cells altered the conduction efficiently of peripheral nerves, extracellular compound 
action potentials were recorded from the sciatic nerves of Sox2 Het control and 
Sox2HetOE mice. These extracellular compound action potential recordings were then 
analysed and used to calculate nerve conduction velocities.  
We observed that at P20, nerve conduction velocities were significantly reduced in 
the sciatic nerves of Sox2HetOE  mice (13.41 ± 0.72 m/s) compared to Sox2 Het 
control mice (15.37 ± 0.44 m/s) (P<0.05, n=13 Sox2HetOE, n=11 Sox2 Homo control) 
[Figure 3.22]. Similarly at P24, a reduction in nerve conduction velocity (NCV) was 
also observed in Sox2HetOE mice (30.43± 2.86 m/s) compared to Sox2 Het control 
mice (37.8 ± 5.31 m/s) (n=2 per genotype) [data not shown]. To determine if NCV 
was also altered in adult mice, further analysis was carried out on P60 mice. 
Likewise, Sox2HomoOE mice exhibited slower nerve conduction velocities (16m/s) 
compared to Sox2 Homo control mice (49m/s) (n=1 per genotype) [data not shown]. 
These experiments demonstrate that overexpression of Sox2 in Schwann cells 
results in a decreased efficiency of peripheral nerves to conduct electrical signals. 
These results however are not surprising as we have previously seen that 
overexpression of Sox2 significantly impairs Schwann cell myelination [see Section 
3.2.2] and therefore would expect that this would impact of the speed and ability of 
impulses to propagate along the nerves of Sox2OE mice. 
Patients with CMT disease typically show signs of ataxia and reduced sensory 
function. Similarly in mouse models of CMT type-1 disease, mice have also been 
show to exhibit signs of unsteady gait and abnormalities in motor performance 
(Wrabetz et al., 2006, Saporta et al., 2012). We therefore wanted to further 
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characterise the phenotype of the Sox2OE mice, by carrying out motor/sensory 
functional testing. Control and Sox2OE mice at 6 and 8 weeks of age were therefore 
placed onto a rota-rod and the latency to fall was recorded. At 6 weeks of age, no 
significant difference in latency to fall was observed between Sox2 Het control and 
Sox2HetOE mice (P>0.05, n=4 Sox2HetOE, n=7 Sox2 Homo control) [Figure 3.22]. 
However, a significant reduction in latency to fall was observed in Sox2HomoOE mice 
at 6 weeks of age, compared to Sox2 Het control mice (P<0.001, n=6 Sox2HomoOE, 
n=7 Sox2 Homo control) [Figure 3.22]. Again, at 8 weeks of age no significant 
difference in latency to fall was observed between Sox2 Het control and Sox2HetOE 
mice (P>0.05, n=4 Sox2HetOE, n=4 Sox2 Homo control), whilst a significant difference 
in latency to fall was observed between Sox2HomoOE mice and Sox2 Het control mice 
(P<0.05, n=6 Sox2HomoOE, n=4 Sox2 Homo control) [Figure 3.22]. 
We next went onto analyse the sensory function of Sox2 control and Sox2OE mice at 
6 weeks of age. Toe pinch testing revealed that whilst 100% of both Sox2 (Het and 
Homo) control and Sox2HetOE mice responded to light pressure, only 40% of 
Sox2HomoOE mice were able to respond (n=7 Sox2 control, n=3 Sox2HetOE, n=5 
Sox2HomoOE) [Figure 3.23]. Furthermore, Von Frey hair testing revealed that 
Sox2HomoOE mice had a significant impaired ability to respond to light touch stimulus 
compared to Sox2 (Het and Homo) control mice (P<0.01), however no significant 
difference in responsiveness was observed between Sox2HetOE and Sox2 control 
(Het and Homo) mice at 6 weeks of age (P>0.05) (n=11 Sox2 control, n=5 Sox2HetOE, 
n=5 Sox2HomoOE) [Figure 3.23].  
Together these results are consistent with our previous findings that overexpression 
of Sox2 in Schwann cells impairs nerve function and further suggest that Sox2 
overexpression induces a phenotype similar to that of a peripheral neuropathy. 
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Figure 3. 22 Nerve conduction velocity and motor function is reduced in Sox2 
overexpressing mice. Graph (A) comparing the nerve conduction velocity of sciatic nerves 
taken from control and Sox2HetOE mice at P20 (n=11 control, n=13 Sox2HetOE). Graphs (B & 
C)  showing the latency to fall using rotarod testing of control, Sox2HetOE and Sox2HomoOE 
mice at 6 weeks (B) and 8 weeks (C) of ages. (6 weeks: n=7 control, n=4 Sox2HetOE, n=6 
Sox2HomoOE. 8 weeks: n=4 control, n=4 Sox2HetOE, n=6 Sox2HomoOE). 
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Figure 3. 23: Sensory function is reduced in Sox2HomoOE mice. Graph (A) showing the 
percentage of control, Sox2HetOE  and Sox2HomoOE mice which responded to toe pinch testing  
at 6 weeks of age (n=7 control, n=3 Sox2HetOE, n=5 Sox2HomoOE). Graph (B) showing the 
withdrawal threshold (g) for control, Sox2HetOE and Sox2HomoOE mice at 6 weeks of age to 
various Von Frey filaments (n=11 control, n=5 Sox2HetOE, n=5 Sox2HomoOE). 
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3.3 Discussion 
The results in this chapter clearly show that Sox2 functions as a negative regulator of 
Schwann cell myelination and sustained expression of Sox2 during development and 
in adulthood leads to the onset of a phenotype similar to that of a peripheral 
neuropathy, such as congenital hypomyelinating neuropathy and Charcot-Marie-
Tooth type-1 disease.  
3.3.1 Sox2 impairs Schwann cell myelination 
Schwann cells that come into contact with large diameter axons (>1µm) are destined 
to differentiate into a myelinating Schwann cell and ensheath axons in a 1:1 ratio. In 
contrast, Schwann cells that make contact with small diameter axons (<1µm), 
differentiate into non-myelinating Schwann cells, and ensheath multiple axons with a 
thin layer of cytoplasm (Bhatheja and Field, 2006). Axons have been shown to be 
responsible for determining the phenotype of Schwann cells, through their 
expression levels of Neuregulin-1 (Nrg1) type-III which acts as an instructive signal 
for myelination. Expression levels of Nrg1 type-III in axons has been shown to 
correlate with their level of myelination; small diameter axons express low levels of 
Nrg1 type-III and thus do not drive Schwann cells to myelinate, whereas large 
diameter axons express high levels of Nrg1 type-III and induce Schwann cells to 
myelinate (Nave and Salzer, 2006). Nonetheless, overexpression of  Nrg1 in Nrg1 
type III transgenic mice, has been shown to drive the hypermyelination of small 
diameter axons (Michailov et al., 2004). High expression levels of Nrg1-III (notably 
on large diameter axons) signal via the ErbB2/ErbB3 heterodimer receptors 
expressed on Schwann cells. This activates a range of signalling cascades; including 
the phosphatidylinositol 3-Kinase (PI3K)/Akt signalling, phospholipase C-gamma 
(PLC-γ) dependent NFATc4 activation, Oct6 activated expression and cAMP 
elevation within promyelinating Schwann cells, all of which aim to activate Krox20; a 
zinc finger transcription factor required to drive myelination (Kao, 2009). Krox20 is 
essential for the suppression of negative myelin regulators such as cJun, Notch and 
Sox2, and the increased expression of myelin proteins such as P0 and MBP 
(Parkinson et al., 2008, Parkinson et al., 2004, Le et al., 2005a, Woodhoo et al., 
2009).  
Studies have shown that Schwann cells overexpressing Sox2 fail to myelinate co-
cultured dorsal root ganglia (DRG) axons and upregulate the expression of myelin 
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related genes in vitro, indicating that suppression of Sox2 is essential for Schwann 
cell myelination (Le et al., 2005a). In vitro evidence thus suggests that Sox2 is a 
negative regulator of Schwann cell myelination, however the functional role of Sox2 
on myelination in vivo remains open for investigation, as previous studies have 
demonstrated that the functional role of a protein in vitro, may not parallel in vivo 
(Lewallen et al., 2011, Golan et al., 2013).  Although the role of Sox2 on Schwann 
cell myelination has not been fully studied, increasing evidence in vivo confirms Sox2 
to be a marker of immature Schwann cells (Decker et al., 2006, Bremer et al., 2011, 
Le et al., 2005a). We thus set out to investigate the effect Sox2 overexpression 
would have on Schwann cell function, by generating Schwann cell specific Sox2 
overexpressing mice.  
 
Phenotypically Sox2HomoOE mice displayed characteristics similar to mouse models of 
congenital hypomyelinating neuropathy (CHN) and Charcot-Marie-Tooth type 1 
(CMT-1) disease; they were smaller in size, had poor movement and displayed 
hindlimb clasping when lifted by the tail (Le et al., 2005).  Histologically, Sox2HomoOE 
sciatic nerves were very similar to those of patients with CHN; at P7, P21 and P60 
the nerves were very hypomyelinated, with a high percentage of axons being 
unmyelinated, the nerves did not display axonopathy or onion bulbing, hallmarks that 
differentiate CHN from other neuropathies. Whilst CHN can be either non-
progressive or slowly progressive, we observed a slowly progressive phenotype in 
our Sox2HomoOE mice; we saw that myelin thickness decreased and the number of 
unmyelinated axons increased with age.  
 
In order to determine the mechanism by which Sox2 impairs Schwann cell 
myelination, we analysed the expression of myelin proteins. Overexpression of Sox2 
was shown to reduce the gene and protein expression of Krox20, as well as the 
protein expression of P0 and MBP throughout Schwann cell development and in 
adult nerves. Krox20 expression is essential during development for the activation of 
Schwann cell differentiation, as disrupted Krox20 expression has been shown to 
block Schwann cells at the early promyelinating stage (Topilko, 1994). In addition, 
Krox20 is essential for the initiation of myelination and for myelin maintenance, as it 
coordinates the expression of numerous myelin associated genes including; P0, 
MBP, peripheral myelin protein 22, periaxin and myelin associated glycoprotein 
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(MAG), as well as genes encoding enzymes required for cholesterol and myelin lipid 
biosynthesis, such as HMG-CoA reductase, choline kinase and stearyl coA 
desaturase (Le et al., 2005a, Nagarajan et al., 2001, Decker et al., 2006, LeBlanc et 
al., 2005, Topilko et al., 1994). It thus comes to no surprise that mutations in Krox20, 
or disruptions to its expression are associated with the development of various 
peripheral myelopathies; CHN, CMT and Dejerine–Sottas syndrome (Le et al., 
2005a, Nagarajan et al., 2001, Timmerman et al., 1999, Warner et al., 1998) 
 
The major peripheral myelin protein, P0 also plays an essential role in Schwann cell 
myelination, enabling myelin compaction and adhesion between myelin layers. 
Mutations or disruptions in its expression have therefore been associated with 
impaired/irregular myelination and the onset of peripheral neuropathies such as 
CMT-1B (Giese et al., 1992, Saporta et al., 2012). MBP on the other hand is less 
essential for myelin formation, but plays an important role in the compaction and 
stabilisation of intracellular peripheral myelin (Notterpek et al., 1999, Shine and 
Sidman, 1984, Martini et al., 1995). Whilst mice lacking MBP (MBP--) myelinate 
normally, mice with compound heterozygous mutations in both MBP and P0 (P0
+-
/MBP+-) show a worse peripheral myelinopathy than single mutant P0 (P0
+-) mice 
(Martini et al., 1995).  
 
From previous studies mentioned above, it’s clear that Krox20, P0 and MBP are 
important for Schwann cell myelination and that the ability of Sox2 to directly repress 
their expression will result in detrimental consequences. As Sox2 overexpressing 
mice show a simultaneous reduction in the expression of all three components 
(Krox20 and P0, and MBP), we believe this explains the mechanism by which 
Schwann cell myelination is impaired in these mice, and why Sox2HomoOE mice 
demonstrate characteristics of peripheral neuropathies associated with disrupted 
Krox20, P0 and MBP expression. 
 
In addition to targeting Schwann cell myelin proteins, overexpression of Sox2 
dramatically reduced the protein and gene expression of a well characterised cell 
adhesion molecule Necl4 in vitro (unpublished data from Dr R.Doddrell), as well as in 
the nerves of Sox2HetOE  mice (unpublished data from Dr Xin-Peng Dun; this study). 
Necl4 is a transmembrane protein which mediates glial-axon interaction by binding to 
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axonal Necl1 and Necl2 (Maurel et al., 2007, Spiegel et al., 2007). Whilst Necl1, 
Necl2 and Necl3 are dispensable for myelination, Necl4 plays an essential role in 
facilitating normal myelin formation (Maurel et al., 2007, Spiegel et al., 2007, Golan 
et al., 2013). Knockdown of Necl4 by shRNA (Maurel et al., 2007) and the 
expression of dominant mutant forms of Necl4 (Spiegel et al., 2007) have been 
shown to result in a marked reduction in Schwann cell myelination in vitro. A more 
recent study analysing Necl4 null and Necl4 mutant transgenic (mbp-Cadm4dCT) 
mice further confirmed that Necl4 is essential for the proper establishment of 
myelinated nerve fibres (Golan et al., 2013). However, in contrast to the in vitro 
studies, Golan et al., (2013) showed that disrupted Necl4 expression in vivo causes 
an initial delay in myelin formation, followed by hypermyelination and myelin 
abnormalities. Although the Necl4 null and Necl4 mutant mice are not histologically 
similar to Sox2 overexpressing mice, which we might have expected from earlier in 
vitro studies, they do similarly show reduced motor function and hindlimb clasping 
(Maurel et al., 2007, Spiegel et al., 2007, Golan et al., 2013). We might predict that 
the ability of Sox2 to suppress Necl4 may be a contributing factor to the impaired 
normal myelination. Although we do not observe hypermyelination within the nerves 
of Sox2 overexpressing mice, this could be due the dual ability of Sox2 to also 
suppress the expression of Krox20, a key regulator of myelin lipid synthesis and 
myelin protein expression (Nagarajan et al., 2001). Necl4 is also reported to be 
essential for the establishment of correct axon-glial contact points; Necl4-/- mice 
showed abnormal distribution of Caspr (a paranodal protein marker), and an 
accumulation of Caspr and Kv1 channels (marker of the internodal region) away 
from the Na+ channel-containing nodes of Ranvier. This was suggested to reflect 
unwinding of the paranodal loops in the absence of Necl4 [See Figure 1.2] (Golan et 
al., 2013).  
3.3.2 Sox2 downregulates the expression of Sox10 
Sox10 is highly expressed throughout Schwann cell development and is essential for 
the specification and differentiation of peripheral glial from neural crest cells (Britsch 
et al., 2001). Sox10 thereafter plays a fundamental role in regulating Schwann cell 
development and differentiation by activating the gene expression of Oct6, a key 
POU domain transcription factor required for the transition of immature Schwann 
cells into promyelinating Schwann cells (Finzsch et al., 2010, Jagalur et al., 2011). In 
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order to drive promyelinating Schwann cells into the myelinating stage, Sox10 then 
synergises with both Oct6 and NFATc4 independently, to activate the transcription of 
Krox20, by binding to the Myelin Specific Enhancer (MSE) region (1.3kb cis-
regulatory element of the Krox20 promoter). In addition to activating Krox20, Sox10 
activates the transcription of P0, by co-operating with NFATc4 and binding to the P0 
promoter, as well as synergising with Krox20 to further enhance P0 expression, by 
binding to the P0 gene within intron 1 (Kao et al., 2009, Jagalur et al., 2011, LeBlanc 
et al., 2006). 
As Sox10 plays such a fundament role in Schwann cell development, we were 
surprised to observe that overexpression of Sox2 reduced the expression of Sox10 
in vitro and at later time-points in adult Sox2HomoOE mice (P60), nonetheless this 
function is consistent with its role as a negative regulator of myelination. We expect 
that the ability of Sox2 to alter the expression of Sox10 is likely to be a major part of 
the mechanism by which Sox2 impairs myelination and thus myelin protein 
expression, as selective deletion of Sox10 has been shown to stall Schwann cells at 
the immature Schwann cell phase, and prevents the upregulated expression of Oct6, 
Krox20, MBP and P0 (Finzsch et al., 2010). Sox2 was also shown to reduce the 
expression of Oct6 expression in vitro (unpublished data by Dr R.Doddrell in our 
group), which further supports our hypothesis that Sox2 is able to regulate Sox10, 
thus reducing its ability to regulate its downstream targets.  
 
In addition to being crucial for Schwann cell differentiation and myelination, studies 
have also confirmed that Sox10 expression is essential for myelin maintenance, but 
not for the survival of adult Schwann cells (Finzsch, 2010; Bremer, 2011). As we 
observed an apparent progressive decline in the expression of Sox10 between P7 
and P60 in our Sox2HomoOE mice, as shown by fluorescent imaging [Figure 3.13], this 
further explains why myelin thickness decreased with increased age.  
 
Although we observed in vivo that Sox2 is capable of reducing Sox10 expression at 
later stages of Schwann cell development, Sox2 did not completely eliminate Sox10 
expression from Schwann cells. For this reason we believe this is why the phenotype 
observed in the Sox2HomoOE mice is less severe than that previously observed in 
studies carried out on Sox10∆𝑒𝑆𝑇 mice (Schwann cell specific Sox10 deleted mice) 
which show symptoms of shiverer type tremors, an abnormal, straddled position of 
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the hindlimb, poor motor coordination and which eventually die by 7 weeks of age 
(Finzsch et al., 2010). Furthermore, studies on homozygous Sox10LacZ/lacZ mutant 
mice (in which the complete open reading frame of Sox10 has been replaced with a 
LacZ sequence) reported that these mice die during embryonic development and do 
not develop any peripheral glia; Schwann cells or satellite cells (Britsch et al., 2001). 
 
While Sox genes are regulated by a range of different mechanisms including auto-
regulation, regulation by other Sox proteins and post transcriptional modification, it is 
not known how Sox2 and Sox10 genes are regulated in Schwann cells, or how they 
may regulate one another (Kamachi and Kondoh, 2013). It would be of great interest 
to determine whether Sox2 reduces the gene expression of Sox10, as well as 
downstream targets of Sox10 which are not co-regulated by Oct6 or Krox20, such as 
S100B and ErbB3 receptor expression (Fujiwara et al., 2014, Prasad et al., 2011, 
Britsch et al., 2001). Many genes have been reported to be regulated by Sox10 in 
Schwann cells, including desert hedgehog (Küspert et al., 2012), myelin proteins P0 
and PMP22 (Jones et al., 2011, Peirano et al., 2000, Finzsch et al., 2010), LGI4, 
ciliary neurotrophic factor (CNTF) (Ito et al., 2006, Srinivasan et al., 2012), and more 
recently Id2, Id4, Sox5, Notch1, HMGA2, Mycn and Hes1 (Personal communications 
with members of John Svaren group, University of Wisconsin-Madison), however 
most are co-regulated by Krox20. In order for Sox proteins to exert their gene 
regulatory function, they are often required to form complexes with partner 
transcription factors (Kamachi and Kondoh, 2013). As Sox10 often forms complexes 
with Krox20, it’s difficult to identify sole targets of Sox10 alone. 
 
It would be equally interesting to examine the mechanism by which Sox2 reduces 
Sox10 expression, for example whether Sox2 interacts directly with Sox10 thus 
reducing its activation. In addition to investigating whether Sox2 prevents Sox10 
from binding to the promoter region of its downstream targets. This could be 
achieved through chromatin immunoprecipitation (ChIP) experiments, using 
antibodies against Sox10 in wild-type and in Sox2 overexpressing nerves in adult 
P60 nerves. Furthermore, it would be interesting to determine whether the addition of 
exogenous Sox10 to cultured Sox2 adenoviral infected Schwann cells, restored 
myelination in Schwann cell/DRG co-cultures. 
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3.3.3 Sox2 maintains Schwann cells in an immature state  
Immature Schwann cells are marked by the expression of Sox2, cJun, and Notch, all 
of which aid to enhance Schwann cell proliferation (Le et al., 2005a, Parkinson et al., 
2004, Woodhoo et al., 2009)(David Parkinson, unpublished data). As immature 
Schwann cells differentiate and myelinate, the expression of these immature 
Schwann cell markers declines, coinciding with their expression being restricted to 
the immature state during development (Parkinson et al., 2004; Le et al., 2005, 
Woodhoo et al., 2009). Overexpression of Sox2 in Schwann cells reduced myelin 
thickness and significantly increased the percentage of unmyelinated axons, which 
were in a 1:1 ratio with Schwann cells. As Sox2 is highly expressed within immature 
Schwann cells and is capable of impairing myelination, we expected that Sox2 would 
restrict Schwann cells to the immature / promyelinating stage (Le et al., 2005; this 
study). In support of this, we observed high expression levels of cJun within the 
nerves of Sox2HomoOE mice compared to controls. cJun has previously been shown to 
only be expressed within immature and repair (dedifferentiated) Schwann cells, as 
cJun protein levels  and the JNK-cJun signalling pathway are suppressed by Krox20; 
which is upregulated in Schwann cells as they transition from  immature/repair cells 
into myelinating Schwann cell (Parkinson et al., 2004).  
To further determine whether Schwann cells were retained at the immature or 
promyelinating Schwann cell stage, it would be of interest to carry out further 
experiments analysing the expression levels of promyelinating Schwann cell 
markers, such as Oct6 and Brn-2 within the sciatic nerves of control and Sox2HomoOE 
mice. We might expect that if Sox2 maintains Schwann cells at the immature/ 
promyelinating phase, levels of Oct6 would be increased within the nerves of 
Sox2HomoOE mice, compared to controls.  
Although Oct6 expression induced by cAMP was previously shown to be completely 
impaired in Sox2 adenoviral infected Schwann cells in vitro (unpublished data by Dr 
R.Doddrell in our group), we might expect Oct6 to still be weakly expressed within 
the nerves of Sox2HomoOE mice, similarly to its upstream regulator Sox10 which was 
shown to also be weakly expressed within Sox2HomoOE mice, in contrast to the vitro 
analysis, where Sox10 was completely impaired. This further highlights the 
difference between in vitro and in vivo experiments. Oct6 and Brn2 are highly 
expressed within Schwann cells from P1 to P8, however their expression begins to 
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decline from then onwards, until they can no longer be detected at P30/P32. Thus in 
order to make a comparative analysis of differences in the expression of Oct6 and 
Brn-2 in the nerves of control and Sox2HomoOE mice, analysis should be carried out 
from P30 onward (Jaegle et al., 2003, Arroyo et al., 1998). 
Overall it is clear that Sox2 acts to antagonise the Schwann cell promyelination 
pathway, by maintaining Schwann cells at the immature/promyelinating Schwann cell 
phase. This was supported by the high expression of two immature Schwann cell 
makers, cJun and the cell adhesion molecule N-cadherin (which will be discussed 
further in section 3.3.4) within the nerves of Sox2HomoOE mice. The ability to 
proliferate is also a hallmark of immature Schwann cells, as mature myelinating 
Schwann cells lose their ability to proliferate (Parkinson et al., 2004). As we 
observed an increased level of proliferation in the nerves of Sox2HomoOE mice (this 
will be discussed in more detail in section 3.3.6), this provides additional support to 
the evidence that Schwann cells are retained in an immature state.  
3.3.4 Sox2 regulates cell adhesion proteins 
Due to their exceptional plasticity, Schwann cells play a remarkable role in the ability 
of the peripheral nervous system to regenerate following nerve injury. One of the 
critical functions of Schwann cells during nerve repair is to dedifferentiate and assist 
with the guidance of regrowing axons across the wounded site and back to their 
targets (Parrinello et al., 2010). This process firstly requires Schwann cells to cluster 
together and form cord like structures, which is regulated by Sox2 (Parrinello et al., 
2010). Following nerve injury, fibroblasts migrate into the nerve bridge (the site of 
injury) and express ephrin B ligand, which binds to EphB2 receptors expressed on 
Schwann cells, causing Schwann cell upregulation of Sox2 expression. Sox2 was 
shown to play an important role in Schwann cell clustering by inducing the re-
localisation of N-cadherin to cell-cell contact junctions, thus promoting cell sorting: 
the separation of Schwann cells and fibroblasts into two separate groups (Parrinello 
et al., 2010). Upon N-cadherin relocalisation, protein levels of N-cadherin appeared 
elevated, however no increase in N-cadherin messenger RNA (mRNA) was 
observed (Parrinello et al., 2010). This suggested that the Sox2 caused post 
transcriptional changes that lead to increased stabilization of the N-cadherin protein.  
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N-cadherin is also strongly expressed in immature Schwann cells during 
development, however as Schwann cells differentiate and begin to myelinate, the 
expression of N-cadherin is downregulated and E-cadherin expression is 
upregulated (Crawford et al., 2008). In early Schwann cell development N-cadherin 
localises to the Schwann cell-axon interface, mediating both Schwann cell-axon and 
Schwann cell-Schwann cell interaction, as well as neurite outgrowth (Wanner et al., 
2006, Wanner and Wood, 2002). As neural outgrowth comes to an end and the 
requirement for Schwann cell-cell interaction is reduced in order to allow for 
structural transformation within the nerve (such as myelination), the expression of N-
cadherin expression is reduced, coinciding with the decrease in Sox2 expression 
during Schwann cell differentiation and maturation (Wanner et al., 2006). As 
expected, N-cadherin was weakly expressed within the nerves of adult Sox2 control 
mice, however strong expression of N-cadherin was detected within the nerves of 
adult Sox2HomoOE mice (Wanner and Wood, 2010). The data revealed that Sox2 was 
able to regulate and maintain N-cadherin expression in Schwann cells during 
development, however the mechanism by which Sox2 is able to achieve this remains 
unclear. Further experiments would need to be carried out to determine whether 
Sox2 is able to increase the expression of N-cadherin by analysing both N-cadherin 
protein and gene expression at different time-points during development, in both 
control and Sox2HomoOE nerves. Nonetheless, as previously reported by Parrinello et 
al. (2010), we might expect that Sox2 post-transcriptionally modified or stabilized N-
cadherin protein, rather than increasing its gene expression levels. Analysis of the 
Affymetrix gene array carried out by Dr R.Doddrell in our group, did not reveal N-
cadherin to be significantly increased in Sox2 adenoviral infected Schwann cells, 
compared to GFP adenoviral infected Schwann cells (controls) (1.9 fold increase, 
P=0.12). 
As N-cadherin has only been reported to be expressed in Schwann cells prior to 
myelination and after nerve injury, this data further supports our theory that Schwann 
cells are maintained in an immature state by the overexpression of Sox2.  
N-cadherin is classically though to transduce intracellular signals by interacting with 
β-catenin, which in turn associates with the actin cytoskeleton though binding α-
catenin; forming a cadherin-β-catenin-α-catenin signalling complex (Meng and 
Takeichi, 2009, Ivanov et al., 2001). In Schwann cells, β-catenin co-localises with N-
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cadherin at the Schwann cell-axon interface and co-immunoprecipitates with N-
cadherin on the initiation of myelination (Lewallen et al., 2011). β-catenin was also 
shown to compensate for N-cadherin in its absence, reducing the severity of the 
delay in Schwann cell myelination (Lewallen et al., 2011). In the nerves of 
Sox2HomoOE mice, β-catenin was highly expressed, whereas only weak expression of 
β-catenin was detected in control nerves. We expect that as a downstream effector 
of N-cadherin, N-cadherin and β-catenin would co-localised within the nerves  of 
Sox2HomoOE mice as demonstrated by Lewallen et al. (2010), however as both 
antibodies for these proteins were raised in the same species (mouse) we were 
unable to double labelled nerve sections for both proteins. Nonetheless, we were 
able to demonstrate for the first time that Sox2 is capable of either increasing or 
maintaining high protein expression levels of both N-cadherin and β-catenin in 
Schwann cells in vivo.  
In order to determine whether Sox2 increased the expression of N-cadherin and β-
catenin, or rather whether it stabilized the protein expression further analysis would 
need to be carried out. Western blot experiments using sciatic nerve lysates taken 
from control and Sox2HomoOE mice at different time-points throughout Schwann cell 
development for e.g. at P0, P7, P14, P21 and P60 could be carried out to determine 
whether Sox2 increases the expression of both N-cadherin and β-catenin. In 
laryngeal cancer Hep-2 cells, Sox2 has also been shown to enhance N-cadherin and 
Wnt/β-catenin protein expression, thus promoting migration, invasion and epithelial-
mesenchymal transition (Yang et al., 2014a). It is possible that this functional role of 
Sox2 to regulate N-cadherin and β-catenin expression is conserved across different 
cell types. Furthermore, although the study by Yang et al., (2014) did not analyse N-
cadherin and β-catenin protein localisation, it is possible that the ability of Sox2 to 
drive N-cadherin and β-catenin relocalisation is also a conserved function.  
3.3.5 Sox2 increases the mRNA expression of Neuroserpin  
Neuroserpin, also known as Serpini 1, is a member of the serpin superfamily, and 
has been shown to play an important role regulating a range of biological processes 
by inhibiting the function of members of the trypsin-like serine protease family. 
Serpins are able to selectively target and inhibit the function of proteases, through 
their exposed mobile reactive centre loop (RCL). The RCL covalently attaches to the 
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target protease via an ester bond, and induces the serpin to undergo the stressed to 
relaxed transition, consequently causing the protease to be moved from the top to 
the bottom of the serpin, where it is distorted into a conformation that allows for the 
acyl enzyme intermediate to be hydrolysed, leading to its inactivation (Rashid et al., 
2014, Huntington et al., 2000).  
Neuroserpin has been shown to be primarily synthesised and secreted by axons in 
the central and peripheral nervous system, where it regulates proteolytic events, 
such as inhibiting the activation of tissue plasminogen activator (tPA) and to a 
smaller degree urokinase plasminogen activator (UPA). A balance in the expression 
of plasminogen activators in the brain is important as deficiencies or overexpression 
can have adverse effects leading to impaired learning; mice lacking tPA show 
interference with long-lasting long term potentiation and reduced performance in two-
way active avoidance learning (Huang et al., 1996), whilst mice overexpressing UPA 
perform poorly in tasks of spatial, olfactory, and taste-aversion learning (Meiri et al., 
1994). Given its function in modulating proteolytic events, neuroserpin has been 
suggested to participate in modulating synaptic reconstruction during neuronal 
development and synaptic plasticity in the adult nervous system (Osterwalder et al., 
1996, Krueger et al., 1997). 
Mutations in serpins results in a delay in protein folding and a delay in their ability to 
be cleared from the endoplasmic reticulum, leading to the onset of a class of 
conditions referred to a serpinopathies (Roussel et al., 2011). Neuroserpin, has been 
associated with many neurological diseases, including dementia, cerebrovascular 
disease, epilepsy, multiple sclerosis and schizophrenia (Yepes and Lawrence, 
2004). In particular, mutations in the neuroserpin gene leads to aberrant 
polymeration of neuroserpin in the endoplasmic reticulum, causing a form of 
dementia known as Familial Encephalopathy with Neuroserpin Inclusion Bodies 
(FENIB). The disease is characterised by eosinophilic neuronal inclusion of 
neuroserpin in the cerebral cortex and the substantia nigra (Roussel et al., 2011). 
Mutations in neuroserpin have also been associated uncontrolled tPA activity, and 
therefore increased seizure occurrence and neurotoxicity (Yepes and Lawrence, 
2004, Kaur et al., 2004).   
Previously published data has shown that neuroserpin also plays a role in regulating 
cell-cell contact, by increasing the expression of N-cadherin at the plasma 
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membrane contact regions of cells. This was shown in PC12 cells overexpressing 
neuroserpin, as increased levels of neuroserpin correlated within increased cell–cell 
adhesion, cell cluster size as well as N-cadherin expression (Lee et al., 2008).  
Furthermore, PC12 cells infected with a mutant form of neuroserpin (NSR362A) 
incapable of recognising tissue plasminogen activators (tPA), still demonstrated 
increased cell-cell adhesion similar to PC12 cells overexpressing wild type 
neuroserpin. This demonstrated that the functional ability of neuroserpin to regulate 
cell adhesion was independent of its enzymatic inhibitory function (Lee et al., 2008). 
Nonetheless, the mechanism by which neuroserpin regulates N-cadherin expression 
remains unknown. 
Schwann cells infected with a Sox2 overexpression adenovirus demonstrated cell 
clustering, similar to that observed in PC12 cells overexpressing neuroserpin (Lee et 
al., 2008, Dun et al., paper submitted: under review). Neuroserpin mRNA was show 
to be massively upregulated by Sox2, identified by an Affymetrix array screen (55 
fold increase) and semi-quantitative RT-PCR analysis carried out on Schwann cells 
infected with a GFP expressing adenovirus (controls) and Schwann cells infected  
with a Sox2 expressing adenovirus (unpublished data by Dr R.Doddrell; Dun et al 
(paper submitted: under review)). Neuroserpin mRNA was also upregulated in the 
sciatic nerves of Sox2HomoOE mice, further confirming neuroserpin to be a direct target 
of Sox2 both in vitro and in vivo.  
Dr R.Doddrell (unpublished data) identified a four consensus Sox core-binding 
elements (SCBE) consisting of A/T, A/T, CAA, A/T in a 500bp DNA region 9kb 
upstream of the neuroserpin promotor (Mertin et al., 1999). As Sox2 is commonly 
known to act as a transcriptional enhancer or repressor, it therefore possible that 
Sox2 may regulate the expression of neuroserpin through binding one of these 
identified SCBEs upstream of the neuroserpin promoter, thus enhancing its 
transcriptional activation.  
We proposed that Sox2 was able to regulate N-cadherin expression by enhancing 
the expression of neuroserpin. Sox2 was show to dramatically increase the 
expression of neuroserpin both in cells and secreted into the cell culture medium, as 
well as the expression of N-cadherin. Nonetheless, enforced expression of 
neuroserpin within Schwann cells failed to induce Schwann cell clustering as well as 
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to upregulate the expression of N-cadherin and induce re-localisation to the cell 
membrane (Dun et al. paper submitted: under review). Furthermore, silencing of 
neuroserpin expression through siRNA in Schwann cells, did not affect the ability of 
Schwann cells to cluster when stimulated by fibroblasts [unpublished data Dr 
S.Parrinello, UCL, London, UK].  
These results demonstrated that contradictory to the data published by Lee et al. 
(2008), in PC12 cells neuroserpin does not appear to directly mediate cell clustering, 
nor does it mediate N-cadherin expression and relocalisation in Schwann cells (Dun 
et al. paper submitted: under review).  
Little is known about the transcriptional regulation of neuroserpin in vivo, and 
therefore the strong regulation of neuroserpin we have shown by Sox2 in Sox2HomoOE 
nerves if of great potential interest. Sox2 is highly expressed in the CNS during early 
development and is known to preserve neural progenitor cells identify, it would thus 
be of interest to determine whether Sox2 partly regulates neuroserpin expression 
during CNS development. 
Neuroserpin is highly upregulated following ischemic nerve injury and shown to be 
neuroprotective by preventing ischemia induced neuronal apoptosis, microglia 
activation, and promoting the preservation of the blood brain barrier (Yepes and 
Lawrence, 2004, Gu et al., 2015, Cinelli et al., 2001). As Sox2 is highly upregulated 
in Schwann cells following peripheral nerve injury (Parrinello et al., 2010, Parkinson 
et al., 2008), it would also be interesting to see if Sox2 is upregulated in CNS 
following ischemic injury, and whether it is responsible for upregulating neuroserpin 
allowing for neuroprotection. 
3.3.6 Sox2 increases proliferation in Schwann cells  
Overexpression of Sox2 has widely been reported in several tumours, including lung 
cancer, breast cancer, ovarian cancer and glioma (Weina and Utikal, 2014, Lu et al., 
2010a, Chen et al., 2008). It was further reported to enhance proliferation in these 
cancers and to also be oncogenic (Lu et al., 2010a, Chen et al., 2008, Yang et al., 
2014a, Weina and Utikal, 2014). In particular Sox2 was shown to be highly 
expressed within the squamous cell tumours and adenocarcinomas isolated from 
patients with lung cancer, as well as in breast cancer, with levels of Sox2 expression 
correlating with tumour grade and cyclin D1 expression (a marker of proliferation). In 
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the nervous system, overexpression of Sox2 was shown to inhibit neuronal 
differentiation, and to also play a functional role in enhancing proliferation in crest 
cells (Wakamatsu et al., 2004). More specifically in Schwann cells, overexpression of 
Sox2 enhanced the proliferative response of these cells to β-neuregulin. While, Sox2 
has been shown to enhanced proliferation in many cells types, the effect of Sox2 on 
Schwann cell proliferation in the presence of a range of mitogenic stimulus (such as 
Nrg1 and BDNGF) driving proliferation in vivo has not been examined. 
In agreement with its previously published role in enhancing proliferation, we showed 
for the first time that Sox2 was capable of promoting proliferation in Schwann cell in 
the nerves of Sox2HomoOE mice during development (postnatal day 7) and during 
adulthood (postnatal day 60). This data further supports to the ability of Sox2 to 
maintain Schwann cells in an immature state, as mature Schwann cells are non-
proliferative.  
In breast cancer cells, Chen et al. (2008) identified that Sox2 promoted proliferation 
by synergising with β-catenin and binding to a Sox core binding element region 
(C(T/A)TTG(T/A)(T/A)) located between 86 to 234bps proximal to the CCND1 gene 
promoter. Together Sox2 and β-catenin promoted the gene expression of CCND1, 
and thus its protein product cyclin D1; a critical regulator of G1/S cell cycle transition 
in breast cancer cells (Chen et al., 2008). It would be interesting to see if Sox2 
activated the transcription expression of cyclin D1 in Schwann cells, thus promoting 
Schwann cell proliferation.   
p27kip1 plays a role in regulating the cell cycle by binding and inhibiting multiple 
cyclin-dependent kinases and was recently shown to have a regulatory effect on 
Sox2. Overexpression of p27 in both mouse embryonic fibroblasts and transduced 
embryonic stem cells reduced Sox2 expression, while silencing p27 expression in 
fibroblasts, lungs, retina and the brain resulted in a defective repression of Sox2, as 
well as delayed silencing of Sox2 during the differentiation of pluripotent cells (Li et 
al., 2012). p27 was shown to regulate the transcriptional expression of Sox2 by 
forming a complex with p130, E2F4 and SIN3A at a critical regulatory element 
responsible for Sox2 expression, termed the Sox2-SRR2 enhancer (Li et al., 2012, 
Sikorska et al., 2008). A further study by Herreros-Villanueva et al. (2013) revealed 
that Sox2 is also able to regulate the gene expression of p27kip1 in pancreatic cancer 
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cells (LC3.6 cells) by directly binding to the promoter/enhancer regions, and 
promoting cell cycle progression (Herreros-Villanueva et al., 2013). From these 
studies it appears that p27kip1 is able to directly suppress Sox2 expression, however 
when the expression of Sox2 is rapidly upregulated as seen in many cancers, Sox2 
feeds back and blocks the expression of p27kip1, causing increased cell cycle 
progression.  
More specifically in relation to Schwann cells, Krox20 has been shown to mediate 
the induction of p27, thus inducing Schwann cell exit from the cell cycle during 
development (Parkinson et al., 2004). As Sox2 reduced Krox20 expression and 
overexpression of Sox2 in pancreatic cancer cells has been shown to block p27 kip1 
function, it would be interesting to see whether the expression of p27kip1 is altered, 
along with its downstream cyclin-dependent kinase targets, in the nerves of 
Sox2HomoOE mice compared to Sox2 controls mice.  
Sox2 has been shown to be expressed in 40-50% of schwannomas; a benign 
Schwann cell tumour which forms in the nerves sheath, resulting from uncontrolled 
proliferation (Shivane et al., 2013). More recently, Sox2 was shown to disrupt the 
Hippo signalling pathway (a key regulator of proliferation and apoptosis) in 
osteosarcoma cells and glioblastoma tumours, by transcriptionally repressing the 
tumour suppressor scaffolding protein NF2 (neurofibromin 2, merlin) and 
upregulating YAP (Yes associated protein) expression, which functions as an 
oncogene in many cancers (Basu-Roy et al., 2015). The Hippo-pathway is 
conserved across multiple cells types including Schwann cells, and mutations in the 
NF2 gene or disruptions to its expression is associated with schwannoma formation 
(Rouleau et al., 1993, Hanemann, 2008). As Sox2 has been shown to increase 
proliferation (in this study) and alter the Hippo-pathway (Basu-Roy et al., 2015), it 
would be of interest to see whether sustained overexpression of Sox2 alters the NF2 
expression in Sox2HomoOE Schwann cells and leads to schwannoma development in 
nerves taken from  Sox2HomoOE mice at later time-points, such as 6 months or 12 
months of age. In order to check for the presence of schwannomas, nerve sections 
taken from control and Sox2HomoOE mice could be stained with Haematoxylin and 
Eosin (H&E) and then analysed for characteristics of schwannoma tumours. 
Schwannomas often show Antoni patterning; highly cellular areas composed of 
bundles of Schwann cells that have a spindle like morphology (Antoni type A 
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pattern), or loosely textured or microcytic areas composed of Schwann cells  which 
may merge with one another (Antoni type B pattern). Furthermore, schwannomas 
often have areas of nuclear alignment or palisading, forming parallel nuclear arrays 
or Verocay bodies (cellular areas, surrounded by nuclear palisades) (Hilton and 
Hanemann, 2014).   
3.3.7 Overexpression of Sox2 causes an inflammatory nerve 
environment 
Models of inherited peripheral demyelinating neuropathies such as Charcot Marie 
Tooth (CMT) type 1A, B and X disease demonstrate substantially enhanced nerve 
inflammation, which leads to the amplification of disease progression (Martini and 
Willison, 2015).  Both the innate and adaptive immune response have been 
implicated in models for inherited peripheral neuropathies (Martini and Willison, 
2015). Macrophages have been shown to be recruited to the peripheral nerves in 
models of CMT-1 disease, where they sense and move towards defective Schwann 
cells and play a pivotal role in mediating myelin and axonal damage (Carenini et al., 
2001, Groh et al., 2015, Kobsar et al., 2005). Blocking the activation of macrophages 
by colony stimulating factor-1 (CSF-1), a secreted cytokine produced by endoneurial 
fibroblasts, resulted in a robust reduction in the number of macrophages in the 
nerves of CMT-1B and -1X mouse models and severely ameliorated the neuropathy; 
improved axonal structures and improved nerve function (Klein et al., 2015, Groh et 
al., 2012). Furthermore, reducing but not eliminating the expression of monocyte 
chemoattractant protein 1 (MCP-1/ CCL2), a chemokine produced by Schwann cells 
and involved in macrophage attraction and activation, reduced the recruitment of 
macrophages and alleviated the demyelinating phenotype in CMT-1B and CMT-1A 
mouse models (Fischer et al., 2008a, Kohl et al., 2010a).  
T-and B-lymphocytes are also recruited and increase demyelination in the nerves of 
CMT-1B (P0het) and CMT-1X (connexin 32 mutant) mouse models (Carenini et al., 
2001, Kobsar et al., 2003); CMT-1B and CMT-1X  mouse models crossbred with 
Rag1 (recombinase activating gene 1) deficient mice lacking mature T-and B-
lymphocytes, showed marked amelioration of demyelination, fewer axonopathic 
changes and a reduction in macrophage number (Kobsar et al., 2003). Surprisingly 
however, removing T-and B-lymphocytes from CMT-1A (PMP22 overexpressing 
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transgenic mice) mouse models did not alleviate disease progression (Kohl et al., 
2010b). These studies demonstrate the critical role macrophages and immune cells 
play in enhancing demyelination and neuropathology. 
Having discovered that Sox2 overexpression results in a phenotype similar to 
models of CMT-1 disease [See section 3.2.1-3.2.3] in Sox2HomoOE mice, we set out to 
investigate whether our mouse model also demonstrated a strong influx of 
inflammatory immune cells. Sox2HomoOE mice showed an increased number of both 
macrophages and T-lymphocytes into their poorly myelinated nerves. A slight 
increase (although not significant) in immune cells was observed from early 
developmental time-points (P7) in Sox2HomoOE mice, and increased with age (up until 
P60); which further correlated with the worsening phenotype and disease 
progression observed in these mice. A similar observation was previously observed 
in CMT-1A, CMT-1X and CMT-1B mouse models, whereby the number F4/80+ 
macrophages and CD8+ T-lymphocytes were significantly elevated with increasing 
age and disease progression (Carenini et al., 2001, Kobsar et al., 2005, Kobsar et 
al., 2003). A shown in this study and previous studies, macrophages in 
demyelinating nerves outnumber that of T-lymphocytes, suggesting that they are the 
major culprit in disease progression (Kobsar et al., 2003, Kobsar et al., 2005, 
Carenini et al., 2001). It would be interesting to see whether administration of the 
CSF-1 receptor inhibitor, which was previously identified by Klein et al., (2015) to 
reduce macrophage influx and act as a treatment for CMT-1 neuropathies, would 
ameliorate the worsening phenotype observed in Sox2HomoOE mice, as a potential 
anti-inflammatory therapy.  
The MEK 1/2-ERK 1/2 signalling pathways were revealed to be upregulated in the  
CMT-1A mouse model and to regulate the expression of MCP-1 (Kohl et al., 2010a). 
Furthermore, blocking the MEK 1/2-ERK 1/2 signalling cascade using a 
pharmacological inhibitor (PD184352), reduced the expression of MCP-1 (Kohl et al., 
2010a). Activation of the MEK 1/2-ERK 1/2 pathways via a tamoxifen induced Raf 
kinase transgene in healthy Schwann cells was shown to induce Schwann cell 
demyelination, motor defects, the recruitment of inflammatory cells into the 
peripheral nerve and activate the expression of MCP-1 (Napoli et al., 2012). As the 
MEK 1/2- ERK 1/2 cascade has been proven to play a pivotal role in linking 
Schwann cell pathology with the inflammatory response, it would be of interest to 
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see whether the MEK 1/2- ERK 1/2 signalling cascade is elevating in the nerves of 
Sox2HomoOE mice, along with its downstream target MCP-1, in order to attempt to 
understand the mechanism by which overexpression of Sox2 leads to an increased 
recruitment of macrophages.  
A recent study by Xia et al. (2015) identified Sox2 to be highly expressed in 
neutrophils, where it acts as a cytoplasmic pattern recognition receptor. Upon the 
recognition of microbial DNA, Sox2 was shown to trigger the expression of genes 
encoding for pro-inflammatory molecules, in a TAB2-TAK1 dependent manner, 
which leads the activation of NF-kB and AP-1; thus causing an immune response. 
Although highly upregulated in neutrophils, Sox2 was not expressed in any other 
immune cells including macrophages, eosinophils or basophils (Xia et al., 2015).  
This study highlights a new and novel role for Sox2 in regulating the immune 
response and suggests new possibilities for Sox2 being involved in triggering an 
inflammatory response in a range of cells.  A previous study by Napoli et al. (2012), 
identified that activation of the Raf-ERK signalling pathway in Schwann cells caused 
blood nerve barrier (BNB) breakdown, and an influx of immune cells into the nerve. 
As we observe such as dramatic increase in immune cells in the nerves of adult 
Sox2HomoOE mice, it would be interesting to see whether overexpression of Sox2 
causing blood nerve barrier (BNB) breakdown, as a mechanism that allows for the 
infiltration of immune cells into the nerve. BNB breakdown could be analysed in by 
injecting mice with Evans blue, an azo dye with a high affinity for serum albumin. 
Following BNB breakdown, Evans blue can be traced from the blood vessels into the 
endoneurium and perineurium (Napoli et al., 2012). 
Although we have observed a striking increase in the number of macrophages 
recruited to the nerves of Sox2HomoOE mice, we are unsure whether the environment 
in the nerves of these mice is pro-inflammatory and thus destructive. TNF-α and IL-
1β have been linked to macrophage activation and tissue destruction, whilst 
cytokines such as IL-10 and IL-4 have been shown to mediate an anti-inflammatory 
environment (Ellis and Bennett, 2013). To clarify whether the overexpression of Sox2 
in Schwann cells orchestrates a pro-inflammatory environment, future experiments 
using an antibody array should be carried out comparing the cytokine profile of 
nerves taken from control and Sox2HomoOE mice. Analysis of the Affymetrix gene 
array carried out by Dr R.Doddrell in our group (mentioned earlier in Section 3.2.7), 
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identified that Sox2 did not significantly alter the transcript of IL-10 (-1.5x, P=0.4), IL-
1α (-2.0x, P=0.5) or IL-1β (-1.2x , P=0.8), but did significantly alter the transcript of 
MCP-1 (-3.1x, P=0.02), CSF-1 (-4.7x, P=0.03), granulocytes-macrophage colony-
stimulating factor (-1.4x, P=0.6), and vascular endothelial growth factor -B (1.6x 
P=0.004). 
3.3.8 Overexpression of Sox2 in Schwann cells causes functional 
impairment 
Overexpression of Sox2 in Schwann cells causes severe hypomyelination of axons, 
as well as a significant increase in the number of unmyelinated axons in the nerves 
of Sox2HetOE (during development) and Sox2HomoOE mice. As a result these mice 
demonstrated a phenotype similar to that of mouse models of CMT-1 and patients 
diagnosed with CMT-1; they exhibit poor movement, slower nerve conduction 
velocities and reduced motor function (Klein et al., 2015, Saporta et al., 2012, Jani-
Acsadi et al., 2008, Wrabetz et al., 2006). CMT disease is also classically associated 
with reduced sensitivity to heat and touch in the feet and lower legs of diagnosed 
patients, we therefore analysed whether the overexpression of Sox2 impaired 
sensory function within the nerves of Sox2HomoOE mice and revealed that sensitivity to 
toe pinching and Von Frey filament testing was severely reduced (Reilly, 2001). In 
some cases of CMT-1 and CMT-2 diagnosed patients experience neuropathic and 
nociceptive pain, however as we did not test for this we cannot state whether this 
was experienced by Sox2HomoOE mice (Gemignani et al., 2004, Carter et al., 1998). 
The results obtained from carrying out functional testing coincided with our 
hypothesis that as a negative regulator of Schwann cell myelination, Sox2 
overexpression induced a phenotype similar to CMT-1 demyelinating neuropathy. 
The mechanisms by which Sox2 reduces sensory function is unclear. We believe 
that it could be due to a direct effect of Sox2 impairing myelination of fast conducting 
Aδ sensory fibres, which are involved in relaying information regarding acute pain 
and pressure, or as an indirect effect caused by potential damage to sensory nerve 
fibres due to an influx of inflammatory cells [this is discussed in more detail in section 
4.3.4].  
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3.3.9 Deleting Sox2 as a therapy for peripheral demyelination  
Our results show that Sox2 acts as a negative regulator of Schwann cell myelination 
by impairing the expression of myelin proteins and hindering Schwann cell 
myelination, resulting in a phenotype similar to that of a peripheral neuropathy such 
as CMT-1 disease in our Sox2HomoOE mice. Unpublished data from Dr Maurizio 
D’Antonio’s group (at San Raffaele University) has further identified that the 
transcription factors Sox2, cJun and Id2 are upregulated in the nerves of P0S63del 
transgenic mice (CMT-1B mouse model).  Serine 63 mutations in P0 protein 
(P0S63del) results in the protein being retained in the endoplasmic reticulum (ER), 
causing ER stress, activation of the unfolded protein response (UPR) and Schwann 
cell demyelination (Wrabetz et al., 2006). P0S63del mutations also affects the ability 
of wild type P0 to exit the ER and assist in myelin formation (Fratta et al., 2011). As 
Sox2 is upregulated in P0S63del mice, it could be assumed that it contributes to the 
disease pathology. Sox2 null mice generated by cross breeding Sox2 conditional 
floxed mice with P0Cre mice showed increased myelin thickness at P3, although 
myelin thickness appears to be undistinguishable from control nerves by P7 
(unpublished data by Dr Xin-Peng Dun in our group; unpublished data by Dr 
Francesca Florio at San Raffaele University). As Sox2 is a negative regulator of 
Schwann cell myelination and ablation of Sox2 has been shown to increases 
Schwann cell myelin thickness, we might expect that removal of Sox2 from 
P0S63del transgenic mice (CMT-1B) would alleviate the disease progression and 
improve myelination.  This was however not proven to be the case, ablation of Sox2 
from P0S63del nerves worsens the phenotype; mice demonstrated an enhanced 
reduction in myelin basic protein expression and an increase in the percentage of 
unmyelinated axons compared to P0S63del nerves (unpublished data by Dr 
Francesca Florio at San Raffaele University).  In P0S63del nerves Sox2 may 
therefore provide a protective effect by reducing the expression of P0S63del and 
thus reducing ER stress and activation of the unfolded protein response (UPR) 
(unpublished data by Dr Francesca Florio at San Raffaele University). As we can see 
from this unpublished study, Sox2 does not always exert a pathological effect and 
may in some cases be protective. Sox2 has also been shown to be upregulated in 
the mouse model of CMT-1A (Tg(Pmp22)Kan Mice) which overexpress PMP22  
(Fledrich et al., 2014). It would be interesting to see whether the upregulated 
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expression of Sox2 in CMT-1A disease is also protective; reducing the protein 
expression of PMP22 via its negative myelin regulatory function might be beneficial.  
 
The transcription factor cJun, a negative regulator of Schwann cell myelination 
(Parkinson et al., 2008), has been shown to be highly upregulated in pathological 
nerves but not healthy nerves (Hutton et al., 2011). Patients diagnosed with axonal 
neuropathies, CMT-1A and acquired demyelination neuropathies showed high cJun 
immunoreactivity in the nuclei of Schwann cells and in the cytoplasm, whereas no 
cJun expression was detected in normal nerves (Hutton et al., 2011). Experiments 
carried out on C3 mice (mouse model of CMT-1A), further revealed that cJun was 
highly expressed within the nerves of these animals, compared to controls (Hantke 
et al., 2014). Selective deletion of cJun in C3 mice (C3/Schwann cell-cJun-/-) was 
shown to worsen the phenotype, resulting in an increased sensory-motor deficit and 
an increase in sensory axon loss, caused by PMP22 overexpression (Hantke et al., 
2014). This study highlighted that in CMT-1A disease, Schwann cells upregulate 
their expression of cJun as an adaptive response to disease, allowing for axonal 
protection and the support of sensory-motor performance. 
During development, inhibition of cJun by Krox20 promotes Schwann cell 
myelination and normal Schwann cell development (Parkinson et al., 2004). Studies 
therefore analysed whether ablation of cJun in Schwann cells would promote 
Schwann cell remyelination and regeneration following nerve injury as a potential 
therapy. Experiments carried out on cJun null mice following nerve injury revealed 
that cJun plays a protective role in promoting motor neuron survival, in addition to 
promoting the Schwann cell repair program and axon regeneration (Fontana et al., 
2012, Arthur-Farraj et al., 2012). The JNK-cJun pathways has also recently been 
identified to be a key regulator of myelinophagy during Wallerian degeneration, 
which is essential for effective Schwann cell myelin degeneration, myelin clearance 
and thus nerve repair and regeneration following injury (Gomez-Sanchez et al., 
2015). Blocking the JNK-cJun pathways by either treating wild type mice with JNK 
inhibitor (SP600125) or conditional depleting cJun from Schwann cells in mice (cJun 
null mice), revealed that myelin protein breakdown and autophagic flux was 
significantly reduced at 5 days after injury (Gomez-Sanchez et al., 2015). These 
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studies demonstrate that both cJun and Sox2 can exert protective and beneficial 
effects in response to disease and injury when regulated correctly.   
3.3.10 Sox2 in the PNS vs CNS 
Previous work has shown that Sox2 plays an essential role in the development of the 
peripheral nervous system, as misexpression or mutations of Sox2 result in failure to 
form the neural crest and impaired differentiation of neural crest cells into peripheral 
neurons and glia (Wakamatsu et al., 2004). Schwann cells express Sox2 during the 
immature Schwann cell stage, however for immature Schwann cells to myelinate, 
Sox2 levels must be reduced (Le et al., 2005a).  We further confirm that maintained 
expression of Sox2 in Schwann cells during development impairs myelination and 
leads to the development of a peripheral neuropathy. Despite what we observe in 
Schwann cells, the function of Sox2 appears to be different in oligodendrocytes.  
Reactivation of Sox2 mediated by tumour suppressor protein Brca1 and the 
chromatin remodelling protein Brahma in cultured oligodendrocyte precursors 
(OPCs) was previously shown to cause cell fate reversal of OPCs and conversation 
into multipotent neural stem-like cells (NSLCs)  (Kondo and Raff, 2004). However, a 
more recent study by Hoffmann et al. (2014) identified Sox2 to be involved in 
promoting the terminal differentiation of oligodendrocytes. Despite being highly 
expressed throughout oligodendroglia development, Sox2 was shown not to exert 
any functional effect in these cells; removal of Sox2 did not alter proliferation or 
survival, nor did it affect emigration of OPCs from the ventricular zone to their final 
destination in the mantle and marginal zone (Hoffmann et al., 2014). Instead, Sox2 
was shown to be involved in regulating the timely translation of two critical 
transcription factors required for early oligodendrocyte differentiation, maturation and 
myelination; Sox2 repressed the expression of miR145, thus enabling the translation 
of  myelin gene regulatory factor (myrf) and mediator complex subunit 12 (Med12) 
(Hoffmann et al., 2014, Emery et al., 2009, Vogl et al., 2013). Sox2 was also shown 
to directly bind to the promoter of MBP, driving its expression in differentiating 
oligodendrocytes (Hoffmann et al., 2014).  
In contrast to the study by Hoffmann et al. (2014), Zhao et al. (2015) stated that they 
were unable to confirm the involvement of Sox2 in oligodendrocyte terminal 
differentiation.  Zhao et al. (2015) identified that Sox2 does in fact play a functional in 
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in regulating OPC proliferation and survival, as cultured OPCs taken from Sox2 null 
mice showed lower expression of the proliferation marker Ki67 and also an 
increased number of cells with pyknotic nuclei (indicative of cell death), compared to 
cultured OPCs taken from control mice. Even though this study stated that Sox2 is 
not involved in OPC differentiation, an impairment in OPC differentiation was 
observed in Sox2-deficient cells compared to controls, this was indicated by a 
reduction in Olig2+/MBP+ cells. Nonetheless, Zhao et al. (2015) attributed this 
impairment to a reduction in the number of Sox2-depleted OPCs in culture rather 
than their inability to differentiate and myelinate; it was however noted that Sox2 may 
be required to prime OPCs for full differentiation, which coincides partly with the 
study by Hoffmann and colleagues (ibid). 
The study by Zhao et al. (2015) further stated that overexpression of Sox2 in OPCs 
impaired differentiation and therefore downregulation of its expression is required for 
normal myelination. While Hoffmann at al. (2014) showed that Sox2 was involved in 
OPC terminal differentiation, they did not stated that Sox2 was required at later time-
points, as Sox2 was shown to be very weakly expressed in the spinal cord at P30. 
Thus, it is possible that Sox2 may only be involved in the timely onset of 
differentiation and that maintained expression may have negative effects.  
Following toxin induced CNS demyelination, Sox2 was also identified to be re-
expressed in OPCs, where it regulated proliferation, OPC recruitment and survival 
(Zhao et al., 2015).  Zhao et al. (2015) reported that remyelination was impaired in 
OPC specific Sox2 null mice following demyelination, however suggested this to be a 
consequence of reduced OPC recruitment, rather than the role of Sox2 in OPC 
differentiation. This suggestion was further supported by experiments which showed 
that depletion of Sox2 in OPC during the differentiation stage (11-14 days post 
lesion) did not affect OPC differentiation, whilst depletion of Sox2 in OPCs during the 
recruitment stage, significantly reduced differentiation (Zhao et al., 2015).  
The study by Zhao et al. (2015) eluded to a similar role of Sox2 in OPCs, to that 
which we observe in immature Schwann cells; the ability to regulate proliferation and 
impair differentiation when overexpressed. The study further identified a new role of 
Sox2 in regulating the OPC recruitment and expansion following demyelination. On 
the other hand Hoffmann et al. (2014) identified a new and novel role for Sox2 in 
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driving oligodendrocyte terminal differentiation, and its ability to compensate for Sox3 
in this process, when Sox3 is depleted from oligodendrocytes. These studies both 
highlight exciting new functions for Sox2 in oligodendroglial cells, however due to 
their conflicting conclusions regarding the involvement of Sox2 in oligodendrocyte 
differentiation, its role in this process remains uncertain.  
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3.3.11  Conclusion 
Sox2 is able to retain Schwann cells in an immature highly proliferative state, by 
reducing the expression of Krox20; an essential transcriptional regulator of Schwann 
cell myelination, as well as its downstream myelin protein targets P0 and Krox20. We 
have also shown that Sox2 alters the expression and nuclear localisation of Sox10 in 
Schwann cells at later developmental time-points, however further experiments need 
to be carried out clarify this. As Sox2 impairs Schwann cell myelination, this leads to 
hypomyelination of axons, reduced nerve conduction velocity, and impaired motor 
and sensory function. Surprisingly, overexpression of Sox2 was further shown to 
enhance the recruitment of immune cells to hypomyelinated nerves, which is also 
observed in mouse models and patients with CMT-1. We confirm that Sox2 is a 
negative regulator of Schwann cells myelination and maintained expression of Sox2 
induces a phenotype similar that seen in mouse models of CMT-1 disease. 
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Chapter 4 Sox2 overexpression impairs nerve repair and functional   
recovery following injury.  
 
4.1 Introduction 
Following peripheral nerve injury, axons distal to the site of injury degrade and 
Schwann cells dedifferentiate into a repair Schwann cell state, helping to facilitate 
nerve repair and regeneration. Recent studies have identified that in order for 
Schwann cells to dedifferentiate and orchestrate an effective injury response that 
allows for nerve regeneration, they must downregulate the expression of myelin 
related genes, and re-express markers of immature Schwann cells, such as cJun 
and Notch, and re-activate the p38 and extracellular-regulated kinase 1/2 (ERK1/2 ) 
mitogen-activated protein kinase (MAPK) signalling pathways (Arthur-Farraj et al., 
2012, Jessen and Mirsky, 2008, Napoli et al., 2012, Yang et al., 2012, Woodhoo et 
al., 2009). This change in Schwann cell signalling and gene expression thereon 
facilitates neuronal survival, blood nerve barrier breakdown, the recruitment of 
macrophages and the clearance of axonal and myelin debris, thus providing an 
environment suitable for axonal regrowth and regeneration. Once axons have 
regenerated and re-innervated their target tissues, Schwann cells must 
downregulate the expression of immature markers, redifferentiate and remyelinate 
regenerating axons in order to complete the repair process (Navarro et al., 2007).   
Recent studies have identified that Sox2 is also re-expressed in Schwann cells 
following nerve injury, and helps to facilitate the re-localisation of N-cadherin to cell-
cell contact junctions on Schwann cell membranes, enabling Schwann cell sorting 
and the guidance of axons across the nerve bridge (Parkinson et al., 2008, Arthur-
Farraj et al., 2012, Parrinello et al., 2010). Although re-expression of Sox2 is 
important during the early stages of nerve injury, it is not clear how continued 
expression of Sox2 will affect nerve regeneration and functional recovery of motor 
and sensory neurons. We therefore aimed to investigate the effect of continued Sox2 
expression on Schwann cell function, nerve repair and functional recovery for up to 
21 days post crush injury (21DPI). 
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4.2 Results 
4.2.1 Sox2 overexpression impairs Schwann cell remyelination 
after injury 
We have previously shown (Chapter 3) that overexpression of Sox2 leads to severe 
hypomyelination in adult Sox2HomoOE mice and the progressive onset of a 
hypomyelination peripheral neuropathy. In contrast, Sox2HetOE mice show declined 
expression of Sox2 and GFP from P21 onwards, with myelination returning to normal 
by adulthood in these animal (P60); no significant difference was observed between 
the g-ratio of Sox2HetOE  (0.65 ± 0.02) and control mice (0.66±0.03) (P>0.05) [Figure 
3.4]. As we wanted to investigate the effect of continued Sox2 expression following 
sciatic nerve injury in adult mice with normal myelinated axons, we decided to carry 
out these experiments using Sox2HetOE and Sox2 Het control animals between the 
ages of 6 and 8 weeks. We hypothesized that following PNS injury the 
accompanying dedifferentiation of Schwann cells would cause re-activation of Sox2 
and GFP expression in the Sox2HetOE animals. Immunohistochemical analysis 
showed re-expression of GFP expression in the sciatic nerves of Sox2HetOE animals 
at 7 day post cut injury (7 DPC) and 14 and 18 days post crush injury (14 and 18 
DPI), compared to Sox2 Het controls at  similar time-points [data not shown]. 
Furthermore, increased levels of Sox2 were maintained at 21 DPI in Sox2HetOE 
animals, compared to Sox2 Het controls; in which Sox2 and GFP were undetectable 
(n=4) [Figure 4.4].   
Using both transmission and scanning electron microscopy, we evaluated Schwann 
cell remyelination in the sciatic nerves of Sox2 Het control and Sox2HetOE mice taken 
distal to the site of injury (distal nerve stump) at 21DPI.  
To verify that myelination was normal in the sciatic nerves of Sox2 Het control and 
Sox2HetOE mice, were analysed scanning electron micrographs of uninjured nerve 
taken from both these animals. We observed that myelination was normal in the 
sciatic nerves of Sox2 Het control and Sox2HetOE mice prior to injury, as numerous 
thick and compact myelin sheaths were detected (n=2 Sox2 Het control, n=4 
Sox2HetOE) [Figure 4.1]. We next analysed sciatic nerve sections taken distal to the 
site of injury, from the same Sox2 Het control and Sox2HetOE animals at 21 DPI. In 
the nerves of Sox2 Het control mice, myelination was normal at 21 DPI; numerous 
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thick compact myelin sheaths were observed, suggesting that remyelination had 
occurred normally. In contrast, remyelination appeared to be impaired in the distal 
nerves of Sox2HetOE mice 21DPI; myelin sheaths were much thinner and there 
appeared to be a reduction in the overall number of myelin sheaths (n=2 Sox2 Het 
control, n=4 Sox2HetOE) [Figure 4.1].  
We next analysed the same uninjured and injured nerves via transmission electron 
microscopy (TEM), in order to obtain higher resolution images at higher 
magnification. This allowed for accurate measurements of myelin thickness and 
counts of unmyelinated axons to be made.   
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Figure 4. 1: Scanning electron micrographs of uninjured and injured sciatic nerves. 
Uninjured sciatic nerves (A & B) taken from sox2 Het control (A) and Sox2HetOE adult mice (B) 
show numerous thick myelin rings. Injured (crushed) distal sciatic nerves (C & D) taken from 
Sox2 Het control (C) and Sox2HetOE (D) mice 21DPI; note Sox2HetOE nerves are 
hypomyelinated with fewer myelin rings, compared to Sox2 Het control nerves (n=2 Sox2 
Het control, n=4 Sox2HetOE). A,B,C and D, inset 2x magnification.  
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Transmission electron micrographs showed that while axons in the Sox2 Het control 
nerves were remyelinated normally, many axons within the sciatic nerves of 
Sox2HetOE mice were hypomyelinated 21 DPI. The average g-ratio for Sox2 Het 
control mice was 0.69 ± 0.027, whereas the average g-ratio for Sox2HetOE mice was 
significantly increased to 0.86 ± 0.028 (P<0.01, n=4). Furthermore, the total 
percentage of unmyelinated axons at 21DPI was significantly increased from 1.1 ± 
0.3 % in the sciatic nerves of Sox2 Het control mice, to 27.8 ± 10.2% in the sciatic 
nerves of Sox2HetOE mice (P< 0.05, n=4) [Figure 4.2]. Analysis of axonal diameter 
size revealed that there was also a significant shift in the percentage of axons 
towards having a larger diameter in the sciatic nerves of Sox2HetOE mice, compared 
to Sox2 Het controls; the average axonal diameter in Sox2 Het control nerves was 
1.38 ± 0.02 µm, whereas the average axonal diameter in Sox2HetOE nerves was 
significantly larger at 1.62 ± 0.02 µm (P <0.001, n=4) [Figure 4.2].  
Further analysis by TEM was carried out on the distal sciatic nerve stump sections 
taken from Sox2 Het control and Sox2HetOE mice, to determine whether axonal 
sorting was normal 21 days post injury (21 DPI). In the sciatic nerves of both Sox2 
Het control mice and Sox2HetOE mice, all small diameter axons (<1µm) had effectively 
been sorted into groups and ensheathed by non-myelinating Schwann cell forming 
Remak bundles. Additionally, all larger calibre axons (>1µm) appeared to have been 
effectively sorted, and were in a 1:1 relationship with a Schwann cell (n=4) [Figure 
4.2 and 4.3].  
We further investigated the ultrastructure of the regenerating nerves using TEM and 
observed an abundant number of macrophages, still present within the sciatic nerves 
of Sox2HetOE mice, compared to Sox2 Het controls 21 DPI. More strikingly, the 
macrophages present within the nerves appeared to be associated with 
demyelinating axons and to also be degenerating myelin, suggesting that 
remyelination and demyelination was occurring. In the sciatic nerves of Sox2 Het 
control mice a couple of macrophages remained and myelin ovoid structure could 
still be observed 21 DPI, however this was to a much lesser extent, compared to 
Sox2HetOE mice (n=4) [Figure 4.3].  
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Figure 4. 2: Overexpression of Sox2 hinders remyelination. Transmission electron 
micrographs of sciatic nerves sections taken from control (A) and Sox2HetOE nerves (B) at 21 
DPI (n=4). (C) Scatter plot displaying the g-ratios of individual axons in relation to their axon 
size (n=4). (D) Graph showing the average g-ratio of control and Sox2HetOE nerves 21 DPI; 
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note the g-ratio is significantly increased in Sox2HetOE mice compared to controls (P=0.005, 
n=4). (E) Graph showing the total percentage of unmyelinated axons in the sciatic nerves of 
control and Sox2HetOE mice (n=4). (F) Graph showing the percentage distribution of axons in 
relation to their size; note, a shift in the population of axons towards having a larger diameter 
in the sciatic nerves of Sox2HetOE mice at 21 DPI (n=4). (G) Graph showing the average axon 
diameter of control and Sox2HetOE nerves at 21 DPI; note the axon diameter is significantly 
larger in the sciatic nerves of Sox2HetOE mice at 21 DPI (P<0.001, n=4).  
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Figure 4. 3: Increased number of macrophages and myelin debris in the nerves of 
Sox2 overexpressing mice at 21 DPI . Transmission electron micrographs of Sox2 Het 
control (A & B) and Sox2HetOE (C & D) nerves at 21 DPI. In the nerves of Sox2HetOE mice, 
numerous macrophages and lipid droplets can be observed at both low (C) and high (D) 
magnifications. In comparison, very few macrophages and lipid vacuoles can be detected 
within the nerves of Sox2 Het control mice (A & B). MØ, Macrophage; MO, Myelin Oviod; 
LD, Lipid droplet.  
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4.2.2 Sox2 overexpression impairs the re-expression of myelin 
proteins after injury 
As we have observed that continued Sox2 expression impairs Schwann cell 
remyelination, we next wanted to investigate whether continued Sox2 expression 
hindered the re-expression of myelin proteins following sciatic nerve injury. To test 
this we carried out immunohistochemical and western blot analysis on the distal 
sciatic nerve stump taken from Sox2 Het control and Sox2HetOE mice at 21 DPI.  
The expression of Sox2 and GFP remained high, with Sox2 localising to the nucleus 
in the sciatic nerves of Sox2HetOE mice at 21 DPI. In comparison, the expression of 
Sox2 was clearly reduced, and no GFP was observed in the sciatic nerves of Sox2 
Het control mice at 21 DPI (n=3) [Figure 4.4]. 
Further analysis of myelin associated proteins revealed that MBP re-expression was 
severely impaired within the distal sciatic nerve stump of Sox2HetOE mice at 21 DPI; 
expression levels of MBP were extremely low and very few MBP positive myelin 
rings could be observed (n=3) [Figure 4.4]. Similarly, expression levels of Krox20 
appeared to be very low, with very few Krox20 positive nuclei being detected within 
the distal sciatic nerve stump of Sox2HetOE mice (n=3) [data not shown]. In contrast, 
MBP was highly expressed within the distal sciatic nerve stump of Sox2 Het control 
mice, with numerous MBP positive myelin rings being observed (n=3) [Figure 4.4]. In 
addition increased levels of Krox20, and numerous Krox20 positive nuclei were 
observed in the distal sciatic nerve stump of Sox2 Het control mice at 21 DPI (n=2) 
[data not shown].These experiments were repeated by western blot and showed that 
continued expression of Sox2 at 21 DPI impaired the re-expression of both MBP 
[data not shown] and P0 [Figure 4.4] (n=3 control, n=4 Sox2
HetOE). 
 From these results we can conclude that continued expression of Sox2 following 
sciatic nerve injury impairs the ability of Schwann cells to re-express myelin 
associated proteins and effectively remyelinate regenerating axons, even though 
axon/Schwann cell association is normal at 21 DPI [See Figure 4.2 and Figure 4.3]. 
As we previously identified in Chapter 3 that Sox2 overexpression maintains 
Schwann cells in an immature state, which was further confirmed by the maintained 
expression of other immature Schwann cell markers such as cJun and N-cadherin. 
We therefore wanted to identify whether overexpression of Sox2 after nerve injury 
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would further retain Schwann cells in an immature/repair Schwann cell state, and 
thus the upregulated expression of other immature Schwann cell markers. To 
confirm this, we immunolabelled distal nerve stump sections taken from Sox2 Het 
control and Sox2HetOE mice with antibodies for cJun at 21 DPI.  
Surprisingly, cJun expression was still detectable and clearly localised at the nucleus 
within the nerves of Sox2 Het control mice at 21 DPI; this was unexpected as 
analysis by electron microscopy had shown that all Schwann cells appeared to have 
redifferentiated and remyelinated normally. Further analysis of Sox2HetOE nerves 21 
DPI revealed that cJun expression was highly detectable and to a much more 
elevated extent, than in the Sox2 Het controls. Furthermore the expression of cJun 
appeared to be much more evenly distributed throughout nerves of Sox2HetOE mice 
(n=2) [Figure 4.5].  
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Figure 4. 4: Overexpression of Sox2 impairs the re-expression of myelin proteins 
following injury. Immunolabelling with antibodies against  Sox2 revealed that control 
nerves no longer express Sox2 at 21 DPI (A-C), whereas Sox2 is still highly expressed 
within Sox2HetOE nerves (D-F) at 21 DPI (n=3). Immunolabelling of distal sciatic nerve 
sections with antibodies for MBP (G-L) revealed that control nerves strongly express MBP 
and have numerous MBP positive rings (H & I) at 21 DPI, whereas Sox2HetOE nerves show 
weak expression of MBP and have very few MBP positive rings (K & L) at 21 DPI (n=3). 
Western blot (M) showing high expression of Sox2, and reduced expression of P0 and MBP 
in the distal nerve stump of Sox2HetOE mice at 21 DPI (n=3 control, n=4 Sox2HetOE). Images 
(A-F) taken using 20x objective, images (G-L) taken using 40x objective, scale bars are 
20µm. 
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Figure 4. 5: cJun is elevated in the nerves of Sox2 overexpressing mice at 21 DPI. 
Distal sciatic nerve sections taken from Sox2 Het control and Sox2HetOE mice at 21 DPI were 
Immunolabelling with antibodies against cJun (A-F). Immunofluorescent staining shows 
higher levels of cJun expression and more numerous cJun positive nuclei in the nerves of 
Sox2HetOE mice (D-F), compared to Sox2 Het control mice (A-C) (n=2). Images (A-F) taken 
using 20x objective (D,E,F, inset 50x), scale bar is 20µm. 
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4.2.3 Overexpression of Sox2 maintains Schwann cells in a highly  
 proliferative state 21DPI 
To test whether Sox2 overexpression altered Schwann cell proliferation after injury, 
distal sciatic nerve stump sections taken from Sox2 Het control and Sox2HetOE mice 
at 3, 14, 18 and 21 DPI were stained with antibodies for Ki67.  
At 3 DPI, there did not appear to be a rapid increase in the levels of proliferation, as 
very few Ki67 positive nuclei were detected in the sciatic nerves of both Sox2 Het 
control and Sox2HetOE mice. Furthermore, counts made on the total number of Ki67 
positive nuclei per nerve revealed that at 3 DPI, Sox2 overexpression did not 
significantly increase the number of Ki67 positive nuclei within the nerves of 
Sox2HetOE mice compared to Sox2 Het controls (n=2 per genotype) [data not shown].  
Analysis of Sox2 Het control and Sox2HetOE sciatic nerves at 7 DPC revealed that 
proliferation was increased within Sox2HetOE sciatic nerves, distal to the site of injury 
(89.7 ± 13.3 Ki67 positive nuclei per nerve section), compared to Sox2 Het control 
sciatic nerves, distal to the site of injury (67.2 ± 16.6 Ki67 positive nuclei per nerve 
section). Nonetheless, statistical analysis identified that the increased number of in 
Ki67 positive nuclei in nerves of Sox2HetOE mice was not significant (P>0.05, n=3) 
[Figure 4.6].  
At 14 DPI, staining for Ki67 revealed that there was an increase in the number of 
proliferating cells within the distal sciatic nerve stump sections taken from both Sox2 
Het control and Sox2HetOE mice; a total number of 289 Ki67 positive nuclei was 
detected in the distal nerves of Sox2 Het control mice and a total number of 296 Ki67 
positive nuclei was detected within the distal nerves of Sox2HetOE mice (n=1 per 
genotype). Surprisingly, although Schwann cell proliferation appears to have peaked 
at this time-point, Sox2 overexpression did not appear to dramatically increase 
Schwann cell proliferation above the control threshold. Nonetheless, analysis at 18 
DPI revealed that the total number of Ki67 positive nuclei was dramatically increased 
in the nerves of Sox2HetOE mice (42 ± 24 Ki67 positive nuclei per nerve section), 
compared to Sox2 Homo control mice (4 Ki67 positive nuclei per nerve section) (n=1 
control, n=2 Sox2HetOE) [Figure 4.7]. Similarly, at 21 DPI, a significant increase in 
Schwann cell proliferation was observed at this time-point in the distal sciatic nerve 
stump of Sox2HetOE mice (20.75 ± 3.7 Ki67 positive nuclei), compared to  the distal 
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sciatic nerve stump of Sox2 Het control mice (6.5 ± 2.9 Ki67 positive nuclei) (P< 
0.05, n=4 per genotype) [Figure 4.8].  
These results suggest that overexpression of Sox2 directly after sciatic nerve injury 
does not significantly enhance proliferation above the normal threshold. However, 
continued Sox2 expression following axon regeneration maintains Schwann cells in 
a highly proliferative state. Data collected by Dr Xin-Peng Dun in our group 
[unpublished data], further confirmed that Sox2 expression following nerve injury is 
essential for Schwann cell proliferation, as a significant reduction in Schwann cell 
proliferation was observed in the distal nerve stump of Schwann cells specific Sox2 
null mice, compared to control mice at 7 DPC. Overall these results support previous 
findings, that Sox2 plays a role in enhancing Schwann cell proliferation (Le et al., 
2005a). 
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Figure 4. 6: Overexpression of Sox2 increases Schwann cell proliferation at 7 DPC. Distal sciatic nerve stump sections taken from Sox2 
Het control and Sox2HetOE mice at 7 DPC were immunolabelled with antibodies against Ki67 (A-F). Immunofluorescent staining shows slightly 
more numerous Ki67 positive nuclei in the nerves of Sox2HetOE mice (E & F), compared to Sox2 Het control mice (B & C) at 7DPC. Graph (G) 
showing the total number of Ki67 positive nuclei in the sections of distal sciatic nerves taken from Sox2 Het control and Sox2HetOE  mice 7 DPC; 
note no significant change (P>0.05, n=3). Images taken using 20x objective (D,E,F, inset 40x), scale bar is 20µm.  
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Figure 4. 7: Overexpression of Sox2 increases Schwann cell proliferation at 18 DPI.  Distal sciatic nerve stump sections taken from Sox2 
Het control and Sox2HetOE mice at 18 DPI were immunolabelled with antibodies against Ki67 (A-F). Immunofluorescent staining shows more 
numerous Ki67 positive nuclei in the nerves of Sox2HetOE mice (E & F), compared to Sox2 Het control mice (B & C) at 18 DPI. Graph (G) 
showing the total number of Ki67 positive nuclei in sections of distal sciatic nerves taken from Sox2 Het control and Sox2HetOE  mice at 18 DPI 
(n=1 control,  n=2 Sox2HetOE). Images taken using 20x objective (D,E,F, inset 40x), scale bar is 20µm.  
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Figure 4. 8: Overexpression of Sox2 increases Schwann cell proliferation at 21 DPI. Distal sciatic nerve stump sections taken from Sox2 
Het control and Sox2HetOE mice at 21 DPI were Immunolabelled with antibodies against Ki67 (A-F). Immunofluorescent staining shows 
numerous Ki67 positive nuclei in the nerves of Sox2HetOE mice (E & F), compared to Sox2 Het control mice (B & C) at 21 DPI. Graph (G) 
showing a significant increase in the total number of Ki67 positive nuclei in sections of distal sciatic nerves taken Sox2HetOE  mice, compared to 
Sox2 Het control mice at 21 DPI (P<0.05, n=4). Images taken using 20x objective (D,E,F, inset 50x), scale bar is 20µm.  
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4.2.4 Sox2 overexpression leads to an increased number of 
macrophages within the distal nerve stump at 21DPI  
Following peripheral nerve injury, axons distal to the site of injury trigger a process 
known as Wallarian degeneration, resulting in a cascade of degenerative and 
regenerative cellular and molecular changes within both the nerve and the Schwann 
cell. During this event, the blood nerve barrier is breached and Schwann cells 
upregulate the expression of various cytokines and chemokines including TNFα, IL-
α, Monocyte Chemotactic Protein -1 (MCP-1) and Macrophage Inflammatory Protein-
1α (MIP-1α), which promote the activation and recruitment of macrophage to the site 
of injury (Rotshenker, 2011, Hall, 2005, Napoli et al., 2012, Tofaris et al., 2002).  
In section 4.2.1 we identified the presence of numerous macrophages still within the 
distal sciatic nerve stump of Sox2HetOE mice at 21 DPI by TEM. To follow this up, we 
wanted to quantify and determine whether overexpression of Sox2 resulted in a 
significant increase in the total number of macrophages within the nerves of 
Sox2HetOE mice, compared to Sox2 Het control mice following crush injury. To test 
this, we double immunolabelled distal sciatic nerve stump sections taken from both 
Sox2 Het control and Sox2HetOE mice at 21DPI, with antibodies for F4/80 and Iba1 
(macrophage markers). Sox2HetOE nerves showed prominent F4/80 and Iba1 staining, 
with numerous F4/80+ and Iba1+ cells localised next to a nucleus. In contrast, 
although Sox2 Het control nerves showed F4/80 and Iba1 double positive cells, 
fewer were identified. We quantified the number of F4/80 and Iba1 positive 
macrophages and revealed that there was a significant increase in the number of 
macrophages present within the nerves of Sox2HetOE mice (124 ± 20.5 F4/80+ / Iba1+ 
cells), compared to Sox2 Het control mice (60 ±11.3 F4/80+ / Iba1+ cell) at 21DPI 
(P<0.05) (n = 6 Sox2 Het control, n= 5 Sox2HetOE) [Figure 4.9].  
In order to confirm that the increase in macrophage numbers in the nerves of 
Sox2HetOE mice was in fact due to the overexpression of Sox2 following nerve crush 
injury, we also stained uninjured sciatic nerves taken from the same Sox2 Het 
control and Sox2HetOE mice, with antibodies for F4/80 and Iba1. We were able to 
reveal that there was no significant difference in the number of macrophages present 
within the nerves of uninjured Sox2 Het control and Sox2HetOE mice (P>0.5); in Sox2 
Het control mice the average number of macrophages was 14.3 ± 7.5 per nerve 
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section, and in Sox2HetOE mice the average number of macrophages was 10.5 ± 3.7 
per nerve section (n=3 per genotype) [Figure 4.9].  
In addition to macrophages, neutrophils and T-lymphocytes are also recruited into 
nerves following injury, helping to mediate the inflammatory response and promote 
functional recovery. Neutrophils are the first immune cell to appear to the site of 
injury, infiltrating around 3 DPI, whilst T-lymphocytes and macrophages appear 
slightly later at around 5 DPI (Napoli et al., 2012, Hall, 2005). As we observed an 
increased number of macrophages within the nerves of Sox2HetOE mice, compared to 
Sox2 Het control mice at 21 DPI, we next wanted to determine whether there was 
also an increase in other inflammatory cells within the nerves of Sox2HetOE mice. To 
test this, we stained distal nerve stump sections take from Sox2 Het control and 
Sox2HetOE mice at 21 DPI with antibodies specific for neutrophil marker NIMP, and T-
lymphocyte marker CD3. 
We were able to reveal that there was an increase in the number of NIMP+ cells 
within the distal nerve stump of Sox2HetOE mice (24. 33 ± 9.61 NIMP+ cells), 
compared to Sox2 Het control nerves (7 ± 2.27 NIMP+ cells) at 21 DPI, however this 
was not significant (P=0.21, n=4) [Figure 4.9]. The total number of CD3+ cells was 
also increased within the distal nerve stump of Sox2HetOE mice (20.75 ± 3.7 CD3+ 
cells), compared to Sox2 Het control nerves (11± 2.9 CD3+ cells), however again 
this increase was not significant (P=0.085, n=4) [ Figure 4.9].  
These results confirmed that continued overexpression of Sox2 following nerve injury 
increases the number of inflammatory cells within the regenerating nerves at 21 DPI. 
The presence of macrophages and other inflammatory cells in the nerve following 
regeneration is likely to impact on the ability of Schwann cells to remyelinate, 
consequently hindering functional recovery and having implications in neuropathic 
pain (Ellis and Bennett, 2013, Liu et al., 2000, Ristoiu, 2013). 
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Figure 4. 9: Overexpression of Sox2 leads to an increased number of immune cells 
present in the distal nerve stump at 21 DPI.  Immunofluorescent staining with antibodies 
specific for macrophage markers F4/80 and Iba1 (A-F) shows that Sox2HetOE mice have 
numerous F4/80+ and Iba1+ cells within their nerves at 21 DPI (E & F). In contrast Sox2 Het 
control mice have very few F4/80+ and Iba1+ cells present in their nerves at 21 DPI (B & C). 
(G) Graph showing the total number of macrophages present in the uninjured and injured 
nerves of Sox2 Het control and Sox2HetOE mice at 21 DPI (n=3 per genotype for uninjured 
nerves; n=6 control, n=5 Sox2HetOE for injured nerves). (H) Graph showing the total number 
of CD3+ T-cells in the injured nerves of Sox2 Het control and Sox2HetOE mice at 21 DPI (n=4 
per genotype). (I) Graph showing the total number of NIMP+ neutrophils in the injured nerves 
of Sox2 Het control and Sox2HetOE mice at 21 DPI (n=4 per genotype). Images taken using 
20x objective (B,C,E,F, inset 50x), scale bar is 20µm.               
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4.2.5 Sox2 overexpression hinders functional recovery following 
nerve injury  
Peripheral nerve injury, leads to loss of motor and sensory function, however 
following Wallerian degeneration and proper guidance of regenerating axons, nerves 
are able to repair and re-innervate their target tissue, leading to full functional 
recovery being seen in rodents between  3-4 weeks after crush injury (Yang et al., 
2008). Nonetheless, having observed that Sox2 overexpression directly leads to a 
marked reduction in remyelination at 21 DPI, we wanted to identify whether 
continued Sox2 expression this would affect functional recovery of regenerating 
nerves.  To test this, we compared nerve conduction velocities of uninjured and 
injured sciatic nerves taken from both Sox2 Het control and Sox2HetOE mice at  21 
DPI. In addition, functional recovery of motor axons was assessed by measuring and 
analysing static sciatic index (SSI) of Sox2 Het control and Sox2HetOE animals before 
sciatic nerve crush injury, directly after nerve injury and thereon every 2-3 days up 
until 21days post injury.  
Compound action potentials were recorded from uninjured and injured sciatic nerves 
taken from both Sox2 Het control and Sox2HetOE mice 21DPI, and used to calculate 
nerve conduction velocities. We were able to confirm that no significant difference in 
nerve conduction velocity was observed between Sox2 Het control (61.9 ± 4.1 m/s) 
and Sox2HetOE (61.2 ± 7.3 m/s) uninjured sciatic nerves (P>0.05, n=6 per genotype). 
Nonetheless, following sciatic nerve injury a decrease in nerve conduction velocity 
was observed in the sciatic nerves of Sox2HetOE mice (36.2 ± 3.9 m/s), compared to 
Sox2 Het control mice (43.4 ± 7.9 m/s) at 21 DPI; although this did not appear to be 
significant (P>0.05, n=6 per genotype) [Figure 4.10].  
We next went on to analyse functional recovery using SSI. Prior to sciatic nerve 
injury, no significant difference in motor function was observed between Sox2 Het 
control and Sox2HetOE animals (P>0.5, n=11 Sox2 Het control, n=9 Sox2HetOE). 
Directly following sciatic nerve injury, motor function was dramatically impaired in 
both Sox2 Het control and Sox2HetOE animals; this was identified by the inability of 
these animals to spread their paw (toes spread test) and a dramatic reduction in SSI. 
At 7 DPI slight functional recovery could be observed in both Sox2 Het control and 
Sox2HetOE animals, with no significant difference in recovery being observed between 
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these mice (P=0.16, n=13 per genotype). However at 10 DPI it was clear that 
functional recovery in Sox2HetOE mice was significantly slower than in Sox2 Het 
control mice (P<0.05, n=11 Sox2 Het control, n=12 Sox2HetOE) [Figure 4.10]. 
Functional recovery of motor neurons thereon continued to be significantly slower in 
Sox2HetOE mice compared to Sox2 Het control mice, up until 21DPI (P<0.01). By 
21DPI, motor function was back to normal in the Sox2 Het control mice, with no 
significant difference being observed between SSI measurements before injury and 
SSI measurements at 21 DPI (P>0.05, n=11 prior to injury, n=5 at 21DPI). However, 
as a significant difference was observed between SSI measurements taken before 
injury and SSI measurements taken at 21 DPI in Sox2HetOE animals (P<0.001, n=9 
prior to injury, n=7 at 21DPI); thus revealing that motor function had not returned 
back to normal in these animals by 21 DPI. Further analysis of Sox2 Het control and 
Sox2HetOE SSI measurements at 21 DPI, confirmed that functional recovery was 
significantly reduced in Sox2HetOE animals, compared to Sox2 Het controls at 21 DPI 
(P<0.001, n=5 Sox2 Het control, n=7 Sox2HetOE)  [Figure 4.10]. 
In order to further characterise whether Sox2 overexpression impaired recovery of 
motor function, we assessed toe spread reflex in Sox2 Het control and Sox2HetOE 
animals at 12, 14, 17, 19 and 21 DPI (n=6 per genotype). A scored of either 0, 1 or 2, 
was given in regards to the animals toe spread reflex ability [See Section 2.4.5.3]. By 
14 DPI, 100% of Sox2 Het control animals had regained some motor function, this 
was demonstrated through their ability to extend their leg with slight toe spreading 
(score of 1), in contrast only 33% of Sox2HetOE animals showed regain of slight motor 
function (score of 1), the remaining 67% of Sox2HetOE animals showed no sign of 
regained motor function (score of 0). At 17 DPI, again 100% of Sox2 Het control 
animals showed some motor function with a toe spread reflex score of 1, whilst only 
33% of Sox2HetOE animals scored a toe spread reflex value of 1 and the remaining 
67% of Sox2HetOE animals scoring a toe spread reflex value of 0. These results 
further identified that there had been no additional improvement in motor function 
among both Sox2 Het control and Sox2HetOE animals between 14 and 17 DPI. At 19 
DPI and 21 DPI, an improvement in motor function was observed in both Sox2 Het 
control and Sox2HetOE animals, although recovery of motor function appeared to be 
much slower in Sox2HetOE animals. 50% of Sox2 Het control animals had regained full 
motor function, this was demonstrated through their ability to fully extend their leg 
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and spread their toes (Score of 2), whilst the remaining 50% of Sox2 Het control 
animals scored a toe spread value of 1. In contrast, only 33% Sox2HetOE animals 
scored a toe spread reflex value of 2, another 33% scored a toe spread value of 1, 
and the remaining 33% scored a toe spread value of 0, at both 19 DPI [data not 
shown]  and 21DPI [Figure 4.10]   
Our SSI and preliminary toe spread data further support our hypothesis that 
continued Sox2 expression following nerve injury, reduces nerve repair and 
regeneration and further impairs functional recovery of motor axons.  
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Figure 4. 10: Overexpression of Sox2 reduces functional recovery in Sox2HetOE mice. 
(A) Graph displaying the nerve conduction velocities of uninjured and injured nerves taken 
from Sox2 Het control and Sox2HetOE mice at 21 DPI (n=6). (B) Graph showing the functional 
recovery of control and Sox2HetOE mice following nerve injury; a significant difference in 
function recovery was observed between Sox2 Het control and Sox2HetOE mice from 10 DPI 
to 21 DPI. (C) Graph showing the toe spread reflex (score 0: no leg extension or toe spread; 
Score 1: partial leg extension and partial toe spreading; score 2: full leg extension and full 
toe spreading) of Sox2 Het control and Sox2HetOE mice after crush injury (n=6).  
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4.2.6 Sox2 overexpression hinders recovery of sensory function 
following nerve injury 
For successful recovery of sensory function following nerve injury, sensory axons 
distal to the site of injury must undergo Wallerian degeneration, proximal axons must 
then successfully regrow within a permissive environment and re-innervate their 
target tissue. As we have previously seen that continued Sox2 expression following 
nerve injury reduces nerve conduction velocity and functional recovery at 21 DPI, we 
next wanted to determine whether continued Sox2 expression would affect recover 
of sensory function. To test this we analysed the responsiveness of Sox2 Het control 
and Sox2HetOE mice to toe pinching and light pressure testing at 7, 10, 12, 14, 17, 19 
and 21 DPI.  
In Sox2 Het control and Sox2HetOE mice, sciatic nerve crush injury abolished the 
response to toe pinching in toes 3, 4 and 5 from 1DPI. Sox2 Het control animals 
started to regain responsiveness to toe pinch testing in toe 3 from 10 DPI (16% of 
animals) [data not shown], whilst Sox2HetOE animals did not begin to regain 
responsiveness until 17DPI (16% of animals). By 21 DPI 100% of Sox2 Het control 
animals were able to respond to toe pinch testing in toe 3, whilst only 33% of 
Sox2HetOE animals were able to respond (n=6 per genotype) [Figure 4.11].   In toe 4, 
Sox2 Het control animals regained responsiveness to toe pinch testing from 17DPI 
(16% of animals), with 33% of Sox2 Het control animals being able to respond by 
21DPI. In contrast Sox2HetOE animals did not regain responsiveness in toe 4 until 
21DPI and only 16% of animals were able to respond at this time-point (n=6) [Figure 
4.11]. In toe 5, Sox2 Het control animals regained responsiveness to toe pinch 
testing from 17DPI (16% of animals) and by 21DPI, 50% of Sox2 Het control animals 
were able to respond. In contrast Sox2HetOE animals did not regain the ability to 
respond to in toe 5 by 21DPI (n=6) [Figure 4.11]. 
We next went on analyse responsiveness to light touch using Von Frey filaments. In 
Sox2 Het control and Sox2HetOE mice, sciatic nerve crush injury abolished the 
response to light touch. By 10 DPI, both Sox2 Het control and Sox2HetOE mice had 
regained the ability to respond to light touch, furthermore Sox2 Het control mice 
showed an increased responsiveness to light touch (70 ± 25g) compared to 
Sox2HetOE mice (92 ± 23g), however this was not significant (P>0.05, n=6 per 
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genotype).  At 12, 14, 17, 19 and 21 DPI Sox2 Het control mice continued to show 
improved responsiveness to light touch at a faster rate than Sox2HetOE mice, however 
this improved difference was again not significant (P<0.05, n=6) [Figure 4.11]. By 21 
DPI, Sox2HetOE mice were able to respond to Von Frey filaments as light as 0.06 ± 
0.02g, whilst Sox2 Het control mice were able to respond Von Frey filaments much 
lighter at 0.01 ± 0.002g, although this change was not significant (P=0.07, n=6). 
Although continued Sox2 expression does not significantly impair recovery of 
sensory function, we can conclude that it does reduce the rate of recovery following 
nerve injury. We can assume that functional recovery in some sensory axons such 
as C fibres is not significantly impaired as they are do not require myelination. 
However, mechanoreceptors such as A delta (Aδ) sensory fibres which are 
responsible for responsiveness to touch and pressure, do in fact require thin layers 
of myelin in order to respond to stimulus in a timely manner. As Sox2 overexpression 
leads to hypomyelination, this might explain why sensory recovery is slightly slower 
in Sox2HetOE mice.   
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Figure 4. 11: Overexpression of Sox2 reduces sensory function recovery following 
injury. (A) Graph showing the percentage of Sox2 Het control and Sox2HetOE mice 
responding to pinching of distal parts of toes 3, 4 and 5 at 17, 19 and 21 DPI (n=6). (B) 
Graph showing the responsiveness of Sox2 Het control and Sox2HetOE mice to light pressure 
at 10, 12 and 14 DPI. (C) Graph showing the responsiveness of Sox2 Het control and 
Sox2HetOE mice to light pressure at 17, 19 and 21 DPI (n=6). 
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4.3 Discussion 
Expression of Sox2 following nerve injury is beneficial in the process of Wallerian 
degeneration as it regulates two processes essential for nerve repair and 
regeneration: Schwann cell demyelination and the guidance of regenerating axons 
back to their target tissues. Nonetheless, our data confirms that Sox2 expression 
must eventually be repressed to allow for the timely transition of repair cells into a 
myelinating Schwann cell state, allowing remyelination of regenerating nerve fibres, 
and thus successful nerve repair and functional recovery.  
4.3.1 Maintained Sox2 expression impairs remyelination following     
 nerve injury  
Following nerve injury, Schwann cells undergo a process of adaptive cellular 
reprogramming. It is essential that cJun is activated in these cells, along with other 
negative myelin regulators Sox2, Notch and the ERK 1/2 and p38 mitogen activated 
protein kinase (MAPK) signalling pathway. Reactivation of these factors causes 
Schwann cells to degrade their myelin sheath and differentiate into a transient repair 
cell termed a Bϋngner cell; which is similar to an immature Schwann cell (Jessen et 
al., 2015, Arthur-Farraj et al., 2012, Le et al., 2005a, Yang et al., 2012, Napoli et al., 
2012, Harrisingh et al., 2004). These repair cells express high levels of trophic 
factors including glial derived nerve growth factor (GDNF), Artemin (Artn), leukemia 
inhibitory factor (LIF) and brain derived nerve growth factor (BDNF) which help to 
support the survival of regenerating axons and promote axon growth (Fontana et al., 
2012, Arthur-Farraj et al., 2012). Furthermore, the repair cells form regenerative 
tracts, termed bands of Bϋngner which help to guide regenerating axons back to 
their target (Parrinello et al., 2010). As axons regrow and re-innervate their target 
site, the repair cell then downregulates the expression of cJun, Sox2, Notch and the 
activated ERK 1/ 2 and p38 MAPK signalling pathway. Repair cells then upregulate 
the expression of myelin associated genes, such as Krox20, P0 and MBP enabling 
them to differentiate back into a myelinating Schwann cell. Finally, Schwann cells 
remyelinate regenerating axons, allowing for complete nerve repair and functional 
recovery.  
Previous studies have confirmed that the early expression of these negative myelin 
regulators following nerve injury is essential for Schwann cells to effectively transition 
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into repair cells and promote nerve regeneration. In Schwann cell specific cJun 
depleted (cJun null) mice following nerve injury, Schwann cells fail to dedifferentiate 
and upregulate genes associated with trophic support, and to downregulate genes 
associated with myelination (Parkinson et al., 2008, Arthur-Farraj et al., 2012). 
Furthermore, in cJun null mice proteins associated with cell adhesion and the 
formation of bands of Bϋngner (N-cadherin, p75NTR, and NCAM) are dysregulated, 
resulting in the formation of abnormal regenerative tracts (Arthur-Farraj et al., 2012). 
cJun null mice also exhibit impaired myelin breakdown by autophagy, a striking 
increase in the death of both small and large dorsal root ganglion (DRG) neurons, as 
well as a decrease in axon growth. Functional recovery (sensory & motor) is thus 
severely impaired in cJun null mice, while control mice demonstrate almost full 
recovery by 3-4 weeks. Consequently, cJun was proven to govern all major aspects 
of the injury response including neuronal survival, Schwann cell reprograming, 
myelin degradation and clearance and the formation of regenerative tracts (Arthur-
Farraj et al., 2012, Gomez-Sanchez et al., 2015).  
Studies analysing the role of ERK 1/2 signalling in Schwann cells following nerve 
injury, reveal that inhibition of the ERK 1/2 MAPK signalling pathways using the 
pharmaceutical inhibitor PD0325901, results in a delay of Schwann cell 
downregulation of the expression of myelin-related genes and dedifferentiation 
(Napoli et al., 2012). In contrast, prolonged activation of the ERK 1/2 signalling 
pathways following nerve injury retains Schwann cells in a dedifferentiated state, 
resulting in delayed motor functional recovery (Ibid). Similarly, studies analysing the 
functional role of p38 MAPK in Schwann cells have identified that blocking its 
activation (using a pharmaceutical inhibitor SB203580) results in the impairment of 
Schwann cells to demyelinate, following nerve injury (Yang et al., 2012). 
Experiments by Woodhoo et al. (2009), further confirmed the functional role of Notch 
in regulating Schwann cell demyelination following injury. Absence of RBPJ (the key 
transcriptional regulator of the Notch canonical signalling pathway) resulted in a 
dramatic reduction in Schwann cell demyelination following injury, whilst increased 
Notch signalling accelerates demyelination as demonstrated by elevated expression 
of  the intracellular proportion of the Notch receptor; NICD using P0-Cre
+CALSL-
NICD mice (Woodhoo et al., 2009). From these studies it is clear that the expression 
of these negative myelin regulators is essential for the initiation of Schwann cell 
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dedifferentiation and demyelination to aid with nerve repair. The study by Napoli et 
al. (2012) where ERK1/2 signalling is prolonged, further confirms that that the 
downregulation of these negative regulators is essential for the transition of Schwann 
cells back to the myelinating state, and for the complete functional recovery of motor-
sensory neurons.  
Sox2 has been shown to play an essential role in the re-localisation of N-cadherin to 
Schwann cell contact junctions, enabling Schwann cells to form bands of Bungner 
that aid with axon guidance and regeneration (Parrinello et al., 2010). Data collected 
by Dr Xin-Peng Dun in our group [unpublished data] further confirmed using 
Schwann cell specific Sox2 knockout (Sox2 null) mice, that axon regeneration is 
severely disorganised in these animals following nerve cut injury, compared to 
controls. Although Sox2 has been identified as being important for axon guidance 
and regeneration, the role of Sox2 on Schwann cell differentiation and myelination 
following nerve injury in vivo had not been studied. Using Sox2HetOE mice we thus set 
out to investigate the effect of maintained Sox2 expression on nerve repair and 
regeneration. 
During development Sox2HetOE mice expressed high levels of Sox2, which caused 
reduced Schwann cell myelination and myelin protein expression, compared to 
controls up until postnatal day 21 (P21). However, from P21 the Sox2-IRES-EGFP 
transgene appeared to switch off; neither Sox2 nor GFP was detected in the sciatic 
nerves of P60 Sox2HetOE mice. Furthermore myelination had returned to normal in 
these animals at P60, and no significant difference in motor or sensory function was 
observed between Sox2HetOE and control mice from 6 weeks of age onwards (see 
Chapter 3 Figure 3.4, Figure 3.22 & Figure 3.23]. We hypothesized that following 
PNS injury the accompanying dedifferentiation of Schwann cells would cause 
reactivation of Sox2 and GFP expression in the Sox2HetOE animals. Western blot and 
immunolabelling showed higher levels of Sox2 and GFP induction in Sox2HetOE 
animals compared to controls and that Sox2 expression was maintained at 21 days 
post crush injury (21 DPI) in these animals compared to controls; in which Sox2 is 
undetectable at this later time-point following repair and remyelination of the nerve.  
Continued Sox2 expression following sciatic nerve crush injury was revealed to 
significantly impair Schwann cell remyelination and increase the percentage of 
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unmyelinated axons in a 1:1 relationship with Schwann cells at 21 DPI, which is 
consistent with its role as a negative myelin regulator. Surprisingly, the average axon 
diameter size was increased in the nerves of Sox2HetOE compared to control mice at 
21 DPI, this could possibly be due to improved guidance of regenerating large 
diameter axons in the presences of prolonged Sox2 overexpression. Unpublished 
data by Dr Xin-Peng Dun (in our group) further confirmed that axonal growth rate 
was significantly increased in Sox2HetOE mice compared to controls at 6.5 days after 
crush injury. Often after injury motor axons and sensory axons are misdirected, 
leading to the re-innervation of incorrect targets. BDNF, GDNF and Neurotrophin 3 
(NT3) have been shown to be upregulated predominantly in the affected muscle 
following injury, and thought to drive motor neurons to regrow in the direction of the 
trophic cues (Fex Svennigsen and Dahlin, 2013). As the average axon diameter size 
is significantly increased in Sox2HetOE mice at 21 DPI, it would be interesting to see 
whether the overexpression of Sox2 in Schwann cells enhances axon maturation 
and increases the accuracy of motor axons being directed back to their target. In 
theory if these Schwann cells were then able to myelinate in the presence of Sox2, 
this would lead to improved motor functional recovery. It would also be interesting to 
see whether overexpression of Sox2 leads to an overall increase in the number of 
regenerative nerve fibres that reach their target by 21 DPI. Unpublished data by Dr 
Xin-Peng Dun revealed that Sox2 is able to regulate axonal guidance, by controlling 
the expression of repulsive axon guidance cues such as Robo1 and Slit 3. 
Nonetheless it remains unknown as to whether Sox2 regulates the expression of 
neurotrophins that promote axon growth. Understanding how Sox2 promotes axon 
growth rate would also be of great value, as the longer axons are away from their 
target, the more unlikely it is that successful nerve regeneration will occur. 
For Schwann cells to effectively remyelinate, they must re-express Krox20, along 
with myelin proteins such as protein zero (P0) and myelin basic protein (MBP). 
During Schwann cell development impaired/disrupted Krox20 expression is 
associated with Schwann cell hypomyelination (Topilko et al., 1994, Le et al., 
2005a), while mutations or disruptions in P0 expression is associated with the 
formation of unstable myelin, which finally degenerates leading to Schwann cell 
demyelination and axons becoming hypomyelinated (Giese et al., 1992) [See section 
3.3.1]. True to its role as a negative myelin regulator, Sox2 was proven to impair 
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Schwann cell remyelination, by hindering the re-expression of Krox20, P0 and MBP. 
Furthermore, Sox2 appeared to retain Schwann cells in an immature state, marked 
by the increased expression of cJun in the nerves of Sox2HetOE mice, as well as the 
increased number of proliferating Schwann cells (this will be discussed in Section 
4.3.2). Although cJun is upregulated in the nerves of Sox2HetOE mice, we do not 
predict that Sox2 and cJun co-regulate one another as previously suggested by 
Parkinson et al., (2008), but rather that they are co-expressed as markers of 
immature Schwann cells. Experiments carried out by Dr Xin-Peng Dun confirmed 
that cJun protein expression in the nerves of Sox2 null mice was similar to that of 
controls at 3 and 7 days post cut injury [unpublished data]. Furthermore, Arthur-
Farraj et al. (2012) also showed that Sox2 protein expression was upregulated 
normally in the injured nerves of cJun null mice.  
It is clear that Sox2 is essential for nerve regeneration, as it plays a fundamental role 
in promoting axonal growth (Dr Xin-Peng Dun: unpublished data), as well as the 
guidance of regenerating axons across the nerve bridge and back to their target (Dr 
Xin-Peng Dun unpublished data, Parrinello et al. 2010). However, similar to the 
ERK1/2 signalling pathway after injury (Napoli et al., 2012), we show that Sox2 
expression must be switched off in a timely manner to allow Schwann cells to 
effectively differentiate back into a myelinating Schwann cell, and thus remyelinated 
regenerating nerve fibres.  
4.3.2 Sox2 regulates Schwann cell proliferation following nerve   
 injury 
After nerve injury the peripheral nervous system initiates a sequence of degenerative 
and molecular changes in the distal nerve segment termed Wallerian degeneration. 
One of the earliest events triggered by Wallerian degeneration is Schwann cell 
proliferation, which reaches a maximum at 2-3 days after injury and resulting in a 
marked increase in the number of Schwann cells in the distal nerve segment (Fex 
Svennigsen and Dahlin, 2013, Yang et al., 2008). It is thought that the Schwann cell 
proliferation event occur so that newly produced Schwann cells can replace those 
that have died or are dying. Schwann cells are essential for the production of 
neurotrophic factors that support neuronal survival following injury, promoting axon 
growth and the subsequent guidance of axons back to their target, it would be 
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expected that an abundant number of these cells would therefore be required for 
effective nerve repair and regeneration. Nonetheless, experiments carried out on 
cyclin D1-/- mice which lack proliferating Schwann cells, revealed that Schwann cell 
proliferation during Wallerian degeneration is not essential for the regeneration and 
functional recovery of injured nerves (Yang et al., 2008). Cyclin D1-/- mice 
regenerated normally in every respect when compared to control mice; no significant 
difference in mean axonal densities, remyelination (the formation of axon-Schwann 
cell units), myelin segment length, or motor-sensory functional recovery (assessed 
by static functional index and paw withdraw in response to electrical stimulation) was 
observed between control and cyclin D1-/- mice (Yang et al. 2008). Yang et al., 
(2008) confirmed that while there was an initial difference in Schwann numbers due 
to the rapid on set of proliferation in the nerves of control mice at 7 days post injury, 
compared to cyclin D1-/- nerves, Schwann cell numbers levelled out and were 
equivalent by 14 days post injury. The excess Schwann cells in the nerves of control 
mice were removed by apoptosis. Yang et al., (2008) suggested this process to be a 
possible mechanism that allows for the establishment of correct Schwann-axon 
numbers during peripheral nerve regeneration.  
Although Schwann cell proliferation after nerve injury is not essential for nerve 
regeneration, it is possible that Schwann cell proliferation maybe required for other 
useful functions, such as increasing the net number of Schwann cells to compensate 
for those that naturally die. An inability to replace lost Schwann cells would be 
detrimental in the long term on nerve regeneration and functional recovery (Fex 
Svennigsen and Dahlin, 2013). It was noted by Yang et al. (2008) that the tests used 
to monitor differences in functional recovery between control and cyclin D1-/- mice 
may not have been sensitive enough to detect any delays in physiological recovery, 
and that nerve conduction studies would have be more informative at the 
electrophysiological level.  It is therefore difficult to say whether the lack of Schwann 
cell proliferation is completely unnecessary for the complete regain of motor-sensory 
function.  
Increased expression of Sox2 (this study, Le et al. 2005), activation of Notch 
signalling (Woohoo et al. 2009) and activation of the ERK 1/2 MAPK signalling 
pathways have been shown to enhance Schwann cell proliferation during 
development. Although Schwann cell proliferation has been suggested not to be 
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essential for nerve repair and recovery after injury, the increase in proliferation 
following injury may occur as an indirect effect of Sox2 being re-expressed, and the 
Notch and ERK 1/2 MAPK signalling pathway being reactivated. Alternatively the 
increase in Schwann cell proliferation may be essential for effective guidance of 
regenerative axons to their target, allowing for optimal functional recovery at later 
time-points past 3 weeks after injury. This was not previously accessed in enough 
detail as mentioned above (Yang et al. 2008). Furthermore, Yang et al., (2008) only 
analyses the difference in Schwann cell numbers between control and cyclin D1-/- 
mice up until 14 days post injury, it would be interesting to see whether the 
difference in Schwann cell numbers between control and cyclin D1-/- mice  changed 
again at later time-points after injury. As mentioned earlier, Schwann cell proliferation 
may be essential for the replacement of naturally dying Schwann cells. 
To address whether overexpression of Sox2 increased Schwann cell proliferation 
above the normal threshold following nerve injury, nerve sections taken from control 
and Sox2HetOE mice were stained with antibodies against Ki67 (a marker of Schwann 
cell proliferation). Whilst Schwann cell proliferation was increased at 3, 7 and 14 DPI 
in both control and Sox2HetOE mice, there did not appear to be a significant difference 
in the rate of Schwann cell proliferation between these animals. There are two 
explanations for this; firstly overexpression of Sox2 may not enhance Schwann cell 
proliferation above the normal proliferative threshold after injury, and therefore no 
significant difference is observed. Alternatively, as the protein expression of Sox2 in 
control and Sox2HetOE mice was not measured at these time-points, we cannot 
clearly state that Sox2 was expressed to a significantly elevated level in the nerves 
of Sox2HetOE mice compared to controls. Although we observed slight GFP re-
expression in the nerves of Sox2HetOE by fluorescent imaging at these time-points, it 
is possible that the Sox2IRES-EGFP transgene was not switched back on effectively 
straight away. As a result Sox2 expression may not have been directly elevated 
above the normal level seen in controls until later time-points, such as around 18 DPI 
where we have observed a massive difference in Schwann cell proliferation in the 
nerves of Sox2HetOE mice compared to controls. At 21 DPI we have confirmed that 
Sox2 and GFP in dramatically expressed in the nerves of Sox2HetOE mice, and also 
that Sox2 protein expression (by western blot analysis) is elevated in these animals 
compared to controls. We were therefore able to confirm that continued Sox2 
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expression significantly increases Schwann cell proliferation after injury, and 
maintains these cells in a proliferative immature Schwann cell state. As we are 
unsure as to how soon the Sox2-IRES-EGFP transgene is switched back on in 
Sox2HetOE animals after nerve injury, a more effective approach to see whether 
overexpression of Sox2 increases Schwann cell proliferation directly after nerve 
injury should be used. A previous study by Napoli et al. (2012) used a tamoxifen 
inducible Cre recombination system which allowed for the rapid expression of their 
gene of interest upon tamoxifen administration. It would be useful to use the same 
approach to induce Sox2 overexpression directly after injury, to compare whether the 
overexpression of Sox2 leads to increased Schwann proliferation and faster 
Schwann cell demyelination and dedifferentiation directly after nerve injury compared 
to controls. This would enable us to further identify other functional roles of Sox2 
during nerve injury, in addition to its role in regulating cell adhesion and the formation 
of regenerative tracts (Parrinello et al., 2010). 
4.3.3 Sox2 and neuro-inflammation following nerve injury  
The inflammatory response not only plays a role in removing impairs cells and 
pathogens from the body, but also an active role in promoting wound healing. While 
controlled and moderate inflammation is beneficial for promoting repair, a 
progressive and/or chronic inflammatory response can result in impaired tissue 
recovery and potentially pathology. Wallerian degeneration is a cascade of cellular 
and molecular events that occur in the nerve distal to the site of injury. The innate 
immune response is central to the process of Wallerian degeneration, as it helps to 
support nerve regeneration by removing inhibitory myelin and upregulating 
neurotrophic properties (Rotshenker, 2011).  
Schwann cell myelin is composed of a range of myelin components, including 
myelin-associated glycoprotein (MAG) which is known to inhibit axonal outgrowth 
and branching (McKerracher et al., 1994, Shen et al., 1998). It is therefore essential 
that following Schwann cell demyelination, myelin debris is cleared by resident and 
recruited macrophages to allow for successful nerve regeneration. While Schwann 
cells are capable of clearing myelin debris in the absence of macrophages, the 
presence of macrophages allows for accelerated and more effective myelin 
clearance (Perry et al., 1995, Rotshenker, 2011). Macrophages express surface 
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recognition receptors such as MHC molecules and complement receptor 3 which 
enable them to carry out surveillance and recognise foreign microbes and myelin 
debris which require clearing (Gaudet et al., 2011). 
Blood born macrophages are recruited to the site of injury around 2-3 days after 
injury via IL-1β and TNF-α cytokines and MCP-1 and MIP-1α chemokines expressed 
by Schwann cells. On arrival they proliferate, phagocytose axon and myelin debris, 
produce cytokines that activate Schwann cells and also trophic factors such as nerve 
growth factor (NGF) that aids axon regeneration (Barrette et al., 2008, Gaudet et al., 
2011). Barrette et al. (2008) proved further that macrophages are required for axon 
regeneration, as depletion of CC11b-positive macrophages starting 12 hours prior to 
sciatic nerve crush injury in transgenic mice resulted in a significant impairment in 
motor-sensory functional recovery and locomotor deficits. Surprisingly macrophages 
were also identified to play a role in blood vessel formation/ stabilisation, as 
depletion of CD11b-positive macrophages resulted in a significant decrease in the 
number of CD31+ blood vessel in the distal sciatic nerve stump (ibid). It was recently 
confirmed that macrophages induce blood vessel formation, by secreting VEGF-A in 
response to hypoxia, consequently triggering the polarized vascularisation of the 
nerve bridge (injury site) (Cattin et al., 2015). The newly formed blood vessels were 
subsequently proven to be important for Schwann cells axon guidance, as Schwann 
cells were shown to use these newly formed blood vessels as guidance paths across 
the nerve bridge, taking regrowing axons with them (Cattin et al., 2015). 
 
While macrophages are fundamental for Wallerian degeneration and nerve 
regeneration, they must be cleared from the nerve following axon repair and 
remyelination, in order to prevent chronic inflammation. T-lymphocytes and 
neutrophils also infiltrate into the nerve following nerve injury. T-lymphocytes shape 
the later immune response by producing both pro-and anti-inflammatory cytokines 
which help to further activate or inhibit nearby macrophages and neutrophils (Gaudet 
et al., 2011). As mediators of an inflammatory environment, they must also be 
cleared from the nerve upon axon regeneration and remyelination to allow for 
complete nerve recovery. Macrophages and T-lymphocytes have been previously 
shown to mediate an inflammatory environment in the nerve and induce 
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demyelination and axonal damage (Ip et al., 2006, Kobsar et al., 2005). It is therefore 
possible that impaired immune cell clearance after nerve injury may lead to 
peripheral nerve disorders such as chronic inflammatory demyelinating 
polyneuropathy (CIDP) (Martini et al., 2008). 
Overexpression of Sox2 in Schwann cells was previously show to result in an 
increased number of macrophages and T-cells within the nerves of Sox2HomoOE mice 
compared to controls (at P7 and P60) [Section 3.2.9]. We therefore wanted to 
determine whether Sox2 was also capable of altering the number of immune cells in 
the nerves of Sox2HetOE mice after injury. We confirm that continued expression of 
Sox2 resulted in a significant increase in the number of macrophages in the nerve of 
Sox2HetOE mice, compared to controls at 21DPI. Sox2HetOE mice also exhibited 
increased numbers of T-cells and neutrophils in their nerves at 21 DPI compared to 
controls (this was not significant). Although we have identified that continued 
expression of Sox2 after nerve injury increases the number of immune cells present 
within the nerve, the mechanism by which this is achieved remains unknown. Further 
experiments would need to be carried out in order to elucidate how Sox2 achieves 
this. 
Infiltrating macrophages are known to express pro-inflammatory cytokines such as 
TNFα and IL-1β, which are associated neuropathic pain (Wagner and Myers, 1996). 
Due to the numerous macrophages present in the nerves of Sox2HetOE at 21 DPI, it is 
possible that these mice will develop neuropathic pain and hyperalgesia. In order to 
test for this a hot plate test could be carried out; this would require Sox2HetOE and 
control mice at various time-points after nerve injury for example at 3 and 4  weeks, 
to be placed on to a hot plate and their reaction to pain caused by the heat 
measured.  
After debris clearance, axon regeneration and remyelination is complete, 
macrophages are no longer useful or required. Proteins on the surface of newly 
formed myelin signal to macrophages, causing them to emigrate away from the 
Schwann cell basal lamina and leave the nerve via the circulation into regional lymph 
nodes and spleen, any remaining macrophages are eliminated by apoptosis 
(Kuhlmann et al., 2001). Fry et al., (2007) identified that macrophages in the crushed 
sciatic nerves express Nogo receptors (NgRs) on their surface. Three members of 
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the NgR family have previously been identified NgR1, NgR2 and NgR3, however 
macrophages were shown to only express NgR1 and NgR2 (Fry et al., 2007).  NgR1 
and NgR2 are known to mediate the inhibitory or repulsive effect of myelin proteins: 
NgR1 binds to three axon growth inhibitory molecules i.e. Nogo A, MAG and 
oligodendrocyte-myelin glycoprotein (OMgp), whereas NgR2 binds exclusively to 
MAG. Using a nerve cut injury model, Fry et al. (2007) demonstrated that in the 
absence of newly synthesised myelin, macrophages fail to clear from the injured 
nerve. It was suggested that failure of macrophages to receive a repulsive signal via 
MAG protein-NgR receptor interaction results in macrophages not being eliminated 
from Schwann cell basal lamina (ibid).  Further studies also showed that MAG-
deficient mice exhibited impaired macrophages efflux from the Schwann cell basal 
lamina following Schwann cell remyelination after nerve crush (Fry et al., 2007). As 
continued expression of Sox2 impairs Schwann cells remyelination and therefore 
MAG re-expression (although we have not confirmed this), it is possible that 
surrounding macrophages in the nerves of Sox2HetOE mice do not receive the 
repulsive signal informing them to leave the Schwann cell basal lamina, even though 
axonal regeneration is complete. This may explain why Sox2HetOE nerves contain so 
many macrophages at this later time-point after injury.  
Following nerve injury, Schwann cells immediately induce breakdown of the blood 
nerve barrier (BNB), enabling blood-borne cells and molecules to enter the 
endoneurium (at the damaged site of injury and along the distal nerve stump) and 
initiate a local inflammatory response. A previous study by Napoli et al. (2012) 
showed that Schwann cell activation of the ERK 1/ 2 signalling pathway causes BNB 
breakdown, which can occur independent of trauma. It would be interesting to see 
whether maintained Sox2 expression prevents the reformation of the BNB resulting 
in BNB dysfunction and thus the continued infiltration of immune cells into the nerve. 
In addition to macrophages, Schwann cells distal to the site of injury have also been 
shown to actively express pro-inflammatory cytokines TNFα and IL-1β and anti-
inflammatory cytokines IL-4 and IL-10 (Dubový et al., 2014). The expression of 
inflammatory cytokines by Schwann cells in close contact to regenerating axons 
(GAP43+) at 7 days after nerve crush, was shown not to alter axonal growth. Dubovy 
et al. (2014) suggested that the expression of pro-inflammatory and anti-
inflammatory cytokines by Schwann cells may result in a balanced inflammatory 
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response, and thus be involved in promoting axonal growth. Sox2 has been shown 
to act as a pattern recognition receptor (PRR) in neutrophils, where it orchestrates 
the recognition of microbial double stranded DNA and elicits an immune response 
(Xia et al., 2015). As we have shown that continued expression of Sox2 in Schwann 
cells following nerve injury leads to a sustained inflammatory environment (i.e. an 
increased number of immune cells) in the nerve of Sox2HetOE mice, it would be 
interesting to analyse whether Sox2 mediates this effect by directly manipulating the 
inflammatory response. It would be interesting to see if Sox2  increases the 
expression of macrophages chemoattractant protein 1 (MCP-1) and shifts the 
cytokine expression profile of Schwann cells and macrophages towards being more 
pro-inflammatory, as opposed to maintaining an inflammatory balance (Dubový et 
al., 2014). 
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Figure 4. 12 After nerve injury and regeneration, newly formed myelin emit signals 
that contribute to the resolution of the inflammatory response. Single axon (pink) with 
myelin (blue) and basal lamina (orange), macrophages (green). (1) Following nerve 
regeneration and remyelination macrophages are no required within the basal lamina and 
therefore exit. (2) Proteins such as MAG expressed on the surface of newly formed myelin, 
interact with the receptor NgR and its signalling partner TROY on the macrophage 
membrane. Engagement of this receptor complex leads to local signalling and activation of 
the small GTPase RhoA, resulting in local repulsion and the moving away of macrophages 
from the source (myelin) (Fry et al., 2007). This causes macrophages to exit from the basal 
lamina. Adapted from Guadet et al. (2011).  
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4.3.4 Maintained Sox2 expression reduces functional recovery after   
 nerve injury 
Complete axon regeneration and remyelination after nerve injury, is usually followed 
by motor-sensory functional recovery in rodents between 3-4 weeks after nerve 
crush injury (Yang et al., 2008, Arthur-Farraj et al., 2012). Nonetheless, if Schwann 
cells fail to undergo cellular reprogramming after nerve injury, to support axon 
regeneration by providing trophic support to neurons, inducing myelin clearance and 
assisting with axons guidance, nerve repair and functional recovery is impaired 
(Arthur-Farraj et al., 2012, Fontana et al., 2012). Trans-differentiation of repair 
Schwann cells back to a myelinating state and the remyelination of regenerating 
axons is also critical for successful axon regeneration and the restoration of motor-
sensory function (Fricker et al., 2013). 
Studies using CAG-Cre-ERTM;Nrg1fl/fl mice, demonstrated that impaired Schwann 
cell remyelination after nerve, achieved through the deletion of NRG1-III in motor 
axons, resulted in a decrease in functional recovery (Static Functional Index) and 
nerve conduction velocity (NCV) (Fricker et al., 2013). In contrast, increasing the 
remyelination of regenerating axons following nerve crush injury, by treating mice 
with recombinant human Nrg1-II (rhNrg1-II) improved functional recovery (Chen et 
al., 1998).  
Previous studies have also identified that impaired myelination during development 
or demyelination of axons during adulthood, results in reduced nerve conduction 
velocities, impaired motor-sensory function and the development of a peripheral 
neuropathy such as congenital hypomyelination neuropathy or Charcot-Marie-Tooth 
type-1 disease (Fledrich et al., 2014, Saporta et al., 2012). Promoting remyelination 
of adult axons through the administration of soluble Nrg1 to Schwann cells has thus 
been suggested as a therapy for demyelinating / neurodegenerative diseases (Syed 
and Kim, 2010). A particular study by Fledrich et al. (2014) showed that improving 
Schwann cell remyelination in mouse models of CMT-1A, by treating mice with 
recombinant human NRG1 (rhNRG1), strongly improved motor performance and 
ameliorated the disease. These studies highlight how Schwann cell myelination 
during development and remyelination after nerve injury is essential for normal nerve 
conduction velocity and motor-sensory function.  
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Our experiments have revealed that continued Sox2 expression after nerve crush 
injury, severely impairs Schwann cell remyelination of regenerating axons and 
increases the number of unmyelinated axons in a 1:1 relationship with Schwann cells 
in the nerves of Sox2HetOE mice at 21 DPI. We therefore wanted to determine 
whether impaired Schwann cell remyelination after nerve injury would affect 
functional recovery.  Our data showed that continued Sox2 expression reduced NCV 
(although not significantly) and impaired motor functional recovery (confirmed by 
Static Sciatic Index and Toe Spread Reflex) in the nerves of Sox2HetOE mice at 21 
DPI. Furthermore, continued Sox2 expression was shown to reduce sensory 
functional recovery (confirmed by Toe pinch testing and Von Frey filament 
withdrawal threshold testing) in the nerves of Sox2HetOE mice at 21 DPI. As Schwann 
cell myelination is fundamental for proper nerve function (motor-sensory) it thus 
comes to no surprised that Sox2 impairs functional recovery. It would be interesting 
to see if promoting Schwann cell remyelination through the administration of soluble 
Nrg1 improved motor-sensory functional recovery in the nerves of Sox2HetOE mice at 
21 DPI. 
Studies analysing the role of macrophages and T-lymphocytes in CMT-1A, CMT-1B 
and CMT-1X mouse models, have shown that the inflammatory immune response 
contributes to disease progression, reduced myelin thickness, NCV and impaired 
motor function (Klein et al., 2015). At 21 DPI the number of macrophages, T-
lymphocytes and neutrophils in the nerves of Sox2HetOE mice is dramatic increased 
compared to controls. It is therefore possible that the increased number of immune 
cells in the Sox2HetOE mice further contribute to the reduced functional recovery of 
motor and sensory neurons.  
While we might expect that continues Sox2 expression would impair motor functional 
recovery due to the impaired remyelination of large diameter axons, it was surprising 
to see that sensory functional recovery was also delayed; all small diameter axons 
(<0.1µm) were ensheathed and grouped into normal Remark bundle / structures. 
Nonetheless a subset of large diameter sensory mechanofibres such as Aδ require 
myelination, and thus impaired sorting and myelination of these fibres could explain 
the delay in sensory functional recovery. Sensory axon-derived Nrg-1 is important for 
axon-Schwann cell signalling and therefore normal sensory function (Fricker et al., 
2009). In the absence of sensory-axon derived Nrg1, Nrg1fl/fl;Nav1.8-Cre mice 
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displayed abnormal Remak bundles with numerous closely packed C-fibres, often 
not separated by Schwann cell cytoplasm  (Fricker et al., 2009). These animals also 
showed an increased number of unmyelinated large diameter sensory fibres, a 
significant slowing of A-fibre conduction velocity and reduced sensitivity to 
mechanical stimuli (ibid). The requirement of Nrg1-ErbB signalling in non-myelinating 
Schwann cells for normal sensory function was further confirmed by Chen et al. 
(2003), who carried out analysis on mice that expressed a dominant negative ErbB4 
receptor (DN –ErbB4) in adult non-myelinating Schwann cells. DN-ErbB4 non-
myelinating Schwann cells showed significantly increased cell cycle proliferation and 
cell death at P30 (Chen et al., 2003). Furthermore, transgenic mice overexpressing 
DN-ErbB4 exhibited a distinct loss of sensory C-fibre neurons (ibid). Together these 
studies show that Nrg1-ErbB signalling between sensory axons and Schwann cells is 
necessary for Schwann cell myelination of large diameter (>1µm) sensory axons, the 
survival of sensory C-fibre neurons and thus normal sensory function. It would be 
interesting to see whether Nrg1-ErbB signalling is disrupted in Schwann cells 
myelinating large diameter sensory & motor axons in the nerves of Sox2HetOE mice. 
This could be achieve by carrying out protein expression analysis of ErbB2/ErbB3 
and Nrg1 in the nerves of control and Sox2HomoOE mice at P60, and / or control and 
Sox2HetOE mice at 21 DPI, to determine whether altering Nrg1-ErbB signalling is 
another mechanism by which Sox2 impairs myelination and sensory-motor function.  
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4.4 Conclusion 
This study has shown that continued Sox2 expression in Schwann cells after nerve 
injury severely impairs nerve repair and functional recovery. Sox2 maintains 
Schwann cells in a highly proliferative immature Schwann cells state, as a result 
Schwann cells fail to upregulate the expression of myelin proteins P0 and Krox20 
and remyelinate regenerating axons; Sox2HetOE mice thus demonstrate impaired 
motor and sensory function. Surprisingly, continued Sox2 expression also resulted in 
a sustained inflammatory response within the nerves of Sox2HetOE mice at time-
points as late as 21 days post injury, when the inflammatory response is normally 
resolved.  Our data confirms that Sox2 is a remarkable negative regulator of 
Schwann cell myelination, and that its expression must be reduced following the 
successful re-innervation of regenerating axons, to allow Schwann cell to 
remyelination and mice to regain functional recovery.  
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Chapter 5 p38α negatively regulates Schwann cell myelination 
 
5.1 Introduction 
The p38 mitogen activated protein kinase (MAPK) signalling cascade plays an 
essential role in governing many biological processes, including inflammation, 
apoptosis, proliferation, development and differentiation (Zarubin and Han, 2005). In 
oligodendrocytes p38 MAPK activity has been shown to drive myelin gene 
expression, myelination and remyelination, whilst in Schwann cells its functional role 
still remains unclear (Haines et al., 2008, Chung et al., 2015). Many studies have 
attempted to characterise the role of p38 MAPK activity in Schwann cell plasticity 
and development using specific p38 MAPK inhibitors and mutant mouse models, 
however the results have been conflicting. Whilst p38 MAPK activity has been 
suggested to promote Schwann cell myelination and Krox20 expression during 
development in some studies (Fragoso et al., 2003, Hossain et al., 2012) , others 
suggest that p38 MAPK activity blocks Schwann cell myelination and myelin protein 
expression during development (Yang et al., 2012). Furthermore, studies analysing 
p38 MAPK after nerve injury have shown that it is directly activated after injury and 
helps to initiate the injury response, by activating the expression of inflammatory 
cytokines and driving Schwann cell demyelination (Yang et al., 2012, Kato et al., 
2013, Myers et al., 2003). 
There are four isoforms of p38 MAPK; p38α, p38β, p38ʏ and p38δ, which share 60 
to 70% nucleotide amino acid sequence specific homology. Of these isoforms, p38α 
is ubiquitously expressed and is suggested to be the most functionally relevant 
isoform (Nebreda and Porras, 2000, Mayor et al., 2007). p38α has been shown to 
play critical roles in neuron survival, inflammation and nerve regeneration, this 
therefore makes p38α a good target for studying the function of p38 MAPK activity 
(Zarubin and Han, 2005, Xing et al., 2015, Kato et al., 2013).  
Previous studies have attempted to understand the functional role of p38 MAPK in 
Schwann cells by using pyridinyl imidazole compound inhibitors such as SB203580/ 
SB202190 and PD169316. These inhibitors target both p38α and p38β, without 
affecting p38ʏ and p38δ activity, and thus have been suggested as a good method 
for studying the function of p38α and β (Davies et al., 2000). Nonetheless these 
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inhibitors have been shown to affect other signalling pathways, such as Rip-like 
interacting caspase-like apoptosis-regulatory protein kinase/RIP2/CARDIAK (RICK) 
(Godl et al., 2003). Consequently, as mentioned earlier this has resulted in 
conflicting conclusions and as a result the functional role of p38 MAPK in Schwann 
cells remains uncertain.  Given that p38α is highly expressed in Schwann cells and 
developing nerves, whereas p38β is undetectable (unpublished data by Dr Xin-Pen 
Dun in our lab, Hossain et al., 2012), we generated Schwann cell specific p38α null 
mice (a more specific approach than using pharmacological inhibitors) in order to 
study how p38 MAPK activity affects Schwann cell myelination during development 
and after nerve injury.   
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5.2 Results 
5.2.1  p38 MAPK regulates Schwann cell myelination 
A recent study in our laboratory by Yang et al. (2012) identified p38 MAPK as a 
negative regulator of Schwann cell differentiation and myelination. Yang et al. (2012) 
showed that p38 MAPK signalling was high at embryonic day 17 (E17), but declined 
at postnatal day 1, coinciding with Schwann cell myelination. Furthermore, ectopic 
activation of the p38 MAPK pathway, achieved through infecting Schwann cells with 
a lentivirus expressing MKK6-Glu, a constitutively activated form of MKK6 (a direct 
upstream activator of p38 MAPK) under the control of a doxycycline inducible 
promoter in vitro, and treatment with doxycycline, inhibited cAMP induced Schwann 
cell differentiation and myelin gene expression. Inhibition of the p38 MAPK pathway 
was further shown to enhance Schwann cell differentiation and myelin segment 
formation in Schwann cell-dorsal root ganglion (DRG) co-cultures (Yang et al., 
2012). In contrast, Hossain et al. (2012) identified that inhibiting p38 MAPK activity in 
Schwann cell-DRG co-cultures, resulted in an increase in the number of 
unmyelinated Schwann cells, and reduced the gene expression of two core myelin 
regulatory transcription factors Sox10 and Krox20, as well as the gene expression of 
Protein zero (P0) and Myelin basic protein (MBP). As the evidence from both of these 
studies are contradictory, we wanted to analyse and clarify the effect of p38 MAPK 
on Schwann cell myelination in vivo, without the use of p38 MAPK inhibitors such as 
SB 203580. Pharmaceutical inhibitors of p38 MAPK activity have been suggested to 
lead to incorrect conclusion regarding its role, due to their inhibitory effect on other 
signalling pathways (Godl et al., 2003). We therefore generated mice with Schwann 
cell specific deletion of p38α using Cre-loxP mediated gene targeting. Mice carrying 
conditional LoxP-flanked p38α (p38αfl/fl) alleles (Heinrichsdorff et al., 2008), were 
crossed with mTOTA P0-Cre wild type/ wild type (P0 Cre
+ wt/wt) (Schwann cell specific 
Cre) mice (Feltri et al., 1999); this allowed us to generate mice which were either 
heterozygous for the p38α flox gene and Cre- (p38αfl/wt Cre-) or heterozygous for the 
p38α flox gene and Cre+ (p38αfl/wt Cre+). p38αfl/wt Cre+ mice were then crossed back 
with p38fl/fl mice, allowing us to generate mice that were p38αfl/wt Cre- and p38αfl/wt 
Cre+, as well as mice that were homozygous for the p38α flox gene and Cre- (p38αfl/fl 
Cre-) or homozygous for the p38α flox gene and Cre+ (p38αfl/fl Cre+) [see Figure 
1.13]. In this study, experiments were carried out only on homozygous p38αfl/fl Cre- 
 242 
 
mice (hereafter referred to as control mice) and homozygous p38αfl/fl Cre+ mice 
(hereafter referred to as conditional p38α knockout mice).  
To test whether Schwann cell myelination was altered in the absence of p38 MAPK 
activity, the sciatic nerves from control and p38α knockout (p38α Ko) mice were 
removed and the ultrastructure was examined at postnatal days 2, 6, 21 and 90 
using transmission electron microscopy. 
At postnatal day 2 (P2), the population of axons in the sciatic nerves of p38α Ko 
mice were shifted towards having thicker myelin, compared to axons in the sciatic 
nerves of control mice; the average myelin thickness of control nerves was 0.04 ± 
0.004µm, whereas the average myelin thickness in p38α Ko nerves was slightly 
thicker at 0.07 ± 0.02µm, nonetheless this was not significant (P=0.14, n=3 per 
genotype) [Figure 5.1]. Further analysis revealed however that there was a 
significant increase in the total percentage of myelinated axons in the sciatic nerves 
of p38α Ko mice (43.6 ± 5.7%), compared to control mice (22.2 ± 1.3%) (P=0.02, 
n=3) [Figure 5.1]. This data thus appears to confirm a role of p38α in negatively 
regulating myelination at the developmental stage. 
 
We next went on to analyse myelin thickness in the sciatic nerves of control and 
p38α knockout mice at P6. We observed that there was a shift in axons towards 
having thicker myelin in the sciatic nerves of p38α Ko mice, compared to control 
mice; the average myelin thickness in p38α Ko nerves was higher at 0.54 ± 0.04µm, 
compared to control nerves, which had an average myelin thickness of 0.44 ± 
0.07µm, although this change was not significant (P=0.27, n= 4 control, n=6 p38α 
Ko) [Figure 5.2]. Counts made on the total percentage of myelinated axons revealed 
that there was also no significant difference between p38α Ko mice and control mice 
at P6; in the nerves of p38α Ko mice the total percentage of myelinated axons was 
95 ± 0.98%, whilst in the nerves of control mice, the total percentage of myelinated 
axons was 92 ± 1.67% (P=0.18, n= 4 control, n=6 p38α Ko) [Figure 5.2]. We next 
analysed axon size in the nerves of P6 animals and observed a shift in the 
percentage of axons toward having a larger axon diameter in the nerves of p38α Ko 
mice, compared to control; the average axon diameter in p38α Ko nerves was 1.11 ± 
0.07µm, whereas as the average axon diameter in control nerves was slightly 
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smaller at 0.92 ± 0.04µm, this was however not significant (P=0.08, n= 4 control, n=6 
p38α Ko) [Figure 5.3]. 
 
As we observed an increase in myelin thickness in the nerves of p38α Ko mice 
during the early stages of Schwann cell development (P2 and P6), we next wanted 
to analyse myelin thickness at later stages of Schwann cell development (P21) and 
during adulthood (P90). Analysis at P21 revealed that the population of axons in the 
nerves of p38α Ko mice remained shifted towards having thicker myelin, compared 
to control mice; in p38α Ko nerves the average g-ratio was 0.59 ± 0.01, whereas in 
the control nerves the average g-ratio was slightly higher at 0.62 ± 0.02, although 
this was not significant (P=0.24, n=3 per genotype) [Figure 5.4]. Analysis of the total 
number of myelinated axons, further revealed there was no significant difference in 
the total number of myelinated axons in the nerves of control and p38α Ko mice; all 
axons greater than 1µm in the nerves of these animals were myelinated by P21. We 
next analysed axon diameter size in the nerves of control and p38α Ko animals at 
P21. Surprisingly, again we observed an increase in the diameter size of axons in 
the nerves of p38α Ko mice, compared to control mice; in the nerves of p38α Ko 
mice the average axon diameter was 1.46 ± 0.1µm, whereas in the nerves of control 
mice the average axon diameter was smaller at 1.25 ± 0.1µm, however this again 
was not significant (P=0.24, n=3 per genotype) [Figure 5.4]. 
 
Analysis of adult P90 sciatic nerves further revealed that myelin thickness remained 
slightly thicker in the nerves of p38α Ko mice compared to control mice; the average 
g-ratio was 0.60 ± 0.07 in the nerves of p38α Ko mice, whereas the average g-ratio 
was 0.61 ± 0.02 in the nerves of control mice, although this change was not 
significant (P=0.61, n=3 control, n=4 p38α Ko). Comparisons made between axons 
diameter surprisingly revealed that the average axon diameter size now tended to be 
larger in the nerves of control mice (3.18 ± 0.61µm), compared to p38α Ko mice 
(2.33 ± 0.44µm) at P90, nonetheless this increase in axon diameter size was again 
not significant (P=0.32, n=3 control, n=4 p38α Ko) [Figure 5.5]. 
 
In summary, we observe that removal of p38α in Schwann cells leads to a marked 
early onset of Schwann cell myelination, as well as an increase in the total 
percentage of myelinated axons from as early as P2. Furthermore, there was a 
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tendency for myelin thickness to be slightly (although not significantly) increased in 
p38α Ko mice up until adulthood (P90). These results support our previous data, 
which suggests that the p38 MAPK signalling pathway is a negative regulator of 
Schwann cell myelination (Yang et al., 2012). In addition, we provide further 
evidence showing that p38α is the functional isoform regulating Schwann cell 
myelination, as depletion causes a tendency for increased myelination.  
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Figure 5. 1: Enhanced myelination in the nerves of p38α Ko mice at P2. Transmission 
electron micrographs of sciatic nerve sections taken from control (A) and p38α Ko (B) mice 
at P2. Graph (C) showing a shift in the total percentage of axons, towards having thicker 
myelin in the nerves of p38α Ko mice, compared to controls at P2. Graph (D) showing a 
significant average increase in the total percentage of myelinated axons in the nerves of 
p38α Ko mice, compared to control mice (P=0.02, n= 3 per genotype).   
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Figure 5. 2: Increased myelin thickness in the nerves of p38α Ko mice at P6. Low 
vacuum scanning electron micrographs of sciatic nerves taken from control (A) and p38α Ko 
(B) mice at P6. Transmission electron micrographs of sciatic nerves sections taken from 
control (C) and p38α Ko (D) mice at P6. Graph (E) showing a shift in the total percentage of 
axons towards having thicker myelin in the nerves of p38α Ko mice, compared to control. 
Graph (F) showing the percentage of myelinated axons in the nerves of control and p38α Ko 
mice. Graph (G) showing the percentage of unmyelinated axons in the nerves of control and 
p38α Ko mice (n=4 control, n=6 p38α Ko).   
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Figure 5. 3: Axon diameter is increased in p38α Ko nerves at P6.  Graph (A) showing a 
shift in the total percentage of axons towards having a larger axon diameter the nerves of 
p38α Ko mice, compared to controls. Graph (B) showing an increase in the average axon 
diameter size in the nerves of p38α Ko mice, compared to controls (P=0.08) (n=4 control, 
n=6 p38α Ko). 
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Figure 5. 4: Myelin thickness and axon diameter are both slightly increased in the 
nerves of p38α Ko mice at P21. Transmission electron micrographs of sciatic nerves 
sections taken from control (A) and p38α Ko (B) mice at P21.  Graph (C) showing a shift in 
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the total percentage of axons towards having a lower g-ratio in the nerves of p38α Ko mice, 
compared to controls. Graph (D) showing the average g-ratio in the nerves of control and 
p38α Ko mice. Scatter plot (E) displaying the g-ratio of individual axons in relation to their 
axon diameter size. Graph (F) showing the average axon diameter of axons in a 1:1 with 
Schwann cells in the nerves of control and p38α Ko mice. (n=3 per genotype) 
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Figure 5. 5: Myelin thickness is slightly increased in the nerves of p38α Ko mice at 
P90. Transmission electron micrographs of sciatic nerves sections taken from control (A) 
and p38α Ko (B) mice at P90. Graph (C) showing the average g-ratio of control and p38α Ko 
sciatic nerves. Graph (D) showing the average axon diameter size of control and p38α Ko 
sciatic nerves. Scatter plot (E) displaying the g-ratio of individual axons in relation to their 
axon diameter size (n=3 control, n=4 p38α Ko).   
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5.2.2  p38α regulates myelin protein expression. 
In order for Schwann cells to effectively myelinate large calibre axons (axons >1µm), 
the expression of Schwann cell myelin proteins such myelin protein zero (P0), myelin 
basic protein (MBP), periaxin and myelin associated glycoprotein (MAG) must be 
actively upregulated by transcription factors Krox20 and Sox10. Nonetheless, as 
previously discussed in Chapters 3 and 4, the upregulated expression of myelin 
proteins can be impaired by the sustained or enhanced expression/signalling of 
negative myelin regulators, such as cJun, Sox2, activated Notch and ERK 1/2 MAPK 
signalling, leading to impaired Schwann cell differentiation and myelination. Recently 
Yang et al. (2012) identified that ectopic activation of the p38 MAPK signalling 
pathway in cultured Schwann cells blocked Schwann cell differentiation and the 
upregulated expression of myelin proteins Krox20 and MAG in response to cAMP, 
whereas inhibition of the p38 MAPK pathway enhanced Schwann cell myelin 
segment formation. Furthermore, blocking p38 activity with SB203580 treatment, 
dramatically enhanced the differentiation response of cultured Schwann cells to low 
doses (0.05mM) of cAMP, whereas very few differentiated cells were observed in 
untreated cultures (Yang et al., 2012). As we have observed an increase in myelin 
thickness in the nerves of p38α Ko mice compared to control mice, we therefore 
might expect that Schwann cells differentiate earlier and that myelin protein 
expression would be enhanced in the nerves of p38α Ko mice. We therefore 
analysed the expression of myelin proteins MBP and P0 in the nerves of control and 
p38α Ko mice at P6.  Western blot analysis revealed that both P0 and MBP 
expression was enhanced in the nerves of p38α Ko mice compared to control nerves 
at P6 (n=3 per genotype) [Figure 5.6].  
The results show that inactivation of p38α function in Schwann cells in vivo, leads to 
enhanced myelin protein expression at P6, further supporting our hypothesis that 
p38 MAPK signalling plays a true physiological role in the negative regulation of 
Schwann cell myelination.  
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Figure 5. 6: Enhanced myelin protein expression in p38α Ko nerves at P6. Western blot 
(A) showing reduced expression of p38α, and enhanced expression of P0 and MBP in the 
nerves of p38α Ko mice compared to control mice (n=3 per genotype).  
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5.2.3 Depletion of p38α reduces Schwann cell demyelination  
 following nerve injury 
p38 MAPK has been shown to be re-expressed after nerve injury and to play a role 
in the nerve injury response, by triggering Schwann cell demyelination and 
dedifferentiation. Yang et al. (2012) showed that blocking the p38 MAPK signalling 
pathway following nerve injury attenuated Schwann cell demyelination, leading to 
retained myelin regardless of axon loss. Nonetheless, this study also identified that 
there appeared to be a slight retention of axons in the injury nerves of mice treated 
with the SB203580 inhibitor, suggesting that the inhibitor may also exert non-
Schwann cell dependent effects (Yang et al., 2012). We therefore wanted to follow 
up this study and investigate directly whether inactivation of p38α would also impair 
Schwann cell demyelination after nerve injury. To test this we analysed the 
expression levels of myelin specific proteins in the distal sciatic nerve segment, 
taken from control and p38α Ko mice at 3 and 7 days post cut injury (3 & 7 DPI). 
Western blot analysis confirmed that p38α expression at 3 and 7 DPI and 
phosphorylated p38 (p-p38) expression at 3 DPI was weaker in the nerves of p38α 
Ko mice compared to controls (n=3 per genotype). As we expected p38α to be 
completely ablated from Schwann cells in the nerves of p38α Ko mice (through Cre 
mediated recombination), we presumed that the weakly detected p38α expression 
was from other cells within the nerve tissue such as macrophages and fibroblasts 
(Myers et al., 2003) [Figure 5.7]. The p-p38 antibody used in this experiment targets 
all p38 isoforms and is therefore not specific to p38α isoform. Nonetheless, as we 
observed a dramatic reduction in the expression of p-p38 in the nerves of p38α Ko 
mice compared to controls (n=3), this data further confirms that p38α is the major 
functional isoform responsible for activating the p38 MAPK signalling response.  
Further analysis revealed that inactivation of p38α led to a delay in Schwann cell 
demyelination, as high levels of P0 and MBP expression were still detectable in the 
nerves of p38α Ko mice, compared to control nerves; which showed reduced 
expression of P0 and MBP at 3 and 7 DPI (n=3). Analysis of other MAPK signalling 
pathways, showed that whilst p-ERK 1/2 was not expressed in the nerves of 
uninjured control and p38α mice, it was highly and equally expressed within the 
nerves of control and p38α Ko mice at 3 DPI (n=1 control, n=2 p38α Ko) [Figure 5.7].   
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Figure 5. 7: Inactivation of p38α leads to a delayed reduction in Schwann cell myelin 
proteins following injury. Western blot showing (A) reduced expression of p38α and 
increased expression MBP in the nerves of p38α Ko mice, compared to control nerves at 3 
and 7 DPI (n=3). Western blot (B) showing very weak expression of p-p38α and p-ERK 1/2 
in the intact nerves of control and p38α Ko mice, as well as the weak expression of p-p38α 
in the nerves of 3DPI p38α Ko mice compared to controls; note, equal expression of p-ERK 
1/2 in the nerves of p38α Ko and control mice at 3DPI (n=1 control, n=2 p38α Ko). Western 
blot (C) showing similar levels of P0 in the uninjured nerves of control and p38α mice, 
however after injury P0 expression levels are shown to be stronger in the nerves of p38α Ko 
mice compared to controls at 7DPI (n=3).  
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5.2.4  Inactivation of p38α in Schwann cells tends to increase  
  myelin thickness at 21DPI. 
Inhibition of p38 MAPK activity after nerve injury, through the use of Scios SD-169 
compound; an oral inhibitor of phosphorylated p38 MAPK, has previously been 
shown to reduce Schwann cell TNFα production at 4 days post crush and enhance 
the rate of functional nerve regeneration. In addition the diameter of the regenerating 
axons also appeared to be thicker, with a correspondingly thicker myelin sheath at 
28 day post crush injury in mice treated with SD-169 (Myers et al., 2003). However, 
a more recent study specifically analysed the physiological function of p38α in nerve 
regeneration following crush injury, by generating heterozygous p38α knock-in 
mutant mice (Sevenmaker type Mapk14). These mice contain a heterozygous point 
mutation (conversion of aspartate acid to asparagine) in the p38α docking site 
(D316N); which is responsible for regulating p38α activation and inactivation, thus 
resulting in the dysfunction of p38α (Kato et al., 2013, Mayor et al., 2007). The study 
identified that after injury, limited loss of p38α function resulted in a significant 
reduction in myelin thickness and axon diameter size at 4 weeks post nerve crush 
injury (4 WPI), a significant reduction in functional recovery at 3 and 4 WPI and also 
a delayed but increased expression of inflammatory cytokines, including TNFα and 
IL-1β at 4 WPI (Kato et al., 2013). As these studies are quite inconsistent with 
regards to how p38 MAPK activity affects remyelination and regeneration, and have 
used only heterozygous p38α mutant mice where p38α function is not completely 
lost, we wanted to directly analyse remyelination in the nerves of homozygous p38α 
Ko mice compared to controls after injury. To determine if myelination was altered, 
we analysed transmission electron micrographs of the distal sciatic nerve stump 
sections taken from control and p38α Ko mice at 21 days post crush injury (21 DPI). 
This time-point was chosen as full nerve repair and recovery has been shown to 
occur by 3-4 weeks following nerve crush injury in rodents (This study; Yang et al., 
2008). 
Transmission electron micrographs of distal sciatic nerves taken from control and 
p38α Ko mice at 21 DPI revealed that all axons in a 1:1 with a Schwann cell were 
remyelinated normally.  Myelin thickness appeared slightly thicker and axon diameter 
size appeared slightly smaller in the nerves of p38α Ko mice, compared to controls 
 256 
 
[Figure 5.8 C & D]. To determine if there was a difference in myelin thickness and 
axon diameter size prior to injury in the nerves of control and p38α Ko mice, we also 
analysed transmission electron micrographs of contralateral uninjured sciatic nerve 
sections taken from the same control and p38α Ko mice at 21 DPI. No obvious 
differences in myelin thickness or axon diameter size were observed in the 
contralateral uninjured nerves of control and p38α Ko, although this was not 
quantified (n=3) [Figure 5.8 A & B]. Nonetheless this coincides with our earlier data 
which showed that p38α depletion did not cause any significant chances in myelin 
thickness or axon diameter size in control and p38α Ko mice at P90 [Figure 5.5].  
In order to determine whether myelin thickness and axon diameter were altered in 
the regenerating nerves of control and p38α Ko mice at 21 DPI, we quantified these 
two parameters. We identified that although there was no significant difference in g-
ratio between control and p38α Ko mice at 21 DPI, g-ratio was lower in the nerves of 
p38α Ko mice (0.67 ± 0.06) compared to control mice (0.77 ± 0.02) (P=0.17, n=3). 
Furthermore, axon diameter was slightly reduced in the nerves of p38α Ko mice 
(1.57 ± 0.12um) compared to control mice (1.59 ± 0.03um) at 21 DPI, although again 
this was not significant (P=0.86, n=3).  
In summary, there findings suggest that p38 MAPK plays a role in negatively 
regulating Schwann cell myelination, as inactivation of p38α leads to an increase in 
myelin thickness at 21 DPI. Furthermore, in contrast to the study by Kato et al. 
(2013), we revealed that inactivation of p38α does not significantly affect the 
diameter of regenerating axons.  
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Figure 5. 8: Inactivation of p38α leads to increased myelin thickness at 21 DPI. 
Transmission electron micrographs of uninjured (A & B) and injured distal sciatic nerve 
sections (C &D) taken from control and p38α Ko mice at 21 DPI. Scatter plot (E) displaying 
the g-ratio of individual axons in relation to their axon diameter size: note a shift in axons 
toward having thicker myelin (lower g-ratio) in the nerves of p38α Ko mice (n=3). Graph (F) 
showing the average g-ratio of control and p38α Ko nerves at 21 DPI (n=3). Graph (G) 
showing the average axon diameter size of control and p38α Ko nerves at 21 DPI (n=3).   
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5.3 Discussion 
There has been conflicting evidence from previous studies with regards to the role of 
p38 MAPK in regulating Schwann cell myelination. However, through analysing 
Schwann cell specific p38α knockout (p38 Ko) mice, our data suggests that p38 
MAPK functions closely resemble those of a negative regulator of Schwann cell 
myelination. 
5.3.1 Depletion of p38α activity in Schwann cells enhanced myelin 
thickness. 
Schwann cell development and myelination are regulated by a variety of transcription 
factors and signalling pathways. The specifically timed and tightly regulated 
activation or expression of these cues is essential for the development of Schwann 
cells from Schwann cell precursors, as well as the initiation of Schwann cell 
myelination (Mirsky et al., 2008). It is known that activated Notch signalling, cJun and 
Sox2 are highly expressed in immature Schwann cells (ISC) and inhibit the early 
onset of myelination. Nonetheless, as negative regulators of Schwann cell 
myelination, their expression must be suppressed by factors such as Krox20 in order 
for Schwann cells to initiate myelination (Parkinson et al., 2008, Woodhoo et al., 
2009). 
The role of the p38 MAPK signalling pathway in Schwann cells is currently unclear, 
due to conflicting evidence suggesting that p38 MAPK positively and negatively 
controls Schwann cell myelination (Fragoso et al., 2003, Hossain et al., 2012, Yang 
et al., 2012). Nonetheless, increasing evidence showing that p38 MAPK activity is 
rapidly upregulated following nerve injury and is important for regulating Schwann 
cell demyelination, drives us to believe that p38 MAPK is a negative regulator of 
Schwann cell differentiation and myelination (Yang et al., 2012, Myers et al., 2003).  
 
Many of the results derived from in vivo studies using of pharmaceutical p38 MAPK 
inhibitors such as SB 203580, PD169316 and SD-169, to analyse the involvement of 
p38 MAPK in myelination, have resulted in conflicting conclusions (Fragoso et al., 
2003, Hossain et al., 2012, Myers et al., 2003, Yang et al., 2012). Off target inhibitory 
effects could potentially add to the variability (Davies et al., 2000): SB203580 targets 
p38α and β, as well as RICK (RIP-like interacting caspase-like apoptosis-regulatory 
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protein kinase/ RIP2/ CARDIAK) - a member of the receptor interacting kinase (RIP) 
family and known to promote NF-kB activity and activation of the JNK, ERK 1/2  and 
p38 MAP kinases (Davies et al., 2000, Godl et al., 2003, Kato et al., 2013), whilst 
PD169316 (an analogue of SB203580) has been shown to also block the signalling 
mechanisms of TGF-β and Activin (Fu et al., 2003). A compound which affects the 
functional activity of multiple protein kinases or proteins cannot be used to establish 
the specific functional role of a particular enzyme. In order to validate the existing 
results regarding p38 MAPK activity in vivo, experiments using specific p38 MAPK 
mutants are required (Davies et al., 2000). We therefore generated Schwann cell 
specific homozygous p38α depleted mice, to address the functional role of p38 
MAPK activity in Schwann cells and upon myelination (Nebreda and Porras, 2000, 
Heinrichsdorff et al., 2008, Feltri et al., 1999a). 
 
Similar to other negative myelin regulators, p38 MAPK activity is reported to be high 
within the nerves of embryonic day 17 (E17) rats, but to decline dramatically by 
postnatal day1 (P1); coinciding with the transition of immature Schwann cells into 
mature myelinating cells (Yang et al., 2012). As a negative regulator of myelination, 
we hypothesised that inactivation of p38 MAPK activity from E15 in Schwann cells 
would initiate an early onset of myelination and enhance myelin formation, similar to 
that observed by Yang et al. (2012). Nonetheless, if p38 MAPK activity was in fact a 
positive regulator of myelination, we would expect that its inactivation would result in 
Schwann cell hypomyelination (Fragoso et al., 2003, Hossain et al., 2012). Our data 
showed for the first time without the use of pharmaceutical p38 MAPK inhibitors, that 
complete inactivation of p38α MAPK signalling in Schwann cells results in a slight 
trend towards more axons being myelinated at P2 and a further shift in axons 
towards having thicker myelin at P6 and P21. In support of the study by Yang et al. 
(2012) we also observed an increase in P0 and MBP expression in the nerves of 
p38α Ko mice, compared to controls at P6.  As core regulators of myelination and 
myelin protein expression, it would have been beneficial to have also analysed the 
expression levels of Sox10 and Krox20 at P6, as well as at an earlier time-points 
such as P2; where the difference in the percentage of myelinated axons was 
observed to be most significant. Previous studies have highlighted that inactivation of 
p38 MAPK reduced the gene expression of Sox10 and Krox20, however from our 
data we might expect that the expression of these transcription factors would be 
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increased, thus enhancing myelination (Hossain et al., 2012). p38 MAPK has 
previously been reported to suppress the transcriptional activity of NFATc4 in 
adipocytes, thus preventing adipogenesis (Yang et al., 2002). It is therefore possible 
that p38 MAPK activation may also reduce the activity of NFATc4 in Schwann cells, 
thus reducing myelination though hindering its ability to synergise with Sox10 and 
activate Krox20 (Kao et al., 2009). It would be interesting to analyse NFATc4 
expression in the sciatic nerves of early developing p38α Ko and control mice, to 
determine whether its localisation in the nucleus of Schwann cells is increased in the 
absence of p38α.  
 
In addition to its role in regulating Schwann cell myelination, p38 MAPK has also 
been suggested to mediate laminin induced Schwann cell elongation and alignment 
along axons during the early stages of development, a process prerequisite to 
myelination (Fragoso et al., 2003). We therefore might expect that inactivation of p38 
MAPK in Schwann cells in vivo would result in failure of Schwann cells to elongate 
and align with axons, radially sort axons and thus show signs of dysmyelination 
(Fragoso et al., 2003, Feltri et al., 2002, Feltri et al., 2015). Nonetheless, through 
observational analysis, radial sorting and myelination of axons appeared to be 
normal in p38 Ko mice, and we did not observed any differences between the nerves 
of p38 Ko and control mice at P2, P6, P21 or P90, thus suggesting that p38 MAPK is 
not required for Schwann cell elongation and alignment with axons. Inactivation of 
p38α through P0 Cre driven recombination occurs around E13.5-E15 as revealed by 
lacZ “reporter” mice, however complete removal of the p38α protein from within the 
cell, will depend on its protein half-life. Immature Schwann cells begin to preform 
radial sorting of axons around E12.5 and proceed this until about P10 (Feltri et al., 
2015). Previous studies have observed radial sorting defects in mice which have 
undergone P0 Cre driven recombination and gene deletion around E13.5-E15 (Feltri 
et al., 2002), however as no radial sorting defects were observed in p38α Ko, it is 
possible that p38α either does not play a role in radial sorting or that it exerts its 
functional effects at time-points earlier than E13.5-E15. To determine the role of p38 
MAPK in Schwann cell elongation, alignment and radial sorting more precisely, 
further analysis would need to be carried out on p38α Ko mice, where p38α activity 
is removed at earlier time-points such as E12, through desert hedgehog (DHH) 
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driven Cre recombination or E11, through periostin driven Cre recombination (Jaegle 
et al., 2003, Lindsley et al., 2007, Feltri et al., 1999b).  
p38 MAPK is activated within the distal nerve stump very quickly after nerve injury 
and helps to increase the expression of neurotrophic factors and inflammatory 
cytokines required for Wallerian degeneration, thus enhancing Schwann cell 
demyelination, macrophage recruitment and nerve regeneration (Zrouri et al., 2004, 
Yamazaki et al., 2009, Myers et al., 2003, Yang et al., 2012). Myers et al. (2003) 
discovered that blocking p38 MAPK activity after nerve injury as a therapy for 
inflammatory induced hyperalgesia reduced TNFα production, but also significantly 
increased nerve regeneration rates and enhanced the number of newly formed 
myelinated nerve fibres; axons were larger in diameter with corresponding thicker 
myelin sheaths. In support of this finding Yang et al. (2012) confirmed in vitro that 
inhibition of p38 MAPK activity enhanced myelin formation, whilst activation of p38 
MAPK activity triggered Schwann cell demyelination and dedifferentiation. Together 
these studies imply that p38 MAPK activity negatively regulates myelination and 
nerve regeneration and is required for the early initiation of the Schwann cell injury 
response. 
 
Our findings trend towards those found in earlier studies carried out in our laboratory 
by Yang et al. (2012). We showed for the first time in vivo without the use of 
pharmaceutical inhibitors that p38 MAPK participates in the initiation of myelin 
breakdown and Schwann cell dedifferentiation following nerve injury.  We show that 
impaired p38 MAPK activation after nerve crush injury appears to result in a delay in 
the downregulated expression of myelin proteins, and thus suggests that Schwann 
cell demyelination, which is required for nerve repair and regeneration, is postponed.  
 
Previous studies have also confirmed that ERK 1/2 MAPK is rapidly activated 
following nerve injury, and drives Schwann cell demyelination and dedifferentiation 
(Napoli et al., 2012, Zrouri et al., 2004, Yamazaki et al., 2009). To determine whether 
ERK 1/2 and p38 MAPK are capable of cross signalling/regulating one another, we 
analysed the level of phosphorylated ERK 1/2 in the nerves of p38α Ko mice, 
compared to control mice following nerve injury, but observed no apparent change. 
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These results thus suggest that p38 MAPK does not alter ERK 1/2 MAPK activation 
in Schwann cells. 
 
Our results also identified that inactivation of p38α following nerve injury, results  in a 
trend towards remyelinated nerve fibres having thicker myelin sheaths at 21 days 
post crush injury (21 DPI), although this was not significant. Data from our group 
(G.Dee, unpublished data) also indicated through static sciatic index (SSI) analysis 
that nerve regeneration was slightly accelerated in the absence of p38 MAPK 
activity; although this was not significant. However, in agreement with Myers et al. 
(2003), our results suggest that inactivation of the p38 MAPK signalling pathway 
leads to improved nerve regeneration after injury. To determine whether depletion of 
p38α in Schwann cells leads to accelerated axon growth and remyelination, further 
analysis would need to be carried out at earlier time-points such as 14 DPI, when 
p38 MAPK activity is suggested to peak (Yamazaki et al., 2009), to determine 
whether nerve fibre regeneration is faster and whether the onset of remyelination 
occurs earlier in p38α Ko mice, compared to controls. This could be achieved 
through carrying out nerve whole mount staining to determine whether axonal growth 
rates are altered (Dun and Parkinson, 2015), and transmission electron microscopy 
to analyse remyelination in nerve fibres at 14 DPI.  
 
A recent study by Kato et al. (2013) attempted to address the role of p38 MAPK in 
nerve regeneration through the use of heterozygous p38α mutant sem (severmaker 
type Mapk14) mice. This study discovered that reducing the function of p38 MAPK 
after nerve injury significantly reduced myelin thickness (although did not alter g-
ratio), axon diameter, and nerve regeneration, whilst also leading to a delayed but 
increased inflammatory response at 4 weeks post crush injury. While these results 
contradict earlier findings, this study may not be completely reliable (Yang et al., 
2012, Myers et al., 2003). Following p38α phosphorylation and activation by 
extracellular cues such as TNFα, p38α is normally dephosphorylated upon binding to 
its substrates. However, mutations in the p38α docking domain prevent it from 
binding to its substrate upon activation, and thus becoming dephosphorylated (auto-
repressed). Kato et al. (2013) therefore suggested that this inability of p38α to be 
auto-repressed could be the reason for elevated TNFα expression at 4 weeks after 
injury, rather than a direct effect of reducing p38α activity. It is difficult to state the 
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functional role of p38α from this study as the results identified may be attributed to 
the docking domain mutation (D316N) effect i.e. the inability of p38α to be 
dephosporylated and thus inactivated, rather than the limited loss of p38α function. 
The sem mouse model used in the study by Kato et al. (2013) contains a global 
heterozygous p38α point mutation, thus any effects regarding nerve regeneration 
and inflammation cannot be attributed solely to Schwann cells, and rather all cells 
where p38α is expressed including fibroblasts, immune cells and neurons.  
 
p38 MAPK is known to increase apoptosis and suggested to enhance IL-1β and 
TNFα production within the peripheral nerve after injury (Kato et al., 2013). While IL-
1β activates the expression of neurotropic factors such as nerve growth factor (NGF) 
required for neuronal survival and axon growth, TNFα induces macrophage 
recruitment and Schwann cell demyelination. Both IL-β and TNF-α however, have 
been shown to be responsible for the initiation of neuropathic pain (Ellis and Bennett, 
2013, Nadeau et al., 2011, Watkins and Maier, 2002). p38 MAPK activation peaks at 
14 DPI, and although it begins to decline from this time-point, it remains active within 
the nerves at 28 DPI (Yamazaki et al., 2009). We might therefore speculate that the 
preserved activity of p38 MAPK within Schwann cells up to 28 DPI may result in a 
low grade inflammatory environment which may affect remyelination and nerve fibre 
regeneration, as observed in previous studies (Kato et al., 2013, Myers et al., 2003). 
Thus, although required for the early initiation of Schwann cell demyelination and 
dedifferentiation, which can also be activated by cJun, ERK1/2 and possibly Sox2, 
inactivation of p38 MAPK might possibly be beneficial in the long term and reduce 
the inflammatory response, along with apoptosis of Schwann cells. This effect leads 
to less tissue damage, better nerve regeneration and enhanced remyelination 
(Popovich et al., 1999, Myers et al., 2003). To determine if this is true, experiments 
analysing apoptosis and the inflammatory response, along with nerve fibre growth 
and remyelination, in relation to p38 MAPK activity would need to be analysed in 
control and p38 Ko animals from the initial time of injury up to 21/28 DPI. The 
inflammatory response is critical for effective nerve regeneration, as complete 
ablation of macrophages, IL-1β and TNFα results in severely impaired axon 
regeneration (Barrette et al., 2008, Nadeau et al., 2011). Thus reducing the extent of 
the inflammatory response through p38 MAPK inactivation at later time-points post 
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injury, rather than completely blocking it would be more beneficial (Ellis and Bennett, 
2013, Barrette et al., 2008, Nadeau et al., 2011). 
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5.4 Conclusion 
Using Schwann cell specific p38α knockout mice, we have shown for the first time in 
vivo that p38 MAPK plays a role in regulating Schwann cell myelination during 
development and after injury. In concordance with its previously published role, p38 
MAPK activation shows a tendency to contribute to the initiation of Schwann cell 
demyelination following peripheral nerve injury. However, inactivation of p38 MAPK 
following injury does not appear to have any negative longer term consequences on 
the nerve regeneration process, and actually appears to be beneficial; we observed 
a tendency to slightly increased myelination at 21 days post injury, in agreement with  
previous studies showing improved axon growth (Myers et al., 2003). We predict that 
this improvement may be due to the reduced inflammatory environment as shown by 
Myers et al. (2003), thus enhancing the ability of axons to regrow and Schwann cells 
to remyelinate in the absence of negative regulatory signals. 
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Chapter 6 Discussion 
The transcription factor Sox2, along with activation of the p38 MAPK signalling 
pathways in Schwann cells have been suggested to drive Schwann cell 
demyelination and  promote an immature Schwann cell fate in vitro (Le at al. 2005, 
Yang et al. 2012). However, the direct functional effect of Sox2 on Schwann cell 
myelination in vivo has never been studied, and the functional role of p38 MAPK in 
Schwann cell myelination remains unclear. Using genetically modified mice (Sox2 
overexpressing mice and p38α null mice) these experiments aimed to investigate the 
functional role of both Sox2 and activation of the p38 MAPK signalling pathways in 
Schwann cell myelination during development and after peripheral nerve injury.  
Sox2 has been well characterised as a marker of immature Schwann cells. It is 
highly upregulated during embryonic Schwann cell development but is antagonised 
and downregulated by the increased expression of Krox20, as Schwann cells begin 
to mature and myelinate (Parkinson et al., 2008, Le et al., 2005a). Furthermore, 
Sox2 is re-expressed following peripheral nerve injury, and upon Schwann cell 
demyelination and dedifferentiation (Parinello et al. 2011, Bremer et al. 2011, Decker 
2006). Sox2 has also been shown to exert negative effects on Schwann cell 
myelination; enforced Sox2 expression in Schwann cells co-cultured with dorsal root 
ganglion axons blocked myelination (Le et al., 2005. Parkinson et al., 2008). In vitro 
data collected by Dr R.Doddrell in our lab further expanded on the functional role of 
Sox2 as a negative myelin regulator. In cultured Schwann cells, Sox2 blocked the 
induction of myelin proteins periaxin and P0 by the myelination regulator Krox20, as 
well as the upregulated expression of Oct6. While the role of Sox2 as a negative 
myelin regulator in vitro appears well defined, further experiments were needed to 
clarify the role of Sox2 in Schwann cells in vivo.  Using a conditional overexpressing 
(Sox2-IRES-EGFP) allele of Sox2 and a Schwann cell-specific CRE line (mTOTA P0-
CRE), in the experiments presented here the role of Sox2 in Schwann cells was 
examined for the first time in vivo. We confirmed that continued Sox2 expression 
impairs the transition of immature/promyelinating Schwann cells into a myelinating 
state; this was supported by the continued expression of cJun and N-cadherin in 
immature Schwann cells in the nerves of Sox2 overexpressing (Sox2OE) mice. 
Furthermore, continued Sox2 expression directly prevents Schwann cell myelination 
and impairs the expression of Krox20 and myelin proteins P0 and MBP. Peripheral 
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nerves of Sox2OE mice therefore exhibit profound hypomyelination at all time-points 
during development and in adulthood. Sox2 overexpression also triggers excess 
Schwann cell proliferation and an influx of macrophages into intact Sox2OE nerves. 
Sox2 overexpressing mice further demonstrate reduced nerve conduction velocities 
and impaired motor and sensory function. Overall the continued expression of Sox2 
in Schwann cells results in mice developing symptoms characteristic of a peripheral 
nerve disorder such as Charcot-Marie-Tooth type 1 (CMT-1). Furthermore, we 
identified that the phenotype observed in Sox2 overexpressing mice could be 
reversed following a reduction in Sox2 expression. This study thus demonstrates the 
direct functional effect of continued Sox2 expression in Schwann cells during 
development.  
To further clarify the functional role of Sox2, we examined the effect of continued 
Sox2 expression in Schwann cells following peripheral nerve injury. Sox2 
overexpression was shown to accelerate axonal growth (Dr Xin-Peng Dun, 
unpublished data), however its continued expression inhibited Schwann cell 
remyelination, myelin protein re-expression and functional recovery. Similar to what 
we observed during development, Sox2OE Schwann cells also exhibit an increased 
rate of cellular proliferation and an increased number of macrophages were 
observed in nerves with Sox2OE Schwann cells at 21 days post injury (21DPI).  
Remarkably we found that Sox2 was able to directly modulate the expression of 
Sox10, a critical regulator of Schwann cell specification and myelination (Finzsch et 
al., 2010, Bremer et al., 2011, Britsch et al., 2001). We observed at later time-points 
in development that the overexpression of Sox2 results in a reduction in Sox10 
expression and re-localisation of Sox10 into the Schwann cell cytoplasm. This novel 
finding provides an insight into a potential mechanism by which Sox2 impairs 
myelination and leads to a progressive worsening in the phenotype observed in 
Sox2OE mice. Further investigations of how Sox2 regulates Sox10 expression, and 
whether Sox2 antagonises the binding of Sox10 to the promotor regions of its 
downstream targets such as Oct6, Krox20 and P0, remains essential. Further 
experiments would help to elucidate the exact mechanism by which Sox2 prevents 
Schwann cell differentiation and myelination. 
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Sox2 has been identified to be upregulated in mouse models of CMT-1 disease, 
including CMT-1A caused by mutations in PMP22 (Fledrich et al., 2014) and CMT-
1B caused by mutations in P0 (unpublished data by Dr Francesca Florio at San 
Raffaele University). It is possible that Sox2 expression may be upregulated in CMT-
1A mouse models as a marker of immature Schwann cells and an inducer of disease 
progression. Nonetheless as seen in CMT-1B mouse models Sox2 may exert a 
protective effect, by preventing cellular stress in response to the expression of 
mutant myelin proteins (Dr Francesca Florio, unpublished data).  
In our study we have demonstrated that overexpression of Sox2 in Schwann cells 
may have clinical relevance, Sox2OE mice show similar characteristics and 
symptoms to those observed in mouse models of CMT-1 disease and congenital 
hypomyelinating neuropathy i.e. reduced myelination and nerve conduction 
velocities, impaired motor-sensory function, and an increased inflammatory response 
in the peripheral nerves.  It would be interesting to see whether Sox2 is upregulated 
and/or is a contributing factor to the development of demyelinating peripheral 
neuropathies in patients. We have observed that decreasing Sox2 expression in 
mice that exhibit characteristics of a peripheral neuropathy due to elevated Sox2 
protein levels, can reverse the phenotype and thus allow Schwann cells to regain 
their myelination function. This data suggests that targeting Sox2 as a potential 
therapy might provide beneficial in ameliorating peripheral nerve disorders such as 
congenital hypomyelinating neuropathy if Sox2 is observed to be severely elevated. 
As mentioned above, Sox2 induced a phenotype in Sox2 overexpressing mice 
similar to that of Charcot-Marie-Tooth disease. Enforced expression of Sox2 in 
Schwann cells in vitro identified that Sox2 regulates the expression of a number of 
genes (Dr R.Doddrell, unpublished data) which have been shown to cause forms of 
CMT; N-myc downstream regulated gene 1 (NDRG1), neurofilament light (Nefl) and 
lipopolysaccharide-induced TNF factor (LITAF) (Berger et al., 2004, Kalaydjieva et 
al., 2000, Okuda et al., 2004, Züchner et al., 2004, Sinkiewicz-Darol et al., 2015, 
Street et al., 2003). Furthermore, we identified in vivo that Sox2 directly reduces P0 
and Krox20 expression in Schwann cells; two proteins known to be altered in forms 
of CMT-1 disease. Understanding the mechanisms that regulate Schwann cell 
myelination is critical for designing effective treatments for demyelinating peripheral 
neuropathies. We show that Sox2 is a direct negative regulator of Schwann cell 
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myelination able to alter the expression of genes and proteins shown to cause forms 
of CMT-1 and also promotes a phenotype of a peripheral neuropathy when 
overexpressed. Sox2 might therefore be a valuable therapeutic target in peripheral 
nerve disorders that show aberrant expression of Sox2.  
The inflammatory response is activated upon peripheral nerve injury and helps to 
ensure successful nerve regeneration and functional recovery when regulated 
correctly. Nonetheless, when the inflammatory response is not resolved following 
nerve repair and remyelination, this can lead to the onset of a peripheral nerve 
disorder and impaired functional recovery. Upon Schwann cell demyelination and 
dedifferentiation (marked by the re-expression of Sox2), as seen in studies where 
Krox20 and Sox10 have been inactivated in Schwann cells during adulthood (Decker 
et al., 2006, Bremer et al., 2011), macrophages begin to infiltrate into the 
endoneurial space and clear myelin debris. In the nerves of Sox2HomoOE mice, which 
displayed impaired myelination and numerous immature/promyelinated Schwann 
cells, the number of macrophages was significantly increased. From these studies 
there appears to be a correlation between the number of demyelinating and 
dedifferentiating Schwann cells, and the increased number of macrophages 
infiltrating the nerves. It is possible that upon Schwann cell demyelination and 
dedifferentiation in the absence of trauma or upon long term failure to differentiate, 
Schwann cells activate the ERK 1/2 signalling pathway. In mouse models of CMT-1 
disease the MEK 1/2-ERK 1/2 signalling cascade is activated in mutant Schwann 
cells and directly mediates the expression of macrophage chemoattractant protein -1 
(MCP-1), which causes macrophage recruitment (Fischer et al., 2008b, Kohl et al., 
2010a). The ERK 1/2 signalling cascade is also known to induce blood nerve barrier 
(BNB) breakdown in the absence of trauma,  leading to the infiltration of immune 
cells into the nerve (Napoli et al., 2012). It would be interesting to see whether the 
ERK 1/2 signalling pathway and the expression of MCP-1 are upregulated in 
Schwann cells, in response to Sox2 overexpression.  Low grade inflammation 
involving macrophages, has been shown to substantially contribute to the 
pathogenesis of demyelinating neuropathies. In particular enhancing disease 
progression in mouse models of CMT-1 disease. Decreasing macrophage numbers 
in the nerves of CMT-1B and 1X mice has been show to ameliorate the disease 
(Martini and Willison, 2015, Martini et al., 2013, Kohl et al., 2010a, Klein et al., 2015). 
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As macrophage numbers are elevated in the nerves of Sox2 overexpressing mice 
during development and after nerve injury, it is possible that they contribute to the 
progressive worsening of the phenotype observed during development, and a 
peripheral nerve disorder after injury.  
In contrast to Sox2, the role of p38 MAPK has been more widely studied in Schwann 
cells. Nonetheless, its functional role in regulating Schwann cell myelination remains 
uncertain due to conflicting results from previous studies. While studies by Fragoso 
et al. (2003) and Hossain et al. (2012) suggest that p38 MAPK acts as a positive 
driver of Schwann cell myelination, a recent study by Yang et al. (2012) identified 
that the p38 MAPK signalling pathway negatively regulates Schwann cell 
myelination. Previous studies have used pharmaceutical inhibitors of the p38 MAPK 
signalling pathway in order to elucidate its functional role. However, as these 
inhibitors also block other signalling pathways (mentioned in section 5.3.1), this 
could be the reason for conflicting conclusions. 
The major functional isoform of p38 MAPK, has been identified as p38α (Nebreda 
and Porras, 2000, Zarubin and Han, 2005). We thus generated Schwann cell specific 
p38α null mice to be able to study the direct functional role of p38 MAPK in Schwann 
cell myelination, as this is a more specific method than using pharmaceutical 
inhibitors. Our data supported the work by Yang et al. (2012), showing that the p38 
MAPK signalling pathway functions to negatively regulate Schwann cell myelination 
and promote demyelination following peripheral nerve injury. Nerves taken from 
p38α null mice showed increased myelin thickness compared to controls throughout 
development (although not significant), as well as an increased expression of myelin 
proteins P0 and MBP (at P6). Analysis after nerve injury revealed the importance of 
p38 MAPK signalling in initiating Schwann demyelination, as p38α null mice failed to 
effectively downregulate the expression of myelin proteins P0 and MBP at 3 and 7 
DPI.  Nonetheless, p38α null mice exhibited slightly accelerated nerve regeneration 
(G.Dee, unpublished data) and increased myelin thickness at 21 DPI, compared to 
control mice.  These results highlighted for the first time in vivo that p38 MAPK acts 
as a negative regulator of Schwann cell myelination, and that in the absence of its 
activity, Schwann cell myelination is enhanced.  
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p38 MAPK is a stress activated protein kinase (SAPK)  known to facilitate responses 
to cellular stresses including pathogens, cytokines and growth factors. p38 MAPK 
therefore plays a fundamental role in mediating the inflammatory response; the 
activation and recruitment of inflammatory cells, the production of pro-inflammatory 
cytokines (IL-1β, TNFα and IL-6) and the induction of inflammatory enzymes such as 
Cox2, iNOS and other inflammatory related molecules (Zarubin and Han, 2005, 
Herlaar and Brown, 1999, Yang et al., 2014b). Accumulating evidence has shown 
the p38 plays a particular role in the macrophage-mediated inflammation by 
regulating the production of inflammatory cytokines such as IL-1β and TNFα (Yang 
et al., 2014b). Reducing the activity of p38 MAPK in peripheral nerves which have 
undergone nerve crush injury, has been shown to reduce the expression of pro-
inflammatory cytokines at early time-points post injury, decrease Schwann cell death 
and improve axon regeneration (Kato et al., 2013, Myers et al., 2003). We therefore 
speculate that in nerves where p38α has specifically been depleted from Schwann 
cells, improved nerve regeneration and remyelination may have been partly due to a 
decrease in the inflammatory response. The previous studies mentioned above have 
analysed nerve repair in response to a global p38 MAPK reduction (Kato et al., 2013, 
Myers et al., 2003), it therefore remains unknown whether specific depletion of p38 
MAPK activity in Schwann cells would reduce the inflammatory response, and thus 
be responsible for the improved nerve regeneration. In future our group is hoping to 
examine whether p38α depletion in Schwann cells reduces the inflammatory 
response, and in particular the number of recruited macrophages to the nerves of 
p38α null mice after nerve injury, compared to controls.   
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6.1 Conclusion  
This work has shown for the first time in vivo using Schwann cell specific Sox2 
overexpressing (Sox2OE) mice that Sox2 functions as a direct negative regulator of 
Schwann cell myelination. Continued Sox2 expression during development and after 
peripheral nerve crush injury prevents Schwann cells from differentiating into a 
myelinating state, upregulating the expression of Krox20 and promyelin proteins and 
thus impairs myelination of axons. Furthermore, we have identified that continued 
Sox2 expression caused an increased macrophage mediated inflammatory response 
within the nerves of Sox2OE mice, and that these mice develop a phenotype of a 
peripheral neuropathy. Similarly, we have indicated for the first time in vivo using 
Schwann cell specific p38α null (p38α Ko) mice, that p38 MAPK can exhibit similar 
functions to that of a negative myelin regulator. Schwann cells depleted of p38α, the 
major functional isoform of p38 MAPK, show a trend towards having an increased 
myelin thickness and an increased expression of myelin proteins during 
development. In addition, following nerve injury, depletion of p38α in Schwann cells 
tends to improved axon regeneration and Schwann cell remyelination. 
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